[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 911
1. Esteghamati A, Khalilzadeh O, Ashraf H, Zandieh A, Morteza A, Rashidi A, Meysamie A, Nakhjavani M: Physical activity is correlated with serum leptin independent of obesity: results of the national surveillance of risk factors of noncommunicable diseases in Iran (SuRFNCD-2007). Metabolism; 2010 Dec;59(12):1730-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physical activity is correlated with serum leptin independent of obesity: results of the national surveillance of risk factors of noncommunicable diseases in Iran (SuRFNCD-2007).
  • Reports on the relationship between leptin and physical activity (PA) at the population level are scarce.
  • The present study examined the relationship between serum leptin concentrations and PA in a nationally representative sample of 3001 Iranian adults aged 25 to 64 years.
  • Serum leptin was measured with an enzyme-linked immunosorbent assay.
  • After adjustment for age, area of residence, smoking, body mass index, and waist circumference, total PA (r = -0.129, P = .038 in men and r = -0.226, P = .006 in women), the duration of vigorous-intensity activity (r = -0.120, P = .044 in men and r = -0.154, P = .019 in women), the duration of moderate-intensity activity (r = -0.114, P = .047 in men and r = -0.160, P = .018 in women), and time spent on sedentary behaviors (r = 0.194, P = .014 in men and r = -0.204, P = .007 in women) were significantly correlated with serum leptin.
  • In both sexes, participants in higher categories of PA had significantly lower serum leptin levels.
  • In conclusion, our results demonstrated an inverse association between leptin concentrations and PA independent of age, sex, smoking, and body adiposity.
  • Our results point to the regulatory effects of PA on serum leptin.
  • [MeSH-major] Exercise. Leptin / blood. Obesity / physiopathology. Population Surveillance

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20580780.001).
  • [ISSN] 1532-8600
  • [Journal-full-title] Metabolism: clinical and experimental
  • [ISO-abbreviation] Metab. Clin. Exp.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


2. Guadagni F, Roselli M, Martini F, Spila A, Riondino S, D'Alessandro R, Del Monte G, Formica V, Laudisi A, Portarena I, Palmirotta R, Ferroni P: Prognostic significance of serum adipokine levels in colorectal cancer patients. Anticancer Res; 2009 Aug;29(8):3321-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of serum adipokine levels in colorectal cancer patients.
  • BACKGROUND: Adipokines may significantly influence the growth and proliferation of tumor stroma and malignant cells within.
  • Reduced adiponectin and increased leptin serum levels were found in colorectal cancer (CRC) patients.
  • Recently, it has been demonstrated that tumor necrosis factor-alpha (TNF-alpha) is able to induce dose-dependent changes in serum adipokine levels.
  • MATERIALS AND METHODS: Baseline leptin, adiponectin and TNF-alpha levels were analyzed in 90 patients with histologically diagnosed primary or newly diagnosed metastatic CRC treated at 'Tor Vergata' Clinical Center and followed up for a median period of 3 years.
  • RESULTS: Serum leptin levels were higher in CRC patients than in controls (p<0.0001).
  • Conversely, serum adiponectin levels were lower in CRC patients than in controls (p<0.0001).
  • Leptin inversely correlated with adiponectin (p<0.005).
  • The leptin/adiponectin (L/A) ratio was eight-fold greater in CRC compared to controls (p<0.0001).
  • CONCLUSION: Serum adipokine levels might have a role in the biology of CRC and the combined measurement of leptin and adiponectin levels might provide useful prognostic information in the management of patients with CRC.
  • [MeSH-minor] Adiponectin / blood. Adult. Aged. Case-Control Studies. Female. Follow-Up Studies. Humans. Leptin / blood. Male. Middle Aged. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Survival Rate. Treatment Outcome. Tumor Necrosis Factor-alpha / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661351.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ADIPOQ protein, human; 0 / Adiponectin; 0 / Leptin; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


3. Bhat GK, Plant TM, Mann DR: Relationship between serum concentrations of leptin, soluble leptin receptor, testosterone and IGF-I, and growth during the first year of postnatal life in the male rhesus monkey, Macaca mulatta. Eur J Endocrinol; 2005 Jul;153(1):153-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between serum concentrations of leptin, soluble leptin receptor, testosterone and IGF-I, and growth during the first year of postnatal life in the male rhesus monkey, Macaca mulatta.
  • OBJECTIVES: Subnormal leptin levels in low birth weight infants may allow for catch-up growth during infancy.
  • Scant data are available that relate growth with circulating leptin during normal infancy in primates.
  • The current study objective was to examine the association between serum leptin, its soluble receptor (sOB-R), testosterone and IGF-I concentrations, and body weight during infancy in male rhesus monkeys.
  • DESIGN: Hormone levels were assessed longitudinally in animals (n = 7) from birth until 1 year of age.
  • RESULTS: Body weight increased during the first 6 months of life and was strongly correlated with rising IGF-I levels and, as IGF-I plateaued and then declined during the second half of the year, body weight gain decelerated.
  • In contrast, leptin levels declined gradually with age during the first year of life in conjunction with increasing body weight.
  • There was no association between body weight gain and serum leptin levels or between serum testosterone and leptin values.
  • Since sOB-R levels also declined with leptin values, it does not appear that levels of bioavailable leptin changed during infancy.
  • CONCLUSIONS: The data do not support the contention that leptin regulates growth during infancy, but the close association between IGF-I levels and body weight suggested that this hormone may regulate growth in infant male monkeys.
  • The failure to observe an association between serum testosterone and leptin concentrations suggested that leptin is not involved in the activation of the hypothalamic-pituitary -testicular axis during this developmental period.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994757.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM08248; United States / NICHD NIH HHS / HD / HD08610; United States / NICHD NIH HHS / HD / HD13254; United States / NICHD NIH HHS / HD / HD41749; United States / NCRR NIH HHS / RR / RR03024
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Leptin; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 3XMK78S47O / Testosterone; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


Advertisement
4. Krcmár J, Kotolová H, Veselá L, Csöllei J, Gonec T, Karpísek M, Bartosová L, Necas J: [Study of a newly synthesized substance with a potential to stimulate beta3-adrenergic receptors]. Ceska Slov Farm; 2006 May;55(3):120-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effects of six-week oral administration of the newly synthesized substance B496 (methyl-4-[2-[2-hydroxy-3-(4-ethylcarbamoyl)phenoxyprophyl]amino]etyl)-phenoxyacetate hydrochloride) on serum glucose, triglycerides, total cholesterol, and leptin levels were studied in male Wistar rats fed with a high-fat diet.
  • The results indicated a significant reduction in serum glucose levels (-26 %, p<0,01), triacylglyceride levels (-21 %, p<0,05) and leptin levels (-43 %, p<0,01).
  • Further the effect of a single intraperitoneal dose (1 mg/kg) of B496 and BRL-37344 on serum leptin levels in the C57Bl/6J mouse was investigated.
  • Administration of BRL-37344 resulted in a significant decrease in serum leptin levels (-55 %, p<0,001).
  • [MeSH-major] Adrenergic beta-Agonists / pharmacology. Leptin / blood. Receptors, Adrenergic, beta-3 / drug effects

  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16838489.001).
  • [ISSN] 1210-7816
  • [Journal-full-title] Ceská a Slovenská farmacie : casopis Ceské farmaceutické spolecnosti a Slovenské farmaceutické spolecnosti
  • [ISO-abbreviation] Ceska Slov Farm
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Adrenergic beta-Agonists; 0 / B496 compound; 0 / Blood Glucose; 0 / Ethanolamines; 0 / Leptin; 0 / Phenoxyacetates; 0 / Receptors, Adrenergic, beta-3; 0 / Triglycerides; 114333-71-0 / BRL 37344; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


5. Jose VJ, Mariappan P, George PV, Selvakumar, Selvakumar D: Serum leptin levels in acute myocardial infarction. Indian Heart J; 2005 Jan-Feb;57(1):39-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum leptin levels in acute myocardial infarction.
  • BACKGROUND: Several studies have shown an association of serum leptin levels with cardiovascular diseases.
  • The present study was undertaken to assess levels of serum leptin in patients presenting with acute ST segment elevation myocardial infarction.
  • The serum leptin levels in patients with myocardial infarction was 6.51 +/- 6.76 ng/ml versus 2.86 +/- 2.22 ng/ml in controls.
  • In the multivariate analysis the odds ratio for serum leptin with myocardial infarction was 1.45 with a 95% confidence interval of 1.2 to 1.8.
  • CONCLUSIONS: Our results suggest that serum leptin level is elevated in patients with acute ST segment elevation myocardial infarction.
  • [MeSH-major] Leptin / blood. Myocardial Infarction / blood

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852893.001).
  • [ISSN] 0019-4832
  • [Journal-full-title] Indian heart journal
  • [ISO-abbreviation] Indian Heart J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


6. Teixeira PF, Cabral MD, Silva NA, Soares DV, Braulio VB, Couto AP, Henriques JL, Costa AJ, Buescu A, Vaisman M: Serum leptin in overt and subclinical hypothyroidism: effect of levothyroxine treatment and relationship to menopausal status and body composition. Thyroid; 2009 May;19(5):443-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum leptin in overt and subclinical hypothyroidism: effect of levothyroxine treatment and relationship to menopausal status and body composition.
  • BACKGROUND: The relationship between thyroid status, including subclinical hypothyroidism (SH) and serum leptin is controversial or uncertain.
  • Therefore we evaluated serum leptin in SH and overt hypothyroidism (OH) and determined the effects of levothyroxine (LT(4)) replacement on serum leptin in these disorders.
  • METHODS: Serum leptin, thyrotropin (TSH), free thyroxine, insulin, glucose, and body composition parameters were compared in 55 SH, 20 OH, and 28 euthyroid (EU) pre- and postmenopausal women.
  • In addition, the effect of LT(4) treatment on serum leptin in SH and OH was assessed.
  • RESULTS: The mean +/- SD (median) serum leptin concentrations in the OH and SH groups were higher than in the EU group (35.1 +/- 27.2 [33.0] and 36.6 +/- 21.9 [30.6] ng/mL, respectively, vs. 23.2 +/- 19.3 [17.9] ng/mL, p = 0.011), but the difference was only significant in postmenopausal women.
  • In premenopausal women there was no correlation between leptin, BMI, or FMI and serum TSH levels (r(s) = 0.009, p = 0.474; r(s) = 0.043, p = 0.367; r(s) = 0.092, p = 0.232).
  • In the postmenopausal women, the partial correlation coefficient between TSH and leptin was present, even when controlling for BMI (r(s) = 0.297, p = 0.042) and FMI (r(s) = 0.275, p = 0.050).
  • LT(4) treatment was associated with a reduction of serum leptin concentrations in the OH group (p = 0.008).
  • In SH group there were no differences between LT(4) replacement or no treatment, since a fall in serum leptin levels was detected in both SH subgroups, despite a more pronounced fall with LT(4) use.
  • CONCLUSIONS: Serum leptin concentrations are elevated in postmenopausal women with SH or OH.
  • A relationship between thyroid status and serum leptin is further supported by the fact that LT(4) treatment, to restore the EU status, reduced serum leptin levels in OH in the absence of significant effects on BMI.
  • In women, hypothyroidism influences either leptin secretion or degradation and this effect is more pronounced in postmenopausal than in premenopausal women.
  • [MeSH-major] Body Composition. Hormone Replacement Therapy. Hypothyroidism / drug therapy. Leptin / blood. Postmenopause / blood. Premenopause / blood. Thyroxine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415994.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Insulin; 0 / Leptin; 9002-71-5 / Thyrotropin; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


7. Gadzinowski J, Kowalska K, Vidyasagar D: Treatment of MAS with PPHN using combined therapy: SLL, bolus surfactant and iNO. J Perinatol; 2008 Dec;28 Suppl 3:S56-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of MAS with PPHN using combined therapy: SLL, bolus surfactant and iNO.
  • In this study, thirteen infants with diagnosis of MAS and PPHN were first treated with conventional respiratory support.
  • Then between 2 and 22h of life they were randomized either to bolus surfactant treatment (n=6) or surfactant lung lavage (SLL, n=7) treatment.
  • The results showed that infants treated with SLL had significant improvements in oxygenation, decreases in MAP and A-a gradients.
  • In conclusion these data show no advantage of SLL therapy over bolus surfactant treatment in infants with MAS complicated by PPHN.

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19057612.001).
  • [ISSN] 1476-5543
  • [Journal-full-title] Journal of perinatology : official journal of the California Perinatal Association
  • [ISO-abbreviation] J Perinatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pulmonary Surfactants; 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


8. Aldoss IT, Blumel SM, Bierman PJ: The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma. Cancer Manag Res; 2009;1:155-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma.
  • There is no consensus on recommendations for the treatment of relapsed and refractory indolent non-Hodgkin lymphoma (NHL).
  • This agent has a high degree of activity against a variety of tumor cell lines.
  • Clinically, bendamustine has demonstrated activity against indolent NHL, chronic lymphocytic lymphoma, multiple myeloma and mantle cell lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4473-9 [18626004.001]
  • [Cites] Anticancer Drugs. 2005 Sep;16(8):871-7 [16096436.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):812-26 [19103723.001]
  • [Cites] Ther Clin Risk Manag. 2008 Aug;4(4):727-32 [19209254.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Semin Hematol. 1988 Apr;25(2 Suppl 2):11-6 [2456618.001]
  • [Cites] Biochim Biophys Acta. 1972 Dec 22;287(3):386-9 [4629776.001]
  • [Cites] Semin Oncol. 2002 Aug;29(4 Suppl 13):12-4 [12170426.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):441-9 [15689582.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Apr;132(4):205-12 [16402269.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4143-9 [16896003.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 May;59(6):759-70 [16957931.001]
  • [Cites] Anticancer Drugs. 2007 Jun;18(5):587-95 [17414628.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1986-92 [17420513.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2316-23 [17597807.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1299-306 [17613757.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Feb;134(2):245-53 [17653574.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Dec;8 Suppl 1:S13-7 [18282361.001]
  • [Cites] Blood. 2008 Jul 15;112(2):330-9 [18451308.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Feb;135(2):227-34 [18719942.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2596-7 [18809766.001]
  • [Cites] Anticancer Drugs. 1996 Jun;7(4):415-21 [8826610.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1110-7 [9060552.001]
  • [Cites] Pharmazie. 1985 Nov;40(11):782-4 [4095129.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Nov;128(11):603-9 [12458340.001]
  • [Cites] Semin Oncol. 2002 Aug;29(4 Suppl 13):4-11 [12170425.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3383-9 [15908650.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Feb;132(2):105-12 [16088404.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7565-73 [16186600.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7985-93 [16204016.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Feb;132(2):99-104 [16292542.001]
  • [Cites] Br J Cancer. 2007 Jun 4;96(11):1692-8 [17486132.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):211-7 [18056679.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):309-17 [18172283.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):204-10 [18182663.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2096-105 [12357363.001]
  • [Cites] Lancet. 2003 Aug 16;362(9383):516-22 [12932382.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1821-7 [15223642.001]
  • [Cites] Leuk Lymphoma. 2004 May;45(5):911-3 [15291348.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2445-9 [15621757.001]
  • [Cites] Haematologica. 2001 May;86(5):485-93 [11410411.001]
  • [Cites] Anticancer Drugs. 2001 Oct;12(9):725-9 [11593053.001]
  • [Cites] Haematologica. 2002 Jan;87(1):33-43 [11801463.001]
  • [Cites] Leuk Lymphoma. 2002 Feb;43(2):327-31 [11999564.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 May;128(5):271-8 [12029443.001]
  • [Cites] Blood. 2008 Dec 15;112(13):4824-31 [18799723.001]
  • (PMID = 21188134.001).
  • [ISSN] 1179-1322
  • [Journal-full-title] Cancer management and research
  • [ISO-abbreviation] Cancer Manag Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3004665
  • [Keywords] NOTNLM ; Treanda / alkylating agent / bendamustine / chronic lymphocytic lymphoma / indolent non-Hodgkin lymphoma
  •  go-up   go-down


9. Fehr M, Templeton A, Cogliatti S, Aebersold F, Egli F, Gillessen S, Cathomas R: Primary manifestation of small lymphocytic lymphoma in the prostate. Onkologie; 2009 Oct;32(10):586-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary manifestation of small lymphocytic lymphoma in the prostate.
  • BACKGROUND: Infiltration of non-haematopoietic organs by small lymphocytic lymphoma/chronic lymphocytic leukaemia (SLL/CLL) is not unusual in late-stage disease and thus quite frequently encountered in post-mortem examinations.
  • However, primary manifestation of SLL/CLL in the prostate is rarely diagnosed.
  • PATIENTS AND METHODS: We report two cases of primary prostatic SLL/CLL, in one case in combination with prostate carcinoma, and discuss diagnostic pitfalls, pathophysiological mechanisms and therapeutic management, together with an overview of the literature.
  • CONCLUSIONS: Lymphocytic infiltration of the prostate associated with obstructive symptoms is rare but can already occur in very early disease.
  • Microscopically, SLL/CLL infiltration can be distinguished from chronic prostatitis by its pattern of infiltration and by immunohistochemistry.
  • As the incidence of both SLL/CLL and prostatic carcinoma increases with age, composite tumours might occur more often in the future.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • [CommentIn] Onkologie. 2009 Oct;32(10):550-1 [19816069.001]
  • (PMID = 19816076.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 17
  •  go-up   go-down


10. Jahan S, Zinnat R, Hassan Z, Biswas KB, Habib SH: Gender differences in serum leptin concentrations from umbilical cord blood of newborn infants born to nondiabetic, gestational diabetic and type-2 diabetic mothers. Int J Diabetes Dev Ctries; 2009 Oct;29(4):155-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender differences in serum leptin concentrations from umbilical cord blood of newborn infants born to nondiabetic, gestational diabetic and type-2 diabetic mothers.
  • To investigate gender differences, if any, in leptin concentrations from umbilical cord blood of new born infants of mothers with type 2 diabetes mellitus (DM), gestational diabetes mellitus (GDM), and Non diabetic (ND) at delivery.
  • Serum leptin concentrations were measured in 105 newborns (53 males and 52 females in the three groups).
  • Pearson correlation coefficient was used to explore the relationship between serum leptin concentrations and anthropometric measures of the fetus and their mother.
  • Both Serum leptin level and serum C-peptide was measured by chemiluminescence based ELISA.
  • The median range of leptin concentration in cord blood was ND group: Male [13.91 (3.22 - 47.63)], Female [16.88 (2 - 43.65)]; GDM group: Male [32 (7 - 76.00)], Female [36.73 (4.80 - 81.20)]; DM group: Male [20.90 (2 -76.00)], Female [32 {2.58 - 80.67)].
  • Cord serum leptin levels correlated with birth weight(r=0.587, p=0.0001), ponderal index (PI) (r=.319, p=0.024)of the babies and body mass index (BMI) (r=-0.299, p=0.035) of their mothers but did not correlate with gestational age, cord serum C-peptide concentration or placental weight at delivery.
  • Leptin concentrations were higher in the female fetus in comparison to the male fetus.
  • We found that there are very strong associations between cord leptin concentrations at delivery and birth weight, ponderal index of the baby, body mass index of the mothers with Type 2 DM.
  • We also found that high leptin levels could represent an important feedback modulator of substrate supply and subsequently for adipose tissue status during late gestation or adipose tissue is the major determinant of circulating leptin levels.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 1995 Sep 25;214(3):1260-7 [7575539.001]
  • [Cites] Eur J Endocrinol. 2001 Jul;145(1):53-8 [11415852.001]
  • [Cites] Science. 1995 Jul 28;269(5223):546-9 [7624778.001]
  • [Cites] Nature. 1994 Dec 1;372(6505):425-32 [7984236.001]
  • [Cites] N Engl J Med. 1996 Feb 1;334(5):292-5 [8532024.001]
  • [Cites] Pediatrics. 1996 Aug;98(2 Pt 1):201-3 [8692618.001]
  • [Cites] Nat Med. 1996 Sep;2(9):949-50 [8782440.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Sep;81(9):3424-7 [8784109.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Nov;81(11):3909-13 [8923837.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Apr;82(4):1293-300 [9100610.001]
  • [Cites] J Clin Endocrinol Metab. 1997 May;82(5):1642-4 [9141565.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Sep;82(9):2849-55 [9284709.001]
  • [Cites] Eur J Endocrinol. 1997 Dec;137(6):655-8 [9437232.001]
  • [Cites] Diabetes. 1998 May;47(5):847-50 [9588462.001]
  • [Cites] Science. 1995 Jul 28;269(5223):540-3 [7624776.001]
  • (PMID = 20336197.001).
  • [ISSN] 1998-3832
  • [Journal-full-title] International journal of diabetes in developing countries
  • [ISO-abbreviation] Int J Diabetes Dev Ctries
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2839129
  • [Keywords] NOTNLM ; Newborn infants / Serum leptin / Type 2 Diabetic / Umbilical cord blood / gestational diabetes mellitus / non diabetic
  •  go-up   go-down


11. McElroy C, Velilla R, Chaudhary H, Al-Abbadi MA: Fine-needle aspiration diagnosis of squamous cell carcinoma in a lymph node involved with small lymphocytic lymphoma: case report and review of the literature. Diagn Cytopathol; 2009 Jan;37(1):48-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration diagnosis of squamous cell carcinoma in a lymph node involved with small lymphocytic lymphoma: case report and review of the literature.
  • Diagnosis of two distinct malignant entities existing concurrently and at the same location (synchronous malignancy) by fine- needle aspiration (FNA) is unusual but may occur.
  • Small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) in particular is associated with an increased incidence of secondary tumor, likely due to associated immunodeficiency.
  • Co-occurrence of some carcinomas such as squamous cell carcinoma (SCC), may show especially aggressive behavior.
  • A 57-year-old Caucasian male presented with recurrent upper extremity lymphedema and diffuse lymphadenopathy of the axillary and cervical regions.
  • FNA of a large cervical lymph node was diagnostic for both atypical lymphocytic proliferation and SCC.
  • Flow cytometric analysis showed the atypical lymphocytic proliferation to be positive for CD5, CD23, CD19, CD20, HLA-DR, CD38, and the population was kappa light chain restricted.
  • These cells were negative for CD-10 and FMC-7 antigens, suggesting a phenotype of B-cell SLL/CLL.
  • We report a rare occurrence of metastatic SCC to a lymph node infiltrated by SLL/CLL.
  • The diagnosis was achieved by a combination of cytomorphologic examination of FNA smears, immunohistochemical staining of cell block material, and flow cytometry on the sample obtained by FNA.
  • To the best of our knowledge, only three cases of SCC metastasis to SLL/CLL diagnosed by FNA have been reported in the English literature.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymph Nodes / pathology. Neoplasms, Multiple Primary / diagnosis. Oropharyngeal Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18973126.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 16
  •  go-up   go-down


12. El-Ferzli GT, Philips JB 3rd, Bulger A, Ambalavanan N: A pumpless lung assist device reduces mechanical ventilation-induced lung injury in juvenile piglets. Pediatr Res; 2009 Dec;66(6):671-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective is to test the effect of the LAD on pulmonary histopathology in juvenile piglets with acute lung injury caused by saline lung lavage (SLL) followed by intermittent mandatory ventilation (IMV).
  • Three- to 4-wk-old piglets were randomized to no intervention (control group), SLL alone (SLL group), SLL + IMV (IMV group), or SLL + IMV + LAD (LAD group) (n = 6 per group).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1989 Oct;96(4):849-51 [2676391.001]
  • [Cites] Early Hum Dev. 2008 Nov;84(11):709-16 [18930613.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 May;105(5):823-32 [7683735.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Mar;107(3):838-48; discussion 848-9 [8127113.001]
  • [Cites] J Pediatr. 1994 Jul;125(1):104-10 [7517446.001]
  • [Cites] Perfusion. 1994;9(4):265-9 [7981464.001]
  • [Cites] J Paediatr Child Health. 1995 Apr;31(2):105-11 [7794609.001]
  • [Cites] Anesthesiology. 1995 Oct;83(4):710-20 [7574050.001]
  • [Cites] J Pediatr. 1996 Jan;128(1):109-17 [8551400.001]
  • [Cites] ASAIO J. 1994 Jul-Sep;40(3):M728-31 [8555610.001]
  • [Cites] Lancet. 1996 Jul 13;348(9020):75-82 [8676720.001]
  • [Cites] Pediatr Pulmonol. 1996 Oct;22(4):263-70 [8905887.001]
  • [Cites] J Paediatr Child Health. 1997 Jun;33(3):202-8 [9259293.001]
  • [Cites] Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1058-65 [9351603.001]
  • [Cites] ASAIO J. 1997 Sep-Oct;43(5):M821-4 [9360161.001]
  • [Cites] Pediatr Pulmonol Suppl. 1997;16:51 [9443195.001]
  • [Cites] Ann Thorac Surg. 2000 Feb;69(2):351-6 [10735662.001]
  • [Cites] N Engl J Med. 2000 May 4;342(18):1301-8 [10793162.001]
  • [Cites] Intensive Care Med. 2000 Sep;26(9):1334-42 [11089761.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Mar;121(3):542-51 [11241090.001]
  • [Cites] Biol Neonate. 2001 Jul;80(1):74-80 [11474154.001]
  • [Cites] Ann Thorac Surg. 2001 Sep;72(3):899-904 [11570380.001]
  • [Cites] ASAIO J. 2001 Sep-Oct;47(5):486-91 [11575823.001]
  • [Cites] J Pediatr. 2001 Oct;139(4):478-86 [11598592.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Oct 1;164(7):1154-60 [11673202.001]
  • [Cites] Pediatr Res. 2002 Sep;52(3):387-92 [12193673.001]
  • [Cites] Ann Thorac Surg. 2002 Oct;74(4):1011-6; discussion 1017-8 [12400738.001]
  • [Cites] Pediatr Res. 2003 Feb;53(2):245-53 [12538782.001]
  • [Cites] Crit Care Med. 2003 Mar;31(3):885-92 [12627001.001]
  • [Cites] Eur Respir J Suppl. 2003 Aug;42:2s-9s [12945994.001]
  • [Cites] Respir Physiol Neurobiol. 2004 Jan 15;139(2):167-77 [15123000.001]
  • [Cites] Anesthesiology. 2004 Sep;101(3):722-8 [15329597.001]
  • [Cites] Minerva Pediatr. 2004 Aug;56(4):373-80 [15457135.001]
  • [Cites] JAMA. 1986 Aug 15;256(7):881-6 [3090285.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Jan;157(1):294-323 [9445314.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1332-47 [9563759.001]
  • [Cites] J Pharmacol Toxicol Methods. 1998 Aug;40(2):101-7 [10100499.001]
  • [Cites] Clin Chest Med. 2006 Dec;27(4):601-13; abstract viii [17085249.001]
  • [Cites] Clin Physiol Funct Imaging. 2007 Mar;27(2):67-90 [17309528.001]
  • [Cites] J Pediatr. 2007 Jul;151(1):10-5 [17586183.001]
  • [Cites] Neonatology. 2007;92(1):19-25 [17596733.001]
  • [Cites] Intensive Care Med. 2007 Aug;33(8):1423-33 [17563879.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Sep 15;176(6):575-81 [17641159.001]
  • [Cites] Crit Care Med. 2008 Jan;36(1):183-7 [18090370.001]
  • [Cites] Int J Mol Med. 2008 Apr;21(4):513-9 [18360698.001]
  • [Cites] J Perinatol. 2008 May;28 Suppl 1:S47-56 [18446178.001]
  • [Cites] Ann Thorac Surg. 2008 Aug;86(2):410-7; discussion 417 [18640306.001]
  • [Cites] BMC Pulm Med. 2008;8:10 [18625067.001]
  • [Cites] J Pediatr Surg. 1992 Jan;27(1):40-3 [1552442.001]
  • (PMID = 19687779.001).
  • [ISSN] 1530-0447
  • [Journal-full-title] Pediatric research
  • [ISO-abbreviation] Pediatr. Res.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD046513-02; United States / NICHD NIH HHS / HD / K08 HD046513; United States / NHLBI NIH HHS / HL / R01 HL092906; United States / NICHD NIH HHS / HD / K08 HD046513-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS149422; NLM/ PMC2796292
  •  go-up   go-down


13. Wang YH, Huang TS, Liang HW, Su TC, Chen SY, Wang TD: Fasting serum levels of adiponectin, ghrelin, and leptin in men with spinal cord injury. Arch Phys Med Rehabil; 2005 Oct;86(10):1964-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fasting serum levels of adiponectin, ghrelin, and leptin in men with spinal cord injury.
  • OBJECTIVES: To measure serum levels of adiponectin, ghrelin, and leptin in men with spinal cord injury (SCI) and to investigate possible correlations between these serum levels and various factors, such as body mass index (BMI), age, injury level, and duration of injury.
  • MAIN OUTCOME MEASURES: Serum levels of adiponectin, ghrelin, and leptin and BMI.
  • RESULTS: Serum leptin levels in subjects with SCI (mean, 7.0+/-0.5 mg/mL) [corrected] were significantly higher than those in able-bodied controls (mean, 4.7+/-0.6 mg/mL) [corrected] (P<.01).
  • The group with tetraplegia had higher serum leptin levels than the group with paraplegia, but this did not reach a statistically significant level (8.2+/-1.1 ng/mL vs 6.4+/-0.5 mg/mL [corrected] P=.097).
  • There were significant differences in serum leptin levels among the 3 groups by 1-way analysis of variance (P=.008).
  • Serum adiponectin levels in subjects with SCI (7.1+/-0.5 mg/mL) [corrected] were higher than those in able-bodied controls (5.6+/-0.5 mg/mL) [corrected] but this was not statistically significant (P=.08).
  • In contrast, serum levels of ghrelin in subjects with SCI (302.0+/-17.5 pg/mL) were similar to those in the controls (264.0+/-27.0 pg/mL) (P=.24).
  • Serum leptin levels correlated positively with BMI (SCI, r=.698, P<.001; controls, r=.782, P<.001), whereas serum adiponectin (SCI, r=-.527, P<.001; controls, r=-.315, P=.057) and ghrelin (SCI, r=-.368, P<.001; controls, r=-.447, P=.006) levels correlated negatively with the BMI in both subjects with SCI and controls.
  • CONCLUSIONS: Men with SCI have significantly higher serum leptin levels than able-bodied controls, and serum leptin levels correlated with the degree of neurologic deficit.
  • Men with SCI had a tendency toward higher serum adiponectin level than able-bodied controls.
  • Serum levels of ghrelin in men with SCI were similar to those of controls.
  • [MeSH-major] Leptin / blood. Peptide Hormones / blood. Spinal Cord Injuries / blood

  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arch Phys Med Rehabil. 2007 May;88(5):688
  • (PMID = 16213239.001).
  • [ISSN] 0003-9993
  • [Journal-full-title] Archives of physical medicine and rehabilitation
  • [ISO-abbreviation] Arch Phys Med Rehabil
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ghrelin; 0 / Leptin; 0 / Peptide Hormones
  •  go-up   go-down


14. Sabattini E, Orduz R, Campidelli C, Zinzani PL, Callea V, Zupo S, Cutrona G, Morabito F, Ferrarini M, Pileri S: B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens. J Clin Pathol; 2007 Jun;60(6):627-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens.
  • BACKGROUND: The course of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) partly depends on the mutational status of the variable region of immunoglobulin heavy chain genes (IgV(H)), which defines two subgroups of tumours: mutated and unmutated.
  • METHODS: 26 patients with CLL/SLL detected on BMB and with known IgV(H) mutational status were selected.
  • ZAP70 was determined by immunohistochemistry (IHC) comparing three antibodies from different sources (Upstate, Cell Signaling, Santa Cruz, California, USA) and two different methods (APAAP and EnVision(+)).
  • RESULTS: ZAP70 determination on BMB specimens turned out to be easily feasible with routine procedures with reagents from Upstate and Cell Signaling.
  • CONCLUSIONS: The study confirms the role of ZAP70 as a possible surrogate of mutational status and emphasises its application in routine diagnostics; it discloses a small subset of discordant cases (mutated/ZAP70 weakly positive) that clinically cluster with the more favourable forms.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. ZAP-70 Protein-Tyrosine Kinase / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Hematol. 2000 Jul;7(4):223-34 [10882178.001]
  • [Cites] Am J Clin Pathol. 1996 Oct;106(4):457-61 [8853032.001]
  • [Cites] Blood. 2001 Jul 1;98(1):181-6 [11418478.001]
  • [Cites] Leuk Res. 2001 Nov;25(11):927-32 [11597727.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2633-9 [11675331.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1625-38 [11733577.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1639-47 [11733578.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1023-9 [11807008.001]
  • [Cites] Br J Haematol. 2002 Jan;116(1):142-50 [11841407.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2262-4 [11877310.001]
  • [Cites] Ann Hematol. 2002 Jun;81(6):299-303 [12107557.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1177-84 [12149195.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1410-6 [12149225.001]
  • [Cites] Eur J Haematol. 2003 Jan;70(1):53-9 [12631259.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4944-51 [12595313.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:153-75 [14633781.001]
  • [Cites] Lancet. 2004 Jan 10;363(9403):105-11 [14726163.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):455-62 [15160906.001]
  • [Cites] Mod Pathol. 2004 Aug;17(8):954-61 [15133473.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Aug;153(1):69-72 [15325098.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Aug;18(4):795-805, vii [15325699.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Aug;18(4):807-26, viii [15325700.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Aug;18(4):827-48, viii [15325701.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]
  • [Cites] Leuk Lymphoma. 2004 Oct;45(10):2037-45 [15370248.001]
  • [Cites] J Histochem Cytochem. 1984 Feb;32(2):219-29 [6198355.001]
  • [Cites] J Clin Invest. 1998 Oct 15;102(8):1515-25 [9788964.001]
  • [Cites] J Clin Pathol. 1998 Jul;51(7):506-11 [9797726.001]
  • [Cites] Br J Haematol. 1999 May;105(2):394-401 [10233410.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] J Pathol. 2005 Mar;205(4):507-13 [15685592.001]
  • [Cites] J Clin Invest. 2005 Mar;115(3):755-64 [15711642.001]
  • [Cites] Leukemia. 2005 May;19(5):750-8 [15759031.001]
  • [Cites] Leukemia. 2005 Jun;19(6):1018-24 [15800671.001]
  • [Cites] Cell. 1992 Nov 13;71(4):649-62 [1423621.001]
  • [Cites] N Engl J Med. 1995 Oct 19;333(16):1052-7 [7675049.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • (PMID = 16916999.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase
  • [Other-IDs] NLM/ PMC1955054
  •  go-up   go-down


15. Alexander C, Cochran CJ, Gallicchio L, Miller SR, Flaws JA, Zacur H: Serum leptin levels, hormone levels, and hot flashes in midlife women. Fertil Steril; 2010 Aug;94(3):1037-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum leptin levels, hormone levels, and hot flashes in midlife women.
  • OBJECTIVE: To examine the associations between serum leptin levels, sex steroid hormone levels, and hot flashes in normal weight and obese midlife women.
  • MAIN OUTCOME MEASURE(S): Serum leptin and sex steroid hormone levels.
  • RESULT(S): Correlation and regression models were performed to examine associations between leptin levels, hormone levels, and hot flashes.
  • Leptin levels were associated with BMI, with "ever experiencing hot flashes" (questionnaire), with hot flashes within the last 30 days, and with duration of hot flashes (>1 year, P=.03).
  • Leptin was positively correlated with testosterone, free testosterone index, and free estrogen index and inversely associated with levels of sex hormone-binding globulin.
  • In women with a body mass index>or=30 kg/m2, leptin levels no longer correlated with testosterone levels.
  • CONCLUSION(S): Serum leptin levels are associated with the occurrence and duration of hot flashes in midlife women; however, no correlation was found between leptin and serum estradiol.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
  • [Cites] J Clin Endocrinol Metab. 1995 Aug;80(8):2354-8 [7629229.001]
  • [Cites] Am J Obstet Gynecol. 1993 Mar;168(3 Pt 1):772-80 [8456878.001]
  • [Cites] N Engl J Med. 1996 Feb 1;334(5):292-5 [8532024.001]
  • [Cites] Maturitas. 1996 Apr;23(3):301-5 [8794424.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):318-21 [8989281.001]
  • [Cites] Endocrinology. 1997 Feb;138(2):847-50 [9003026.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Aug;104(8):923-33 [9255084.001]
  • [Cites] Endocrinology. 1998 Feb;139(2):551-8 [9449624.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):453-9 [9467557.001]
  • [Cites] Clin Exp Obstet Gynecol. 1997;24(3):163-6 [9478308.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2541-6 [9482922.001]
  • [Cites] Menopause. 1998 Spring;5(1):43-51 [9689194.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):428-34 [10022396.001]
  • [Cites] Ginekol Pol. 1999 Jan;70(1):1-7 [10349800.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7047-52 [10359836.001]
  • [Cites] Endocrine. 1999 Feb;10(1):19-23 [10403567.001]
  • [Cites] Semin Reprod Med. 2005 May;23(2):117-25 [15852197.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Jul;289(1):E166-71 [15741239.001]
  • [Cites] Am J Obstet Gynecol. 2005 Aug;193(2):347-51 [16098853.001]
  • [Cites] Am J Obstet Gynecol. 2005 Oct;193(4):1353-60 [16202725.001]
  • [Cites] Alcohol Alcohol. 2005 Nov-Dec;40(6):563-8 [16087658.001]
  • [Cites] Maturitas. 2006 Jan 20;53(2):217-25 [15913927.001]
  • [Cites] Maturitas. 2006 Jan 20;53(2):133-43 [16368467.001]
  • [Cites] Obstet Gynecol. 1994 Jul;84(1):29-34 [8008318.001]
  • [Cites] Maturitas. 2006 Jun 20;54(3):260-9 [16423474.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Jul;65(1):125-31 [16817831.001]
  • [Cites] Climacteric. 2007 Feb;10(1):27-37 [17364602.001]
  • [Cites] Fertil Steril. 2007 Jun;87(6):1483-6 [17276432.001]
  • [Cites] Obesity (Silver Spring). 2007 Sep;15(9):2217-24 [17890489.001]
  • [Cites] Am J Epidemiol. 2008 Jan 1;167(1):78-85 [17881385.001]
  • [Cites] Maturitas. 2008 Feb 20;59(2):149-57 [18280066.001]
  • [Cites] Fertil Steril. 2008 Oct;90(4):1161-8 [18304548.001]
  • [Cites] Int J Biometeorol. 1999 Nov;43(3):99-109 [10639901.001]
  • [Cites] J Womens Health Gend Based Med. 2001 Jan-Feb;10(1):67-76 [11224946.001]
  • [Cites] Am J Hum Biol. 2001 Jul-Aug;13(4):453-64 [11400216.001]
  • [Cites] Obstet Gynecol. 2001 Sep;98(3):391-7 [11530118.001]
  • [Cites] Maturitas. 2002 Jan 30;41(1):69-77 [11809345.001]
  • [Cites] J Pediatr Endocrinol Metab. 2001;14 Suppl 6:1417-29 [11837495.001]
  • [Cites] Atherosclerosis. 2002 Apr;161(2):455-62 [11888531.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4522-7 [12364429.001]
  • [Cites] Obstet Gynecol. 2003 Feb;101(2):264-72 [12576249.001]
  • [Cites] Am J Epidemiol. 2004 Jun 15;159(12):1189-99 [15191936.001]
  • [Cites] Endocrinology. 2004 Jul;145(7):3115-21 [15059958.001]
  • [Cites] J Gen Intern Med. 2004 Jul;19(7):740-6 [15209587.001]
  • [Cites] Clin Endocrinol (Oxf). 1985 Mar;22(3):293-312 [3884189.001]
  • [Cites] Ann Clin Biochem. 1985 Sep;22 ( Pt 5):489-97 [4062218.001]
  • [Cites] J Clin Endocrinol Metab. 1987 Apr;64(4):723-9 [3818901.001]
  • [Cites] Int J Obes. 1989;13(1):1-9 [2703288.001]
  • [Cites] Metabolism. 1991 Jan;40(1):101-4 [1984562.001]
  • [Cites] Nat Med. 1995 Nov;1(11):1155-61 [7584987.001]
  • (PMID = 19476935.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / R01 AG018400-02; United States / NIA NIH HHS / AG / AG18400; United States / NIA NIH HHS / AG / R01 AG018400-03; United States / NIA NIH HHS / AG / R01 AG018400-05A2; United States / NIA NIH HHS / AG / R01 AG018400-01A1; United States / NIA NIH HHS / AG / R01 AG018400-06; United States / NIA NIH HHS / AG / R01 AG018400; United States / NIA NIH HHS / AG / R01 AG018400-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones; 0 / Leptin
  • [Other-IDs] NLM/ NIHMS109122; NLM/ PMC3939020
  •  go-up   go-down


16. Kramer CK, von Mühlen D, Barrett-Connor E: Does leptin predict incident hypertension in older adults? Clin Endocrinol (Oxf); 2010 Aug;73(2):201-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does leptin predict incident hypertension in older adults?
  • OBJECTIVE: Leptin is associated with blood pressure (BP) in experimental and cross-sectional studies, but only one previous prospective study of middle-aged men has reported the association between leptin and incident hypertension.
  • We examined the association of leptin levels with incident hypertension in a population-based study of older men and women.
  • POPULATION: Participants were 602 community-dwelling older adults with normal baseline BP levels who attended a research clinic visit between 1984 and 1987 and again 4.4 years later (mean age was 66.2 +/- 11.4; 60.6% were men; mean body mass index (BMI) 24.9 +/- 3.4 kg/m(2)).
  • Leptin was measured by radioimmunoassay.
  • Baseline serum leptin levels were higher in participants who developed hypertension compared to persistent normotensives [median (25th-75th range)] [8.8(5-16) vs 7(4-11) ng/ml, P = 0.002].
  • In logistic regression models, leptin (log-transformed) predicted incident hypertension before and after adjustments for baseline age, BMI, systolic BP, total cholesterol, medications, and previous cardiovascular disease (OR 1.75 95% CI 1.17-2.61, P = 0.006).
  • CONCLUSION: Higher leptin levels were independently associated with increased odds of incident hypertension in older adults.

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hypertension. 2009 Mar;53(3):473-9 [19204185.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Oct;93(10):3922-6 [18682500.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Apr;94(4):1137-44 [19174500.001]
  • [Cites] Am J Hypertens. 2009 May;22(5):577-80 [19229195.001]
  • [Cites] Hypertension. 2009 Jun;53(6):965-72 [19398660.001]
  • [Cites] J Vasc Res. 2009;46(6):609-17 [19571581.001]
  • [Cites] Diabetes Care. 2000 Jan;23(1):57-63 [10857969.001]
  • [Cites] Hypertens Res. 2000 Jul;23(4):303-10 [10912765.001]
  • [Cites] Int J Obes Relat Metab Disord. 2001 Jan;25(1):121-5 [11244467.001]
  • [Cites] Metabolism. 2001 Mar;50(3):325-9 [11230786.001]
  • [Cites] Clin Exp Hypertens. 2001 May;23(4):357-68 [11349826.001]
  • [Cites] J Neuroendocrinol. 2001 Oct;13(10):913-21 [11679060.001]
  • [Cites] J Clin Invest. 2002 Oct;110(8):1093-103 [12393845.001]
  • [Cites] Obes Res. 2003 Jan;11(1):160-6 [12529499.001]
  • [Cites] JAMA. 2003 May 21;289(19):2560-72 [12748199.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4823-31 [14557461.001]
  • [Cites] Nephron. 1976;16(1):31-41 [1244564.001]
  • [Cites] Prev Med. 1976 Jun;5(2):207-15 [935073.001]
  • [Cites] Am J Epidemiol. 1980 Jun;111(6):705-12 [7386445.001]
  • [Cites] Hypertension. 1997 Sep;30(3 Pt 2):619-23 [9322991.001]
  • [Cites] Hypertension. 1998 Jan;31(1 Pt 2):409-14 [9453337.001]
  • [Cites] Eur J Pharmacol. 2005 Aug 22;518(2-3):175-81 [16054621.001]
  • [Cites] J Hypertens. 2006 May;24(5):789-801 [16612235.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Feb;92(2):532-41 [17118991.001]
  • [Cites] Am J Clin Nutr. 2009 Mar;89(3):991S-997S [19176740.001]
  • (PMID = 20148909.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / AG028507-03; United States / NIDDK NIH HHS / DK / R01 DK031801-15; United States / NIA NIH HHS / AG / R01 AG007181-12; United States / NIA NIH HHS / AG / R01 AG007181-13S1; United States / NIA NIH HHS / AG / AG007181-13S1; United States / NIA NIH HHS / AG / R01 AG028507-02; United States / NIA NIH HHS / AG / R01 AG007181; United States / NIA NIH HHS / AG / AG07181; United States / NIDDK NIH HHS / DK / R01 DK031801; United States / NIA NIH HHS / AG / AG007181-13; United States / NIA NIH HHS / AG / R01 AG007181-13; United States / NIDDK NIH HHS / DK / R01 DK031801-16; United States / NIDDK NIH HHS / DK / DK31801; United States / NIA NIH HHS / AG / R01 AG028507-03; United States / NIA NIH HHS / AG / AG028507-02; United States / NIA NIH HHS / AG / AG007181-12; United States / NIA NIH HHS / AG / R01 AG007181-14; United States / NIA NIH HHS / AG / R37 AG007181; United States / NIA NIH HHS / AG / R01 AG028507; United States / NIA NIH HHS / AG / AG028507
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Leptin
  • [Other-IDs] NLM/ NIHMS175266; NLM/ PMC2891171
  •  go-up   go-down


17. Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriguez TR, de Matias JM, Martin J, Dessein PH, Llorca J: Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis. Clin Exp Rheumatol; 2009 Mar-Apr;27(2):222-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis.
  • OBJECTIVE: The adipocytokine leptin regulates weight centrally and participates in the regulation of the immune and inflammatory responses.
  • In the present study we investigated whether inflammation, obesity or both of these characteristics are potential determinants of circulating leptin concentrations in a group of RA patients on periodical treatment with the TNF-alpha-blocker-infliximab due to severe disease.
  • We also assessed whether the infusion of infliximab may alter circulating leptin concentrations in patients with severe RA.
  • Serum leptin levels were determined immediately prior to and after infliximab infusion.
  • RESULTS: There was a positive correlation between body mass index of RA patients and baseline serum level of leptin (rho=0.665, p<0.001).
  • Apart from a significant correlation with VCAM-1 (rho=0.349, p=0.04), no significant correlations between baseline leptin levels and the age at the time of the study or at the onset of the disease, disease duration, ESR and CRP levels, DAS28, lipids, insulin sensitivity, adhesion molecules, resistin, adiponectin, ghrelin or the cumulative prednisone dose at the time of the study were found.
  • Leptin levels did not change upon infliximab infusion (p=0.48).
  • CONCLUSION: In RA patients on TNF-alpha blocker treatment, circulating leptin levels are unrelated to disease activity but constitute a manifestation of adiposity.
  • The beneficial effect of anti-TNF-alpha therapy on cardiovascular mortality in RA does not seem to be mediated by reduction in serum levels of leptin.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Arthritis, Rheumatoid / blood. Arthritis, Rheumatoid / drug therapy. Leptin / blood. Obesity / blood. Tumor Necrosis Factor-alpha / antagonists & inhibitors


18. Bourdon C, Hojna S, Jordan M, Bérubé J, Kren V, Pravenec M, Liu P, Arab S, Pausová Z: Genetic locus on rat chromosome 20 regulates diet-induced adipocyte hypertrophy: a microarray gene expression study. Physiol Genomics; 2009 Jun 10;38(1):63-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In response to HFD, body weight, fat pad weights, adipocyte size, and serum leptin levels increased significantly more in SHR.1N than SHR.
  • Microarray gene expression profiles [Affymetrix, 15,923 genes and expressed sequence tags (ESTs)] showed that multiple genes of molecular pathways involved in lipogenesis were downregulated to a similar level in both strains, whereas genes involved in fatty acid oxidation and energy dissipation were upregulated less in SHR.1N than SHR.

  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hypertension. 2000 Jul;36(1):14-9 [10904006.001]
  • [Cites] Nature. 2008 Aug 21;454(7207):961-7 [18719582.001]
  • [Cites] Cell. 2001 Sep 7;106(5):563-73 [11551504.001]
  • [Cites] JAMA. 2002 Jan 16;287(3):356-9 [11790215.001]
  • [Cites] Diabetes. 2002 Jun;51(6):1876-83 [12031976.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] JAMA. 2003 Jan 1;289(1):76-9 [12503980.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):11888-96 [12529376.001]
  • [Cites] Cell. 2003 Apr 18;113(2):159-70 [12705865.001]
  • [Cites] Hypertension. 2003 May;41(5):1047-55 [12654711.001]
  • [Cites] J Clin Invest. 2003 Dec;112(12):1796-808 [14679176.001]
  • [Cites] Physiol Rev. 2004 Jan;84(1):277-359 [14715917.001]
  • [Cites] Science. 2004 May 28;304(5675):1301-5 [15166374.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2004 Jul;287(1):R112-9 [15001430.001]
  • [Cites] Nature. 2004 Sep 9;431(7005):200-5 [15306821.001]
  • [Cites] Cell. 1982 May;29(1):53-60 [7105184.001]
  • [Cites] Biochem J. 1988 Feb 1;249(3):765-9 [3355496.001]
  • [Cites] Mol Endocrinol. 1988 May;2(5):395-403 [2901666.001]
  • [Cites] J Hypertens. 1989 Mar;7(3):217-21 [2708818.001]
  • [Cites] Science. 1993 Jan 1;259(5091):87-91 [7678183.001]
  • [Cites] J Clin Invest. 1995 Jul;96(1):158-62 [7615786.001]
  • [Cites] J Clin Invest. 1995 Dec;96(6):2914-23 [8675663.001]
  • [Cites] Diabetes. 1997 Sep;46(9):1468-72 [9287048.001]
  • [Cites] Eur J Clin Invest. 1998 Jan;28(1):59-66 [9502188.001]
  • [Cites] J Clin Invest. 1998 Jul 15;102(2):412-20 [9664083.001]
  • [Cites] J Clin Invest. 2004 Dec;114(12):1752-61 [15599400.001]
  • [Cites] J Biol Chem. 2005 Apr 22;280(16):15493-6 [15746100.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Jul;73(1):31-4 [15936931.001]
  • [Cites] Biol Cell. 2005 Jul;97(7):479-86 [15966863.001]
  • [Cites] FASEB J. 2005 Sep;19(11):1567-9 [16009704.001]
  • [Cites] Am J Hypertens. 2005 Oct;18(10):1271-5 [16202847.001]
  • [Cites] Annu Rev Cell Dev Biol. 2005;21:247-69 [16212495.001]
  • [Cites] Obes Res. 2005 Dec;13(12):2122-31 [16421346.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2006 Mar;15(2):173-8 [16481885.001]
  • [Cites] Cell Metab. 2006 Mar;3(3):223-9 [16517409.001]
  • [Cites] Exp Hematol. 2006 Aug;34(8):1106-14 [16863918.001]
  • [Cites] Biochem J. 2006 Sep 1;398(2):153-68 [16898874.001]
  • [Cites] Nature. 2006 Dec 14;444(7121):847-53 [17167472.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4401-6 [17360536.001]
  • [Cites] Int J Obes (Lond). 2007 Jun;31(6):1004-13 [17130847.001]
  • [Cites] J Lipid Res. 2007 Dec;48(12):2751-61 [17872589.001]
  • [Cites] FEBS Lett. 2008 Jan 9;582(1):117-31 [18037376.001]
  • [Cites] Mol Endocrinol. 2008 May;22(5):1023-31 [18202144.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2008 Aug;295(2):E356-67 [18492779.001]
  • [Cites] Curr Hypertens Rep. 1999 Feb-Mar;1(1):42-50 [10981041.001]
  • (PMID = 19383622.001).
  • [ISSN] 1531-2267
  • [Journal-full-title] Physiological genomics
  • [ISO-abbreviation] Physiol. Genomics
  • [Language] ENG
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Leptin
  • [Other-IDs] NLM/ PMC2696153
  •  go-up   go-down


19. Okulicz JF, Lloyd BA, Krause JO, Conger NG: Mycobacterium tuberculosis infection of a presumed Charcot joint. South Med J; 2005 Sep;98(9):924-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 65-year-old male with peripheral neuropathy and small lymphocytic lymphoma presented with erythema and edema of the left foot.
  • [MeSH-major] Arthropathy, Neurogenic / diagnosis. Diagnostic Errors. Mycobacterium tuberculosis / isolation & purification. Tuberculosis, Osteoarticular / diagnosis. Tuberculosis, Osteoarticular / microbiology
  • [MeSH-minor] Aged. Antitubercular Agents / therapeutic use. Drug Therapy, Combination. Foot Ulcer / drug therapy. Foot Ulcer / microbiology. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Male. Peripheral Nervous System Diseases / complications. Synovial Fluid / microbiology

  • Genetic Alliance. consumer health - Tuberculosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217986.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


20. Horoz M, Aslan M, Koylu AO, Bolukbas C, Bolukbas FF, Selek S, Erel O: The relationship between leptin level and oxidative status parameters in hemodialysis patients. Artif Organs; 2009 Jan;33(1):81-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship between leptin level and oxidative status parameters in hemodialysis patients.
  • Both serum leptin level and oxidative stress are increased in hemodialysis (HD) patients.
  • In the present study, we aimed to investigate whether there is association between oxidative status and leptin level in HD patients.
  • Serum leptin level, total peroxide (TP) level, total antioxidant capacity (TAC), and oxidative stress index (OSI) were determined.
  • Serum leptin level, TP level, and OSI were significantly higher in HD patients than controls (all P < 0.001) while TAC was lower (P < 0.001).
  • In HD patients, serum leptin level was significantly correlated with TP level and OSI (r = 0.372, P < 0.001 and r = 0.409, P < 0.001, respectively).
  • The correlation of serum leptin level with TP level and OSI remained statistically significant after adjusting for age, gender, and body-fat percentage (r = 0.446, P < 0.001 and r = 0.463, P < 0.001, respectively).
  • Hyperleptinemia seems to be associated with increased oxidative stress in HD patients, and this association may provide better understanding about the disorders related to either elevated serum leptin levels and/or increased oxidative stress in HD patients.
  • [MeSH-major] Leptin / blood. Oxidative Stress. Renal Dialysis

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178446.001).
  • [ISSN] 1525-1594
  • [Journal-full-title] Artificial organs
  • [ISO-abbreviation] Artif Organs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Leptin; 0 / Peroxides
  •  go-up   go-down


21. Ling JY, Sun XF, Yan SL, He LR, Zhen ZJ, Xia Y: [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases]. Ai Zheng; 2007 Apr;26(4):418-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
  • BACKGROUND & OBJECTIVE: Diagnosis of lymphocytic leukemia and non-Hodgkin's lymphoma (NHL) is based on bone marrow morphology.
  • Immunophenotyping will make diagnosis more precise through analyzing the origin and differentiation status of tumor, which is necessary for treatment and prognosis prediction.
  • This study was to analyze the immunophenotypic characteristics of lymphocytic leukemia and NHL with bone marrow involvement using flow cytometry (FCM).
  • METHODS: Bone marrow specimens from 112 patients with lymphocytic leukemia or NHL with bone marrow involvement were detected by FCM using antibodies of T, B and myeloid cell series.
  • RESULTS: In 45 cases of precursor B lymphoblastic leukemia/lymphoma (B-ALL/LBL), the antigens were mainly CD19, CD10, TdT, CD34, HLA-DR, and CD20.
  • In 32 cases of precursor T lymphoblastic leukemia/lymphoma (T-ALL/LBL), the antigens were mainly CD7, CD5, cytoplasmic (Cy)CD3, TdT, CD34, surface CD3 (sCD3), and HLA-DR.
  • Among the 35 cases of mature B-cell malignancies, 17 cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) mainly expressed CD19, CD20, CD5, HLA-DR, with coexpression of CD19 and CD5; 4 cases of diffuse large B-cell lymphoma (DLBCL) mainly expressed CD19, CD20, CD10, and HLA-DR; 3 cases of Burkitt's lymphoma (BL) mainly expressed CD19, CD10, CD20, and sIgM; 1 case of mantle cell lymphoma (MCL) expressed CD5, CD19, CD20, and HLA-DR.
  • Among the 10 mature T-cell malignancies, 5 cases of unspecialied peripheral T-cell lymphoma (PTCL) mainly expressed sCD3, CD5 and CD7, CD4 or CD8; 1 case of anaplastic large cell lymphoma (ALCL) expressed sCD3 and HLA-DR; 4 cases of NK/T-cell malignancies expressed CD56 and HLA-DR, CD4 or CD8 or CD7.
  • CONCLUSION: Multiparameter FCM can not only provide data of cell lineage and differentiation status but also detect phenotypic aberrancies, which is helpful for minimal residual disease detecting.
  • [MeSH-major] Antigens, CD / analysis. Bone Marrow / immunology. Immunophenotyping. Leukemia, Lymphoid / immunology. Lymphoma, Non-Hodgkin / immunology


22. Shabat S, Nyska M, Eintacht S, Lis M, Bogomolni A, Berner Y, Kestanbaum-Shainkin R: Serum leptin level in geriatric patients with hip fractures: possible correlation to biochemical parameters of bone remodeling. Arch Gerontol Geriatr; 2009 Mar-Apr;48(2):250-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum leptin level in geriatric patients with hip fractures: possible correlation to biochemical parameters of bone remodeling.
  • Since leptin was suggested to be involved in bone remodeling, its possible involvement in fracture formation/prevention was evaluated, by determination of serum leptin level in geriatric population with hip fracture, and evaluation the relationships with biochemical parameters of bone remodeling.
  • Serum leptin level of this total population distributed between 1 and 134ng/ml.
  • 40% of patients were in the normal range of our laboratory (10-40ng/ml), 40% had decreased leptin level (<10ng/ml) and 20% had higher leptin level (>40ng/ml).
  • No correlation was detected between serum leptin level and vitamin D-25(OH)D3, which was under normal range in 60% of the patients.
  • Leptin also did not correlate to ICTP level, which was high in 80% of the patients, suggesting an extensive bone resorption in this population.
  • Evaluation of leptin level in female versus male suggests that leptin level is higher in females than males also in this age (28.4ng/ml vs. 14.4ng/ml, p<0.001).
  • The higher leptin levels in women was accompanied by higher serum levels of glucose, albumin, Ca, cholesterol, Na and FT4.
  • Comparison of 50 patients with the lowest leptin levels (mean of 3.4ng/ml) to 50 patients with highest leptin levels (mean of 34ng/ml), did not indicate differences in both 25(OH)D3 and ICTP between these two populations in spite of the highly significant difference in leptin levels.
  • The high range of serum leptin concentration in these geriatric patients with hip fracture of both sexes, and the absence of any correlation between leptin and the tested parameters of bone resorption and Ca metabolism, teleopeptide type I collagen (ICTP) and 25(OH)D3, does not support a direct massive involvement of serum leptin in hip fracture of the very old population.
  • [MeSH-major] Bone Remodeling / physiology. Hip Fractures / blood. Leptin / blood
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers / blood. Calcifediol / blood. Case-Control Studies. Cohort Studies. Collagen Type I. Dihydroxycholecalciferols / blood. Female. Humans. Male. Peptide Fragments / blood. Peptides. Procollagen / blood. Sex Distribution

  • MedlinePlus Health Information. consumer health - Hip Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18359113.001).
  • [ISSN] 1872-6976
  • [Journal-full-title] Archives of gerontology and geriatrics
  • [ISO-abbreviation] Arch Gerontol Geriatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Collagen Type I; 0 / Dihydroxycholecalciferols; 0 / Leptin; 0 / Peptide Fragments; 0 / Peptides; 0 / Procollagen; 0 / collagen type I trimeric cross-linked peptide; P6YZ13C99Q / Calcifediol
  •  go-up   go-down


23. Thway K, Freeman A, Woodhouse CR, Fisher C: Epithelial-stromal tumor of seminal vesicle in a patient with chromophobe renal cell carcinoma and small lymphocytic lymphoma. Ann Diagn Pathol; 2008 Dec;12(6):433-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial-stromal tumor of seminal vesicle in a patient with chromophobe renal cell carcinoma and small lymphocytic lymphoma.
  • In addition, this was associated with 2 synchronous malignant neoplasms, chromophobe renal cell carcinoma and small lymphocytic lymphoma, both of which were detected incidentally after clinical presentation because of the seminal vesicle mass.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma, Renal Cell / diagnosis. Genital Neoplasms, Male / diagnosis. Kidney Neoplasms / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Neoplasms, Multiple Primary / diagnosis. Seminal Vesicles


24. Mao J, Yang T, Gu Z, Heird WC, Finegold MJ, Lee B, Wakil SJ: aP2-Cre-mediated inactivation of acetyl-CoA carboxylase 1 causes growth retardation and reduced lipid accumulation in adipose tissues. Proc Natl Acad Sci U S A; 2009 Oct 13;106(41):17576-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FACC1KO mice showed prenatal growth retardation; after weaning, however, their weight gain was comparable to that of wild-type (WT) mice on a normal diet.
  • In addition, there was about a 30% decrease in serum insulin-like growth factor I (IGF1), and while the serum leptin level was decreased by about 50%, it did not counteract the osteopenic effects of IGF1 on the bone.
  • Fatty acid analyses of mutant bone lipids revealed relatively higher levels of C18:2n-6 and C18:3n-3 and lower levels of their elongation C20 homologs than that of WT cohorts, leading to lower levels of C20 homologs and bone development.

  • MedlinePlus Health Information. consumer health - Growth Disorders.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1964 Feb;239:375-80 [14169133.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7088-92 [10359843.001]
  • [Cites] Expert Opin Ther Targets. 2005 Apr;9(2):267-81 [15934915.001]
  • [Cites] Cell Metab. 2005 Feb;1(2):107-19 [16054052.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12011-6 [16103361.001]
  • [Cites] Cell Mol Life Sci. 2005 Aug;62(16):1784-803 [15968460.001]
  • [Cites] Mol Cell Biol. 2006 Feb;26(3):1063-76 [16428458.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 30;103(22):8552-7 [16717184.001]
  • [Cites] J Bone Miner Res. 2006 Sep;21(9):1350-8 [16939393.001]
  • [Cites] Transgenic Res. 2006 Oct;15(5):647-53 [16952017.001]
  • [Cites] Endocrinology. 2006 Oct;147(10):4753-61 [16857753.001]
  • [Cites] Bioorg Med Chem Lett. 2007 Mar 15;17(6):1803-7 [17234407.001]
  • [Cites] Gastroenterology. 2007 May;132(6):2103-15 [17498506.001]
  • [Cites] Cell. 2007 Aug 10;130(3):456-69 [17693256.001]
  • [Cites] Nat Med. 2008 Mar;14(3):299-305 [18297084.001]
  • [Cites] Cell. 2000 Jan 21;100(2):197-207 [10660043.001]
  • [Cites] Annu Rev Physiol. 2000;62:413-37 [10845097.001]
  • [Cites] Endocr Rev. 2000 Aug;21(4):393-411 [10950158.001]
  • [Cites] Endocrinology. 2000 Dec;141(12):4436-41 [11108252.001]
  • [Cites] Dev Biol. 2001 Jan 1;229(1):141-62 [11133160.001]
  • [Cites] Prog Lipid Res. 2001 Jan-Mar;40(1-2):125-48 [11137570.001]
  • [Cites] Trends Endocrinol Metab. 2000 Oct;11(8):327-32 [10996528.001]
  • [Cites] Science. 2001 Mar 30;291(5513):2613-6 [11283375.001]
  • [Cites] Biochem J. 2001 Aug 15;358(Pt 1):127-35 [11485560.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):138-43 [11756679.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7515-20 [12810950.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15712-7 [14660788.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3258-63 [14978271.001]
  • [Cites] Methods Enzymol. 1975;35:59-65 [235706.001]
  • [Cites] J Biol Chem. 1983 Sep 25;258(18):11074-81 [6136512.001]
  • [Cites] Annu Rev Biochem. 1983;52:537-79 [6137188.001]
  • [Cites] J Biol Chem. 1985 May 25;260(10):6318-23 [2860106.001]
  • [Cites] J Biol Chem. 1988 May 5;263(13):6447-53 [2896193.001]
  • [Cites] Cell. 1993 Oct 8;75(1):73-82 [8402902.001]
  • [Cites] Genes Dev. 1993 Dec;7(12B):2609-17 [8276243.001]
  • [Cites] Nature. 1994 Dec 1;372(6505):425-32 [7984236.001]
  • [Cites] Gene. 1995 Mar 10;154(2):271-5 [7890176.001]
  • [Cites] Brain Res Dev Brain Res. 1997 Feb 20;98(2):197-203 [9051261.001]
  • [Cites] Annu Rev Nutr. 1997;17:77-99 [9240920.001]
  • [Cites] Nature. 1998 Oct 22;395(6704):763-70 [9796811.001]
  • [Cites] Genes Dev. 1999 Apr 15;13(8):1025-36 [10215629.001]
  • [Cites] J Nutr Biochem. 2004 Nov;15(11):651-6 [15590268.001]
  • (PMID = 19805143.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM063115; United States / NIGMS NIH HHS / GM / GM-63115
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.- / aminoglycoside N1-acetyltransferase; EC 6.4.1.2 / Acetyl-CoA Carboxylase
  • [Other-IDs] NLM/ PMC2762677
  •  go-up   go-down


25. Gogas H, Trakatelli M, Dessypris N, Terzidis A, Katsambas A, Chrousos GP, Petridou ET: Melanoma risk in association with serum leptin levels and lifestyle parameters: a case-control study. Ann Oncol; 2008 Feb;19(2):384-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma risk in association with serum leptin levels and lifestyle parameters: a case-control study.
  • BACKGROUND: Solar radiation has been identified as a principal factor for the causation of melanoma, whereas changing lifestyle patterns associated with obesity and diabetes might also contribute to the increasing incidence of the malignancy.
  • No study has investigated the role of leptin, a hormone whose levels increase in obesity and which has also been related to cancer.
  • Anthropometrical measures were also recorded and blood samples were obtained for determination of serum leptin levels.
  • RESULTS: An excess melanoma risk was observed for sun sensitive individuals and those with high circulating levels of leptin (OR: 1.56, 95% confidence interval 1.07-2.28, P = 0.02), after controlling for obesity indices, diabetes mellitus and education.
  • CONCLUSIONS: Melanoma risk was found to be positively associated with serum leptin levels and inversely with healthy lifestyle factors.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925285.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Leptin
  •  go-up   go-down


26. Rao SN, Gurumurthy GP, Gururajan P, Arumugam SB, Saibabu, Kirthivasan V, Cherian KM: Clinical and biochemical parameters in relation to serum leptin levels in South Indian children and adolescents. Indian J Pediatr; 2010 May;77(5):555-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and biochemical parameters in relation to serum leptin levels in South Indian children and adolescents.
  • OBJECTIVE: To investigate the relationship between serum leptin and lipid profile in South Indian School children and adolescents, and to evaluate the role of serum leptin in obese, overweight and congenital heart diseased children and adolescents; in South Indian population and its correlation with anthropometric and biochemical parameters.
  • Anthropometric variables, lipid profile, fasting serum glucose were analyzed by autoanalyser and serum leptin by ELISA.
  • RESULTS: Serum leptin levels were significantly elevated in obese and overweight children than in control children (36.88+/-18.60ng/mL, 20.64+/-11.18ng/mL vs 7.97+/-2.79ng/mL; p value <0.001), and decreased in congenital heart diseased children than in control children (6.20+/-4.23 ng/mL vs 7.97+/-2.79ng/mL; p value <0.005).
  • CONCLUSIONS: This study provides a good relationship between serum leptin levels and anthropometric and biochemical parameters, such as total cholesterol, triglycerides and LDL-cholesterol.
  • We observed negative correlation between serum leptin and fasting glucose levels and HDL-cholesterol levels were found to be non-significant among the groups.
  • Further studies with large sample size are needed to ascertain the relationship between serum leptin and lipid profile in different groups of children and adolescents.
  • [MeSH-major] Heart Defects, Congenital / blood. Leptin / blood. Lipids / blood. Obesity / blood. Overweight / blood

  • MedlinePlus Health Information. consumer health - Congenital Heart Defects.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1997 Aug 15;100(4):808-13 [9259579.001]
  • [Cites] J Clin Invest. 2000 May;105(9):1243-52 [10791999.001]
  • [Cites] Obes Res. 2003 Apr;11(4):532-40 [12690082.001]
  • [Cites] Eur J Clin Nutr. 2007 Jun;61(6):719-26 [17164827.001]
  • [Cites] Ann Intern Med. 1997 Jan 1;126(1):26-31 [8992920.001]
  • [Cites] Int J Cardiol. 2003 Nov;92(1):93-7 [14602223.001]
  • [Cites] Eur J Epidemiol. 2001;17(10):911-6 [12188009.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Nov;81(11):3909-13 [8923837.001]
  • [Cites] J Intern Med. 1999 Oct;246(4):409-18 [10583712.001]
  • [Cites] Obes Res. 2005 Aug;13(8):1476-84 [16129731.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2148-52 [9215286.001]
  • [Cites] Indian Pediatr. 2007 Apr;44(4):257-62 [17468520.001]
  • [Cites] Pediatrics. 2005 Apr;115(4):e500-3 [15741351.001]
  • [Cites] Indian J Pediatr. 2006 Jul;73(7):593-6 [16877853.001]
  • [Cites] Pediatrics. 1996 Aug;98(2 Pt 1):201-3 [8692618.001]
  • (PMID = 20401706.001).
  • [ISSN] 0973-7693
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Leptin; 0 / Lipids
  •  go-up   go-down


27. Dedeoğlu EN, Erenus M, Yörük P: Effects of hormone therapy and tibolone on body composition and serum leptin levels in postmenopausal women. Fertil Steril; 2009 Feb;91(2):425-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of hormone therapy and tibolone on body composition and serum leptin levels in postmenopausal women.
  • OBJECTIVE: To compare the changes in body composition and in leptin levels in postmenopausal women receiving hormone therapy (HT) or tibolone.
  • MAIN OUTCOME MEASURE(S): Anthropometric indices, leptin levels, tissue fat percentage, total fat, and lean mass measurements were performed at baseline and after 6 months.
  • RESULT(S): The serum leptin levels were in strong correlation with the total fat percentage and total fat mass at baseline.
  • Untreated women had weight gain and a gradual decrease in leptin levels.
  • Women receiving HT had significantly increased leptin levels.
  • Women in the tibolone group, however, had a significant decrease in leptin levels accompanied by decreased total fat mass, fat percentage, and increased total lean mass.
  • The changes in leptin levels were more pronounced in lean women.
  • CONCLUSION(S): Postmenopausal women tend to gain weight accompanied with a reduction in leptin concentrations.
  • Hormone therapy administration increases leptin levels while maintaining body weight and body fat distribution, whereas tibolone use decreases leptin levels, total fat percentage, and total fat mass.
  • [MeSH-major] Adiposity / drug effects. Estrogen Replacement Therapy. Estrogens, Conjugated (USP) / therapeutic use. Leptin / blood. Medroxyprogesterone Acetate / therapeutic use. Norpregnenes / therapeutic use. Postmenopause. Weight Gain / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18249383.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens, Conjugated (USP); 0 / Leptin; 0 / Norpregnenes; C2QI4IOI2G / Medroxyprogesterone Acetate; FF9X0205V2 / tibolone
  •  go-up   go-down


28. Li L, Gao Y, Zhang LL, He DL: Concomitant activation of the JAK/STAT3 and ERK1/2 signaling is involved in leptin-mediated proliferation of renal cell carcinoma Caki-2 cells. Cancer Biol Ther; 2008 Nov;7(11):1787-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant activation of the JAK/STAT3 and ERK1/2 signaling is involved in leptin-mediated proliferation of renal cell carcinoma Caki-2 cells.
  • Serum leptin levels are often elevated in obese people.
  • Leptin has been reported to act as a mitogenic agent and promote renal cancer cell proliferation, whereas the detailed mechanisms still remain to be elucidated.
  • The purpose of this study is to investigate the proliferation and mobility effects in leptin-treated Caki-2 renal cell carcinoma and analyze the alterations of leptin-inducible STAT3 pathways and mitogenic signaling ERK pathways.
  • Our results indicate the constitutive expression of leptin receptor could not be upregulated upon the stimulation of leptin in Caki-2 cells.
  • Leptin increases the proliferation and mobility capabilities of Caki-2 cells via upregulating the expression of both phosphor-ERK and phosphor-STAT3 and these two pathways could be partially abolished by inhibition of the activation of JAK-STAT3 and completely abrogated by inhibition of ERK1/2 pathways.
  • Our results also suggest that mitogenic actions of leptin are not the consequence of altered its receptor expression; whereas the cellular proliferation appears to be working through the cross-talking of JAK-STAT3 and ERK1/2 pathways in renal cell carcinoma caki-2 cells.
  • [MeSH-major] Carcinoma, Renal Cell / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Gene Expression Regulation. Janus Kinase 1 / metabolism. Leptin / metabolism. STAT3 Transcription Factor / metabolism
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation. Flow Cytometry. Humans. Kidney Neoplasms / metabolism. MAP Kinase Signaling System. Obesity / metabolism. Protein Kinase C / metabolism. Signal Transduction

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18787400.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin; 0 / STAT3 Transcription Factor; EC 2.7.10.2 / Janus Kinase 1; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


29. Farooqi IS, Wangensteen T, Collins S, Kimber W, Matarese G, Keogh JM, Lank E, Bottomley B, Lopez-Fernandez J, Ferraz-Amaro I, Dattani MT, Ercan O, Myhre AG, Retterstol L, Stanhope R, Edge JA, McKenzie S, Lessan N, Ghodsi M, De Rosa V, Perna F, Fontana S, Barroso I, Undlien DE, O'Rahilly S: Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med; 2007 Jan 18;356(3):237-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor.
  • BACKGROUND: A single family has been described in which obesity results from a mutation in the leptin-receptor gene (LEPR), but the prevalence of such mutations in severe, early-onset obesity has not been systematically examined.
  • Serum leptin levels were within the range predicted by the elevated fat mass in these subjects.
  • Their clinical features were less severe than those of subjects with congenital leptin deficiency.
  • Circulating levels of leptin were not disproportionately elevated, suggesting that serum leptin cannot be used as a marker for leptin-receptor deficiency.
  • Congenital leptin-receptor deficiency should be considered in the differential diagnosis in any child with hyperphagia and severe obesity in the absence of developmental delay or dysmorphism.
  • [MeSH-major] Metabolism, Inborn Errors / diagnosis. Metabolism, Inborn Errors / genetics. Obesity / genetics. Receptors, Cell Surface / deficiency. Receptors, Cell Surface / genetics
  • [MeSH-minor] Adult. Age of Onset. Basal Metabolism. Body Composition. Child. Diagnosis, Differential. Female. Genotype. Humans. Hyperphagia / blood. Hyperphagia / complications. Hyperphagia / genetics. Hypogonadism / blood. Hypogonadism / complications. Hypogonadism / genetics. Immunologic Deficiency Syndromes / blood. Immunologic Deficiency Syndromes / complications. Immunologic Deficiency Syndromes / genetics. Leptin / blood. Lymphocyte Count. Male. Mutation. Pedigree. Phenotype. Receptors, Leptin


30. Matheny M, Zhang Y, Shapiro A, Tümer N, Scarpace PJ: Central overexpression of leptin antagonist reduces wheel running and underscores importance of endogenous leptin receptor activity in energy homeostasis. Am J Physiol Regul Integr Comp Physiol; 2009 Nov;297(5):R1254-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central overexpression of leptin antagonist reduces wheel running and underscores importance of endogenous leptin receptor activity in energy homeostasis.
  • We used recombinant adeno-associated virus (rAAV)-mediated gene delivery to overexpress a mutant of rat leptin yielding a protein that acts as a neutral leptin receptor antagonist.
  • Leptin antagonist overexpression was confirmed by examination of mRNA levels in the hypothalamus.
  • The degree of antagonist overexpression was sufficient to partially block signal transducer and activator of transcription 3 (STAT3) phosphorylation due to administration of an acute submaximal dose of leptin.
  • In contrast, when leptin was overexpressed in the hypothalamus, WR activity was increased by greater than twofold.
  • At death, adiposity and serum leptin levels were greater in the antagonist group.
  • These data indicate that submaximal central leptin receptor blockade promotes obesity and diminishes WR activity.
  • These findings underscore the critical role of unrestrained leptin receptor activity in long-term energy homeostasis and suggest that even minor disruption of leptin receptor function can promote obesity.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Apr 6;404(6778):661-71 [10766253.001]
  • [Cites] J Clin Invest. 1995 Sep;96(3):1658-63 [7657836.001]
  • [Cites] J Clin Invest. 2000 Jun;105(12):1827-32 [10862798.001]
  • [Cites] Regul Pept. 2001 Jun 15;99(2-3):69-77 [11384767.001]
  • [Cites] Neuroscience. 2001;104(4):1111-7 [11457594.001]
  • [Cites] Neuropharmacology. 2002 Mar;42(4):548-61 [11955525.001]
  • [Cites] Obes Rev. 2000 Oct;1(2):87-94 [12119990.001]
  • [Cites] Endocrinology. 2002 Aug;143(8):3026-35 [12130569.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8878-83 [9238071.001]
  • [Cites] Am J Physiol. 1997 Jul;273(1 Pt 1):E226-30 [9252501.001]
  • [Cites] Diabetes. 1997 Nov;46(11):1782-5 [9356026.001]
  • [Cites] Nat Genet. 1998 Mar;18(3):213-5 [9500540.001]
  • [Cites] Endocrinology. 1998 Sep;139(9):3681-90 [9724018.001]
  • [Cites] Nature. 1998 Oct 22;395(6704):763-70 [9796811.001]
  • [Cites] J Biol Chem. 1999 Jun 18;274(25):17541-4 [10364187.001]
  • [Cites] Nat Biotechnol. 2004 Dec;22(12):1583-7 [15568020.001]
  • [Cites] Diabetologia. 2005 Jun;48(6):1075-83 [15864530.001]
  • [Cites] J Virol. 2006 Feb;80(4):1874-85 [16439543.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Feb;320(2):706-12 [17082312.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R868-74 [17023670.001]
  • [Cites] Front Biosci. 2007;12:3531-44 [17485319.001]
  • [Cites] Behav Brain Res. 2008 Mar 17;188(1):100-8 [18063139.001]
  • [Cites] Diabetes. 2008 Mar;57(3):614-22 [18086903.001]
  • [Cites] Endocrinology. 2008 Jun;149(6):3009-15 [18308842.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2008 Nov;295(5):R1370-5 [18703413.001]
  • [Cites] Exp Biol Med (Maywood). 2002 Sep;227(8):587-600 [12192100.001]
  • [Cites] Methods. 2002 Oct;28(2):158-67 [12413414.001]
  • [Cites] Expert Opin Investig Drugs. 2003 Mar;12(3):373-8 [12605561.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2003 Nov;285(5):R1011-20 [14557234.001]
  • [Cites] Obes Res. 2004 Jan;12(1):150-60 [14742854.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4531-6 [15070752.001]
  • [Cites] Metabolism. 1977 Apr;26(4):371-80 [846405.001]
  • [Cites] Q J Exp Physiol. 1987 Oct;72(4):549-59 [3423201.001]
  • [Cites] Science. 1995 Jul 28;269(5223):543-6 [7624777.001]
  • [Cites] Science. 1995 Jul 28;269(5223):546-9 [7624778.001]
  • [Cites] Annu Rev Physiol. 2000;62:413-37 [10845097.001]
  • (PMID = 19726711.001).
  • [ISSN] 1522-1490
  • [Journal-full-title] American journal of physiology. Regulatory, integrative and comparative physiology
  • [ISO-abbreviation] Am. J. Physiol. Regul. Integr. Comp. Physiol.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / AG-26159; United States / NIA NIH HHS / AG / P30-AG-028740,
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ion Channels; 0 / Leptin; 0 / Mitochondrial Proteins; 0 / RNA, Messenger; 0 / Receptors, Leptin; 0 / STAT3 Transcription Factor; 0 / Stat3 protein, rat; 0 / mitochondrial uncoupling protein
  • [Other-IDs] NLM/ PMC2777784
  •  go-up   go-down


31. Benetti-Pinto CL, Castro N, Grassiotto Oda R, Garmes HM: Leptin and adiponectin blood levels in women with premature ovarian failure and age- and weight-matched women with normal menstrual cycles. Menopause; 2010 Jan-Feb;17(1):174-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin and adiponectin blood levels in women with premature ovarian failure and age- and weight-matched women with normal menstrual cycles.
  • OBJECTIVE: The aim of this study was to evaluate leptin and adiponectin blood levels in women with premature ovarian failure (POF) and women with a normal menstrual cycle.
  • Serum leptin levels were significantly lower in G1 compared with G2 (8.8 +/- 12.2 and 12.2 +/- 9.7 ng/mL; P < 0.05).
  • Serum adiponectin levels were similar in both groups.
  • Leptin levels were positively correlated to weight (r = 0.38; P = 0.03) but were not correlated to BMI and age in women with POF (G1); in G2, they were positively correlated to BMI (r = 0.59; P = 0.0006), weight (r = 0.63; P = 0.0006), and age (r = 0.40; P = 0.02).
  • Adiponectin levels did not correlate to weight, BMI, or age in both groups.
  • CONCLUSIONS: These results suggest that gonadal function loss may decrease leptin circulating levels, independently from age and BMI.
  • [MeSH-major] Adiponectin / blood. Leptin / blood. Primary Ovarian Insufficiency / blood

  • Genetic Alliance. consumer health - premature ovarian failure.
  • MedlinePlus Health Information. consumer health - Premature Ovarian Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19609224.001).
  • [ISSN] 1530-0374
  • [Journal-full-title] Menopause (New York, N.Y.)
  • [ISO-abbreviation] Menopause
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Leptin
  •  go-up   go-down


32. Ruhlen RL, Howdeshell KL, Mao J, Taylor JA, Bronson FH, Newbold RR, Welshons WV, vom Saal FS: Low phytoestrogen levels in feed increase fetal serum estradiol resulting in the "fetal estrogenization syndrome" and obesity in CD-1 mice. Environ Health Perspect; 2008 Mar;116(3):322-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low phytoestrogen levels in feed increase fetal serum estradiol resulting in the "fetal estrogenization syndrome" and obesity in CD-1 mice.
  • RESULTS: In fetuses whose mothers consumed the low-phytoestrogen PMI 5K96 feed, we found a paradoxical significant elevation in endogenous serum estradiol, which was associated postnatally with adverse reproductive outcomes referred to as the "fetal estrogenization syndrome (FES)".
  • The low-phytoestrogen-fed males and females were lighter at birth, but, between weaning and adulthood, they became obese and developed abnormally high serum leptin levels; these males, but not females, showed impaired glucose regulation.

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2056-61 [9050904.001]
  • [Cites] Environ Health Perspect. 2003 Jun;111(8):994-1006 [12826473.001]
  • [Cites] Toxicol Ind Health. 1998 Jan-Apr;14(1-2):239-60 [9460178.001]
  • [Cites] Environ Health Perspect. 1998 Jul;106(7):369-73 [9637793.001]
  • [Cites] Epidemiol Rev. 1998;20(2):157-72 [9919436.001]
  • [Cites] Exp Biol Med (Maywood). 2004 Dec;229(11):1127-35 [15564439.001]
  • [Cites] J Nutr. 2005 May;135(5):1331-5 [15867335.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 10;102(19):7014-9 [15867144.001]
  • [Cites] Birth Defects Res A Clin Mol Teratol. 2005 Jul;73(7):478-80 [15959888.001]
  • [Cites] Environ Res. 2006 Jan;100(1):50-76 [16256977.001]
  • [Cites] Reprod Toxicol. 2006 Apr;21(3):307-12 [16257506.001]
  • [Cites] Endocrinology. 2006 Jun;147(6 Suppl):S56-69 [16690810.001]
  • [Cites] Lab Anim. 2007 Jan;41(1):1-18 [17234046.001]
  • [Cites] Environ Health Perspect. 2007 Jun;115(6):902-8 [17589598.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13056-61 [17670942.001]
  • [Cites] Environ Health Perspect. 2007 Oct;115(10):1467-73 [17938737.001]
  • [Cites] Environ Health Perspect. 2008 Mar;116(3):389-93 [18335108.001]
  • [Cites] Nature. 1999 Oct 21;401(6755):763-4 [10548101.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12729-34 [11070086.001]
  • [Cites] J Nutr. 2001 Feb;131(2):354S-60S [11160560.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4325-8 [11389053.001]
  • [Cites] Exp Biol Med (Maywood). 2001 Dec;226(11):978-81 [11743132.001]
  • [Cites] Comp Med. 2003 Dec;53(6):607-15 [14727808.001]
  • [Cites] Reprod Toxicol. 2004 May;18(3):399-406 [15082075.001]
  • [Cites] J Anim Sci. 1989 Jul;67(7):1824-40 [2670873.001]
  • [Cites] Biol Reprod. 1990 Nov;43(5):751-61 [2291911.001]
  • [Cites] J Vet Diagn Invest. 1990 Oct;2(4):268-73 [2151311.001]
  • [Cites] Endocrinology. 1992 Jun;130(6):3184-90 [1375894.001]
  • [Cites] Biol Reprod. 1992 Nov;47(5):723-9 [1477199.001]
  • [Cites] J Steroid Biochem Mol Biol. 1993 Feb;44(2):147-53 [8382517.001]
  • [Cites] Biol Reprod. 1995 Nov;53(5):1198-207 [8527526.001]
  • [Cites] Environ Health Perspect. 1995 Oct;103 Suppl 7:83-7 [8593881.001]
  • [Cites] Clin Chem. 1996 Jun;42(6 Pt 1):955-64 [8665689.001]
  • [Cites] Med Sci Monit. 2002 Dec;8(12):RA282-92 [12503048.001]
  • [Cites] Clin Chem. 1997 May;43(5):850; author reply 852 [9166244.001]
  • (PMID = 18335098.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES011283; United States / NIGMS NIH HHS / GM / T32 GM008396; United States / NIEHS NIH HHS / ES / ES11283
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin; 0 / Phytoestrogens; 4TI98Z838E / Estradiol
  • [Other-IDs] NLM/ PMC2265041
  • [Keywords] NOTNLM ; casein / estradiol / fat / glucose tolerance / leptin / metabolic syndrome / obesity / puberty / reproductive organs / soy
  •  go-up   go-down


33. Bhattacharya A, Rahman MM, McCarter R, O'Shea M, Fernandes G: Conjugated linoleic acid and chromium lower body weight and visceral fat mass in high-fat-diet-fed mice. Lipids; 2006 May;41(5):437-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This effect was accompanied by decreased serum leptin levels in CLA-fed and CLA + Cr-fed mice, and by higher energy expenditure (EE) and oxygen consumption (OC) in CLA + Cr-fed mice.
  • Serum levels of glucose, insulin, the pro-inflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6), as well as insulin resistance index (IRI), decreased with CLA, whereas CLA and Cr in combination had significant effects on insulin and IL-6 concentrations and IRI.
  • In summary, CLA + Cr decreased body weight and fat mass in high-fat-diet-fed mice, which may be associated with decreased leptin levels and higher EE and OC.
  • [MeSH-minor] Adiponectin / blood. Analysis of Variance. Animals. Dietary Fats / administration & dosage. Dietary Fats / pharmacology. Energy Metabolism / drug effects. Leptin / blood. Male. Mice. Mice, Inbred BALB C

  • MedlinePlus Health Information. consumer health - Body Weight.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obes Rev. 2005 Aug;6(3):247-58 [16045640.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 15;323(2):679-84 [15369804.001]
  • [Cites] Diabetes. 2000 Sep;49(9):1534-42 [10969838.001]
  • [Cites] Am J Clin Nutr. 2004 Oct;80(4):887-95 [15447895.001]
  • [Cites] Diabetes Res Clin Pract. 1996 Mar;31(1-3):27-35 [8792099.001]
  • [Cites] Lipids Health Dis. 2005 Jan 10;4:3 [15642120.001]
  • [Cites] Am J Clin Nutr. 2004 Jun;79(6 Suppl):1199S-1206S [15159257.001]
  • [Cites] Biosci Biotechnol Biochem. 2002 Apr;66(4):916-20 [12036077.001]
  • [Cites] JAMA. 2004 Jun 16;291(23):2847-50 [15199035.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Apr;27(4):522-9 [12664086.001]
  • [Cites] J Nutr Biochem. 2004 Nov;15(11):680-7 [15590272.001]
  • [Cites] Wei Sheng Yan Jiu. 2000 Nov;29(6):370-1 [12520958.001]
  • [Cites] J Biomed Mater Res. 1996 Dec;32(4):655-61 [8953156.001]
  • [Cites] Biochim Biophys Acta. 2002 Apr 15;1581(3):89-99 [12020636.001]
  • [Cites] J Lipid Res. 2002 Sep;43(9):1400-9 [12235171.001]
  • [Cites] J Endocrinol. 1998 Oct;159(1):165-72 [9795354.001]
  • [Cites] Am J Clin Nutr. 2004 Jun;79(6):1118-25 [15159244.001]
  • [Cites] Aging (Milano). 1997 Feb-Apr;9(1-2):73-9 [9177588.001]
  • [Cites] Nutr Rev. 1998 Sep;56(9):266-70 [9763876.001]
  • [Cites] J Nutr. 2005 May;135(5):1124-30 [15867292.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2005 Feb;113(2):67-79 [15772897.001]
  • [Cites] Metabolism. 1998 Apr;47(4):396-400 [9550535.001]
  • [Cites] Diabetologia. 2004 Jun;47(6):1016-9 [15168020.001]
  • [Cites] Am J Physiol. 1998 Sep;275(3 Pt 2):R667-72 [9728060.001]
  • [Cites] Am J Clin Nutr. 2004 Jun;79(6 Suppl):1153S-1158S [15159250.001]
  • [Cites] Diabetes Care. 2002 Sep;25(9):1516-21 [12196420.001]
  • [Cites] J Nutr Sci Vitaminol (Tokyo). 2004 Dec;50(6):416-21 [15895517.001]
  • [Cites] Am J Clin Nutr. 2004 Jun;79(6 Suppl):1169S-1174S [15159253.001]
  • [Cites] Am J Clin Nutr. 2004 Jun;79(6 Suppl):1164S-1168S [15159252.001]
  • [Cites] Lipids. 2002 Jul;37(7):725-8 [12216844.001]
  • [Cites] Diabetes. 2002 Jul;51(7):2037-44 [12086931.001]
  • [Cites] Annu Rev Nutr. 2002;22:505-31 [12055356.001]
  • [Cites] J Bone Miner Res. 2003 Jul;18(7):1206-16 [12854830.001]
  • [Cites] J Dairy Sci. 1995 Nov;78(11):2358-65 [8747326.001]
  • [Cites] Nat Med. 1995 Nov;1(11):1155-61 [7584987.001]
  • [Cites] Diabetes Obes Metab. 2001 Aug;3 Suppl 1:S11-9 [11685824.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Apr 11;303(3):795-9 [12670481.001]
  • [Cites] Lipids. 1997 Aug;32(8):853-8 [9270977.001]
  • [Cites] Prog Lipid Res. 2004 Nov;43(6):553-87 [15522764.001]
  • [Cites] J Am Coll Nutr. 2005 Jun;24(3):200-9 [15930486.001]
  • [Cites] Public Health Nutr. 2004 Feb;7(1A):123-46 [14972057.001]
  • [Cites] Lipids. 2001 Jul;36(7):669-74 [11521964.001]
  • [Cites] Nutrition. 1999 Sep;15(9):720-2 [10467621.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38445-56 [16155293.001]
  • [Cites] JAMA. 1999 Oct 27;282(16):1519-22 [10546690.001]
  • [Cites] Nature. 2000 Apr 6;404(6778):635-43 [10766250.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2003 Sep;285(3):E527-33 [12736161.001]
  • [Cites] J Nutr. 2003 Jun;133(6):1793-9 [12771319.001]
  • [Cites] Diabetes Res Clin Pract. 1995 Jun;28(3):179-84 [8529496.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2665-71 [15181039.001]
  • [Cites] J Nutr. 2000 Oct;130(10 ):2471-7 [11015475.001]
  • [Cites] Am J Clin Nutr. 2004 Jun;79(6 Suppl):1132S-1136S [15159246.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2000 Dec;279(6):R2057-65 [11080069.001]
  • [Cites] Am J Clin Nutr. 1985 May;41(5 Suppl):1132-45 [3993620.001]
  • [Cites] J Nutr. 2002 Oct;132(10):2995-8 [12368384.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):860-1 [10622250.001]
  • [Cites] Diabetes. 2001 May;50(5):1149-57 [11334420.001]
  • [Cites] Nutrition. 2003 Jan;19(1):30-5 [12507636.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2000 Mar;278(3):E563-9 [10710512.001]
  • [Cites] Am J Clin Nutr. 1981 Dec;34(12):2670-8 [7032273.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 17;310(2):562-6 [14521947.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6207-12 [15833818.001]
  • [Cites] Am J Vet Res. 1997 Jun;58(6):594-600 [9185964.001]
  • [Cites] Int J Obes. 1991 Sep;15 Suppl 2:109-15 [1794931.001]
  • [Cites] Obes Res. 2003 Mar;11(3):368-72 [12634431.001]
  • [Cites] J Nutr. 2005 Apr;135(4):778-84 [15795434.001]
  • [Cites] Metabolism. 1992 Jul;41(7):768-71 [1619996.001]
  • [Cites] Diabetes Care. 1994 Dec;17(12):1449-52 [7882815.001]
  • [Cites] Diabet Med. 2000 Sep;17(9):684-5 [11051290.001]
  • [Cites] Nutrition. 2004 Nov-Dec;20(11-12):1008-17 [15561492.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 27;244(3):678-82 [9535724.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • [Cites] Lipids. 1999 Mar;34(3):235-41 [10230716.001]
  • (PMID = 16933788.001).
  • [ISSN] 0024-4201
  • [Journal-full-title] Lipids
  • [ISO-abbreviation] Lipids
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG023648; United States / NIA NIH HHS / AG / AG027562
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Dietary Fats; 0 / Leptin; 0 / Linoleic Acids, Conjugated; 0R0008Q3JB / Chromium
  •  go-up   go-down


34. Al Maskari MY, Alnaqdy AA: Correlation between Serum Leptin Levels, Body Mass Index and Obesity in Omanis. Sultan Qaboos Univ Med J; 2006 Dec;6(2):27-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between Serum Leptin Levels, Body Mass Index and Obesity in Omanis.
  • OBJECTIVE: To ascertain the relationship between serum leptin levels and related variables (weight, Body Mass Index (BMI) and fat percentage) in a group of Omani obese and non-obese healthy subjects.
  • METHODS: Leptin levels were assessed in serum samples from 35 obese Omanis and 20 non-obese healthy subjects.
  • RESULTS: There was a significant difference (p< 0.001) in serum leptin between the obese group (34.78 + 13.96 ng/ml) and the control non-obese subjects (10.6 ± 4.2 ng/ml).
  • Leptin levels were higher in females compared to males.
  • There was a significantly positive correlation between leptin levels in obese subjects with weight (p=0.002), body fat percentage (p=0.0001) and BMI (p=0.001).
  • CONCLUSIONS: We concluded that serum leptin levels are higher in the Omani obese group and correlate positively with body fatness and obesity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1996 Sep;81(9):3424-7 [8784109.001]
  • [Cites] J Clin Endocrinol Metab. 1997 May;82(5):1632-4 [9141562.001]
  • [Cites] J Clin Invest. 1997 May 15;99(10):2398-404 [9153282.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Dec;82(12):4144-8 [9398729.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jun;83(6):2149-55 [9626154.001]
  • [Cites] Kidney Int. 1998 Oct;54(4):1267-75 [9767543.001]
  • [Cites] Horm Res. 1998;50(6):297-302 [9973668.001]
  • [Cites] Adv Physiol Educ. 2003 Dec;27(1-4):70-7 [12760843.001]
  • [Cites] Diabet Med. 2002 Nov;19(11):954-7 [12421434.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Sep;81(9):3419-23 [8784108.001]
  • [Cites] Ann Saudi Med. 2000 Mar;20(2):113-8 [17322705.001]
  • [Cites] Diabetes. 2002 Jun;51(6):1980-5 [12031989.001]
  • [Cites] Physiol Res. 2001;50(5):443-59 [11702849.001]
  • [Cites] Atherosclerosis. 2001 Aug;157(2):495-503 [11472752.001]
  • [Cites] Cesk Fysiol. 2001 Feb;50(1):25-30 [11268559.001]
  • [Cites] East Mediterr Health J. 1999 Jan;5(1):14-20 [10793776.001]
  • [Cites] Nutrition. 1999 Nov-Dec;15(11-12):829-33 [10575656.001]
  • [Cites] J Mol Endocrinol. 1999 Apr;22(2):173-84 [10194520.001]
  • [Cites] Int J Obes Relat Metab Disord. 1999 Feb;23 Suppl 1:22-8 [10193858.001]
  • [Cites] Nat Med. 1995 Nov;1(11):1155-61 [7584987.001]
  • [Cites] Nature. 1994 Dec 1;372(6505):425-32 [7984236.001]
  • [Cites] N Engl J Med. 1996 Feb 1;334(5):292-5 [8532024.001]
  • [Cites] Diabet Med. 1995 Dec;12(12):1122-5 [8750224.001]
  • (PMID = 21748132.001).
  • [ISSN] 2075-051X
  • [Journal-full-title] Sultan Qaboos University medical journal
  • [ISO-abbreviation] Sultan Qaboos Univ Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Oman
  • [Other-IDs] NLM/ PMC3074914
  • [Keywords] NOTNLM ; Body Mass Index / Body weight / Leptin / Obesity / Oman
  •  go-up   go-down


35. Di Carlo C, Tommaselli GA, Gargano V, Sammartino A, Bifulco G, Tauchmanova L, Colao A, Nappi C: Effects of estrogen-progestin therapy on serum levels of RANKL, osteoprotegerin, osteocalcin, leptin, and ghrelin in postmenopausal women. Menopause; 2007 Jan-Feb;14(1):38-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of estrogen-progestin therapy on serum levels of RANKL, osteoprotegerin, osteocalcin, leptin, and ghrelin in postmenopausal women.
  • OBJECTIVE: The aim of this study was to evaluate the effects of estrogen-progestin therapy on serum levels of receptor-activating nuclear factor kappabeta ligand (RANKL), osteoprotegerin, osteocalcin, leptin, and ghrelin in a cross-sectional study of 99 healthy postmenopausal women conducted at the Menopause Clinic of our department.
  • Serum leptin levels were significantly lower in group B than in group A, whereas ghrelin was significantly higher in group B than in group A.
  • Similarly, although several reports suggest that leptin and ghrelin are involved in bone metabolism, we could not detect any important correlation of these two hormones with bone metabolism or bone status in treated and untreated postmenopausal women.
  • [MeSH-minor] Administration, Cutaneous. Bone Density / drug effects. Cross-Sectional Studies. Female. Finger Phalanges / ultrasonography. Ghrelin. Humans. Leptin / blood. Middle Aged. Osteocalcin / blood. Osteoporosis / prevention & control. Peptide Hormones / blood. Receptors, Leptin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Menopause. 2007 Jan-Feb;14(1):7-9 [17194959.001]
  • (PMID = 17075432.001).
  • [ISSN] 1072-3714
  • [Journal-full-title] Menopause (New York, N.Y.)
  • [ISO-abbreviation] Menopause
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 0 / Ghrelin; 0 / Leptin; 0 / Osteoprotegerin; 0 / Peptide Hormones; 0 / Progestins; 0 / RANK Ligand; 0 / Receptors, Leptin; 0 / leptin receptor, human; 104982-03-8 / Osteocalcin
  •  go-up   go-down


36. Argentou M, Tiniakos DG, Karanikolas M, Melachrinou M, Makri MG, Kittas C, Kalfarentzos F: Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery. Obes Surg; 2009 Sep;19(9):1313-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery.
  • BACKGROUND: Leptin, adiponectin, and resistin are adipokines linked to the development of insulin resistance, which plays a central role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
  • We aimed to define adipokine serum levels in severely obese patients undergoing bariatric surgery and to correlate these with anthropometric and metabolic variables, liver function tests, and histopathological parameters of NAFLD and nonalcoholic steatohepatitis (NASH).
  • Serum leptin, adiponectin, and resistin levels were measured, and histology was assessed using Brunt's and Kleiner's scoring systems.
  • RESULTS: Waist/hip ratio was significantly higher in men (p = 0.0001), and leptin (p = 0.036) and adiponectin (p = 0.0001) serum levels were higher in women.
  • In NAFLD patients, serum adiponectin was negatively correlated with activity grade and fibrosis stage, resistin was negatively correlated with steatosis grade (p = 0.033), while leptin was not related to histology.
  • Leptin/adiponectin ratio showed positive association with stage (p = 0.044).
  • In the subgroup of NASH patients, adiponectin was negatively correlated only with stage (p = 0.01), while there was no correlation between leptin, resistin, or leptin/adiponectin and histology.
  • CONCLUSIONS: Serum adiponectin and resistin levels are related to liver histology in bariatric patients and may be indicative of the histological severity of NAFLD and the extent of hepatic steatosis, respectively.
  • Serum leptin levels are not informative of underlying liver histology in severely obese patients.

  • MedlinePlus Health Information. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 1972 Jun;18(6):499-502 [4337382.001]
  • [Cites] Am J Gastroenterol. 1999 Sep;94(9):2467-74 [10484010.001]
  • [Cites] Alcohol Clin Exp Res. 2007 Jan;31(1 Suppl):S15-21 [17331160.001]
  • [Cites] Hepatology. 2003 Apr;37(4):917-23 [12668987.001]
  • [Cites] Hepatology. 2004 Jul;40(1):46-54 [15239085.001]
  • [Cites] Am J Gastroenterol. 2006 Nov;101(11):2629-40 [16952281.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):5122-5 [16968796.001]
  • [Cites] Dig Dis Sci. 2008 Apr;53(4):1088-92 [17934820.001]
  • [Cites] Nutr Rev. 2007 Jun;65(6 Pt 2):S57-63 [17605315.001]
  • [Cites] Hepatology. 2008 Feb;47(2):484-92 [18220286.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2008 May;11(3):267-74 [18403923.001]
  • [Cites] Expert Rev Mol Diagn. 2007 Mar;7(2):195-205 [17331066.001]
  • [Cites] Surg Endosc. 2007 Sep;21(9):1593-9 [17294310.001]
  • [Cites] Hepatology. 2002 Aug;36(2):403-9 [12143049.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Jun;64(6):679-83 [16712671.001]
  • [Cites] Curr Opin Lipidol. 2006 Apr;17(2):170-5 [16531754.001]
  • [Cites] Gastroenterology. 2006 Sep;131(3):934-45 [16952562.001]
  • [Cites] Hepatology. 2005 Jun;41(6):1313-21 [15915461.001]
  • [Cites] Obes Surg. 2005 Feb;15(2):228-37 [15802066.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1848-52 [16697746.001]
  • [Cites] Obes Surg. 2008 Nov;18(11):1430-7 [18500507.001]
  • [Cites] Am J Gastroenterol. 2003 Dec;98(12):2771-6 [14687831.001]
  • [Cites] Liver Int. 2006 Mar;26(2):151-6 [16448452.001]
  • [Cites] Obes Surg. 2005 Mar;15(3):310-5 [15826462.001]
  • [Cites] J Hepatol. 2006 Oct;45(4):600-6 [16899321.001]
  • [Cites] Mediators Inflamm. 2006;2006(6):34295 [17392582.001]
  • [Cites] JAMA. 2001 May 16;285(19):2486-97 [11368702.001]
  • [Cites] J Hepatol. 2008;48 Suppl 1:S104-12 [18304679.001]
  • [Cites] Aliment Pharmacol Ther. 2008 Mar 1;27(5):412-21 [18081738.001]
  • [Cites] Hepatology. 2005 Aug;42(2):490-2 [15977205.001]
  • [Cites] Clin Liver Dis. 2007 Feb;11(1):191-207, x-xi [17544979.001]
  • [Cites] Obes Surg. 2006 Oct;16(10):1351-8 [17059746.001]
  • [Cites] J Hepatol. 2004 Dec;41(6):943-9 [15582127.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3498-504 [15797948.001]
  • [Cites] Obes Surg. 2006 Dec;16(12):1584-93 [17217634.001]
  • [Cites] Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112 [16447287.001]
  • [Cites] Scand J Gastroenterol. 2008;43(9):1128-36 [18609175.001]
  • [Cites] Hepatogastroenterology. 2007 Jul-Aug;54(77):1512-6 [17708287.001]
  • [Cites] Hepatology. 2003 May;37(5):1202-19 [12717402.001]
  • [Cites] Hepatology. 2007 Aug;46(2):582-9 [17661414.001]
  • [Cites] Hepatology. 2007 Sep;46(3):716-22 [17659597.001]
  • [Cites] Gut. 2005 Jan;54(1):117-21 [15591515.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1844-8 [15070954.001]
  • [Cites] Am J Gastroenterol. 2007 Feb;102(2):399-408 [17311652.001]
  • [Cites] Obes Surg. 2000 Aug;10(4):378-9 [11202981.001]
  • [Cites] Gastroenterology. 2008 May;134(6):1682-98 [18471547.001]
  • [Cites] Med Clin North Am. 2007 Nov;91(6):1125-49, ix [17964913.001]
  • [Cites] J Appl Physiol (1985). 1988 Feb;64(2):529-34 [3372410.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Mar;91(3):1081-6 [16394091.001]
  • [Cites] J Hepatol. 2008 May;48(5):829-34 [18321606.001]
  • [Cites] Scand J Gastroenterol. 2006 May;41(5):566-72 [16638699.001]
  • [Cites] Am J Gastroenterol. 2007 Sep;102(9):1931-8 [17511754.001]
  • [Cites] J Pediatr Endocrinol Metab. 2004 Aug;17(8):1069-75 [15379417.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Mar;23(2):193-8 [17268250.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1175-83 [16231364.001]
  • [Cites] Eur J Endocrinol. 2005 Jan;152(1):113-8 [15762194.001]
  • [Cites] Am J Clin Pathol. 2007 Nov;128(5):837-47 [17951208.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • (PMID = 19693638.001).
  • [ISSN] 0960-8923
  • [Journal-full-title] Obesity surgery
  • [ISO-abbreviation] Obes Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adipokines
  •  go-up   go-down


37. Srivastava RK, Krishna A: Adiposity associated rise in leptin impairs ovarian activity during winter dormancy in Vespertilionid bat, Scotophilus heathi. Reproduction; 2007 Jan;133(1):165-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adiposity associated rise in leptin impairs ovarian activity during winter dormancy in Vespertilionid bat, Scotophilus heathi.
  • The aim of the study was to evaluate the seasonal variation in serum leptin levels in a natural population of the female bat, Scotophilus heathi and their relationship to the changes in the body mass, serum insulin level, and ovarian activity.
  • Circulating leptin level varied significantly over the season and correlated positively with the changes in body mass, and circulating insulin and androstenedione (A4) levels.
  • Circulating leptin concentrations showed two peaks; one coincides with the maximum fat accumulation prior to winter dormancy, whereas the second shorter peak coincides with late pregnancy.
  • The in vivo study in S. heathi showed that the increased circulating leptin level during winter dormancy coincides with the decreased expression of ovarian steroidogenic acute regulatory (StAR) protein, and low circulating estradiol (E2) level.
  • At the same time, increased circulating leptin level coincides with increased expression of ovarian insulin receptor and high circulating A4 level.
  • The low circulating leptin level during preovulatory period coincides with the increase in StAR protein but decrease in insulin receptor protein.
  • The in vitro study confirmed the in vivo observations of inhibitory effect of leptin on LH induced StAR expression and E2 production, whereas the stimulatory effect of leptin (high dose) on LH induced expression of insulin receptor protein and A4 production.
  • However, pharmacological dose of leptin produced inhibitory effect on the expression of insulin receptor protein.
  • The results of the present study thus suggest that high circulating leptin level during winter dormancy promotes adiposity and impairs ovarian activity by suppressing StAR-mediated E2 production as well as by enhancing insulin receptor-mediated A4 synthesis thereby contributing anovulatory condition of delayed ovulation in S. heathi.
  • [MeSH-major] Adiposity / physiology. Chiroptera / metabolism. Hibernation / physiology. Leptin / blood. Ovary / metabolism

  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • Hazardous Substances Data Bank. ANDROSTENEDIONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17244743.001).
  • [ISSN] 1470-1626
  • [Journal-full-title] Reproduction (Cambridge, England)
  • [ISO-abbreviation] Reproduction
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insulin; 0 / Leptin; 0 / Phosphoproteins; 0 / steroidogenic acute regulatory protein; 409J2J96VR / Androstenedione; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; EC 2.7.10.1 / Receptor, Insulin
  •  go-up   go-down


38. Zemanová M, Petruzelka L, Pazdrová G, Haluzík M, Novák F, Svobodník A: [Changes in leptin, leptin receptor and fatty acids levels during chemoradiotherapy for oesophageal cancer]. Cas Lek Cesk; 2005;144(12):811-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes in leptin, leptin receptor and fatty acids levels during chemoradiotherapy for oesophageal cancer].
  • Leptin, a protein produced by adipocytes, is an important signalling molecule in energy regulation, metabolism of fatty acids and it can also augment tumour growth of various cancer cell lines.
  • METHODS AND RESULTS: In this study we examined the nutritional status (pre-treatment weight-loss, actual weight, body mass index), serum levels of leptin, soluble leptin receptor, TNF-alpha, IGF-1 and plasma phosphatidyl-cholin fatty acids before the beginning of treatment, after the onset of treatment and shortly before its completion.
  • Concomitant chemoradiation led to transient elevation of serum leptin level despite the weight loss during chemoradiotherapy.
  • [MeSH-major] Esophageal Neoplasms / blood. Fatty Acids / blood. Leptin / blood. Receptors, Cell Surface / blood
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Insulin-Like Growth Factor I / analysis. Male. Middle Aged. Phosphatidylcholines / chemistry. Receptors, Leptin. Tumor Necrosis Factor-alpha / analysis. Weight Loss

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16389753.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Leptin; 0 / Phosphatidylcholines; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 0 / Tumor Necrosis Factor-alpha; 0 / leptin receptor, human; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


39. Korotkova M, Gabrielsson BG, Holmäng A, Larsson BM, Hanson LA, Strandvik B: Gender-related long-term effects in adult rats by perinatal dietary ratio of n-6/n-3 fatty acids. Am J Physiol Regul Integr Comp Physiol; 2005 Mar;288(3):R575-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously shown that the ratio of n-6 to n-3 polyunsaturated fatty acids (PUFA) in the maternal diet affects serum leptin levels and growth of the suckling pups.
  • The aim of the present study was to investigate the long-term effects of various ratios of the dietary n-6 and n-3 PUFA during the perinatal period on serum leptin, insulin, and triacylglycerol, as well as body growth in the adult offspring.
  • At 3 wk of age, the n-6/n-3 PUFA ratios in the serum phospholipids of the offspring were 2.5, 8.3, and 17.5, respectively.
  • At the 28th postnatal wk, mean body weight and fasting insulin levels were significantly increased in the rats fed the n-6/n-3 diet perinatally compared with the other groups.
  • The systolic blood pressure and serum triacylglycerol levels were only increased in adult male rats of the same group.

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Physiol Regul Integr Comp Physiol. 2006 Nov;291(5):R1564
  • (PMID = 15699360.001).
  • [ISSN] 0363-6119
  • [Journal-full-title] American journal of physiology. Regulatory, integrative and comparative physiology
  • [ISO-abbreviation] Am. J. Physiol. Regul. Integr. Comp. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Fatty Acids, Omega-3; 0 / Fatty Acids, Omega-6; 0 / Insulin; 0 / Phospholipids; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


40. Pauwels NS, Bracke KR, Maes T, Pilette C, Joos GF, Brusselle GG: The role of interleukin-6 in pulmonary and systemic manifestations in a murine model of chronic obstructive pulmonary disease. Exp Lung Res; 2010 Oct;36(8):469-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increased levels of interleukin-6 (IL-6) have been demonstrated in sputum and serum of COPD patients.
  • Wild-type (WT) and IL-6 knockout (KO) mice were exposed subacutely (4 weeks) and chronically (24 weeks) to air or cigarette smoke (CS).
  • Subacute and chronic CS exposure significantly increased pulmonary IL-6 mRNA expression in lung tissue and IL-6 protein levels in bronchoalveolar lavage fluid of WT mice.
  • Remarkably, air-exposed IL-6 KO mice have lower body weight, serum leptin levels, and adipose tissue mass compared to air-exposed WT mice.
  • [MeSH-minor] Adipose Tissue, White / drug effects. Adipose Tissue, White / metabolism. Animals. Bronchoalveolar Lavage Fluid / cytology. Cell Count. Cytokines / genetics. Cytokines / metabolism. Disease Models, Animal. Gene Expression / drug effects. Leptin / genetics. Leptin / metabolism. Lymphocytes / drug effects. Lymphocytes / metabolism. Lymphocytes / pathology. Male. Mice. Mice, Knockout. RNA, Messenger / metabolism. Smoking / adverse effects. Tobacco Smoke Pollution / adverse effects

  • MedlinePlus Health Information. consumer health - COPD.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20939756.001).
  • [ISSN] 1521-0499
  • [Journal-full-title] Experimental lung research
  • [ISO-abbreviation] Exp. Lung Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-6; 0 / Leptin; 0 / RNA, Messenger; 0 / Tobacco Smoke Pollution
  •  go-up   go-down


41. Aurangzeb B, Leach ST, Lemberg DA, Day AS: Nutritional status of children with coeliac disease. Acta Paediatr; 2010 Jul;99(7):1020-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The nutritional status of newly diagnosed CD was assessed by anthropometry, Bioelectrical Impedance and serum leptin levels, and contrasted to age and gender matched controls.
  • Mean height and weight for age, other nutritional parameters and serum leptin did not differ between the groups.
  • Serum leptin correlated with BMI in both groups.
  • Variations in nutrition (under to overnutrition) may be seen at diagnosis, without relationship to the presence of symptoms.
  • Leptin levels were not altered specifically in the setting of CD.
  • [MeSH-minor] Adolescent. Anthropometry. Case-Control Studies. Child. Child, Preschool. Electric Impedance. Female. Humans. Infant. Leptin / blood. Male. Nutrition Assessment

  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • MedlinePlus Health Information. consumer health - Child Nutrition.
  • MedlinePlus Health Information. consumer health - Toddler Nutrition.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20178518.001).
  • [ISSN] 1651-2227
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


42. Akinci M, Kosova F, Cetin B, Aslan S, Ari Z, Cetin A: Leptin levels in thyroid cancer. Asian J Surg; 2009 Oct;32(4):216-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin levels in thyroid cancer.
  • BACKGROUND: Leptin has physiological roles in multiple systems, and has possible effects on several carcinogenesis steps.
  • The aim of this study was to investigate the leptin levels in thyroid papillary carcinoma (TPC) patients.
  • TPC patients had a bilateral total thyroidectomy operation and their leptin levels were measured before and 20 days after the operation.
  • RESULTS: Serum leptin levels of TPC patients were higher than in control group subjects (21.15 +/- 14.12 ng/mL vs. 9.89 +/- 0.21 ng/mL, p < 0.05).
  • The leptin levels decreased after total thyroidectomy (13.92 +/- 10.55 ng/mL) compared to prethyroidectomy levels (22.94 +/- 14.67 ng/mL) in 34 patients who came to the follow-up visit (p < 0.05).
  • However, the decreased post-thyroidectomy levels of leptin were still statistically significantly higher than the control group levels.
  • Multivariate regression analysis showed that the leptin levels in TPC patients were not related to age, menopausal status or pathologic occult status but were directly related to the cancer group.
  • CONCLUSION: Leptin levels were elevated in thyroid cancer, decreased after total thyroidectomy, and might be associated with thyroid papillary carcinogenesis.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19892624.001).
  • [ISSN] 0219-3108
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


43. Jaleel F, Jaleel A, Aftab J, Rahman MA: Leptin and blood lipid levels in postmenopausal diabetic women with and without complication of ischemic heart disease. Med Sci Monit; 2006 Sep;12(9):CR382-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin and blood lipid levels in postmenopausal diabetic women with and without complication of ischemic heart disease.
  • BACKGROUND: Recent studies have provided evidence that leptin has significant effects on vascular development and repair.
  • The aim was to determine the levels of leptin and lipid profile in diabetic postmenopausal women with and without the complication of ischemic heart disease and to develop correlation between them.
  • Moreover, the relationship between leptin levels and extent of ischemic changes were determined.
  • The first group comprised normal healthy controls, the second diabetic type 2 patients with no history of ischemic heart disease (I1ID), and the third diabetic patients with IHD.
  • Serum leptin levels were determined by a Kit obtained from DRG and samples were analyzed on ELISA.
  • RESULTS: The results show that leptin and serum lipid levels increased significantly in diabetic patients with IHD compared with diabetic patients without IHD as well as normal subjects.
  • Moreover; the sertum leptin level increased significantly in the diabetic patients with IHD who had positive findings in myocardial perfusion scan compared with those having negative findings.
  • CONCLUSIONS: Hyperleptinemia in diabetic patients shows that leptin contributes to the development of cardiovascular disease in diabetic patients.
  • [MeSH-major] Diabetes Mellitus, Type 2 / blood. Hyperlipidemias / complications. Leptin / blood. Myocardial Ischemia / etiology. Postmenopause / blood

  • Genetic Alliance. consumer health - Heart Disease.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16940932.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Leptin; 0 / Lipids
  •  go-up   go-down


44. Tsukamoto N, Kojima M, Hasegawa M, Oriuchi N, Matsushima T, Yokohama A, Saitoh T, Handa H, Endo K, Murakami H: The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer; 2007 Aug 1;110(3):652-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification.
  • BACKGROUND: Although studies comparing conventional imaging modalities with (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) for the detection of lymphoma and although the relations between (18)F-FDG-PET and histologic types were reported previously, most studies were not systematic and involved relatively small numbers of patients.
  • METHODS: Two hundred fifty-five patients with lymphoma had their disease staged using (18)F-FDG-PET, and 191 of those patients also were assessed using gallium-67 scintigraphy ((67)Ga).
  • The results of these conventional imaging modalities were compared with the results from (8)F-FDG-PET and (67)Ga, and correlations between the imaging results and pathologic diagnoses were evaluated by using the World Health Organization classification system.
  • RESULTS: Of 913 disease sites in 255 patients, (18)F-FDG-PET identified >97% of disease sites of Hodgkin lymphoma (HL) and aggressive and highly aggressive non-Hodgkin lymphoma.
  • For indolent lymphoma, the detection rate of (18)F-FDG-PET was 91% for follicular lymphoma (FL); 82% for extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, irrespective of plasmacytic differentiation; and approximately 50% for small lymphocytic lymphoma (SLL) and splenic marginal zone lymphoma (SMZL).
  • However, the sensitivity of (67)Ga was unexpectedly poor for FL, for mantle cell lymphoma (MCL), and for the nasal type of natural killer/T-cell lymphoma (NK/T-nasal), ranging from 30% to 38%.
  • CONCLUSIONS: (18)F-FDG-PET was useful for all histologic subtypes of lymphoma other than SLL and SMZL.
  • [MeSH-major] Fluorodeoxyglucose F18. Gallium Radioisotopes. Hodgkin Disease / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed / methods
  • [MeSH-minor] Diagnosis, Differential. Humans. Neoplasm Staging / methods. Sensitivity and Specificity. World Health Organization

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17582800.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


45. Levitt MJ, Gharibo M, Strair R, Schaar D, Rubin A, Bertino JR: Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate. J Chemother; 2009 Aug;21(4):434-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate.
  • This pilot study tested the hypothesis that dose intensity/dose density treatment may improve the response rate and remission duration in patients with advanced low grade lymphomas. ten patients with low grade lymphomas: follicular lymphoma grades I and II, marginal zone lymphoma, and small cell lymphocytic lymphoma with progressive disease were studied.
  • This program is well tolerated with a high CR rate, and may serve as a basis for future trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, Follicular / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Prednisone / administration & dosage. Prognosis. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19622463.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 5-P30-CA 072720-13
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


46. Jalil A, Amir S, Majeed R, Jalil F: Circulating leptin levels in elderly subjects with and without cerebrovasular disease. J Coll Physicians Surg Pak; 2010 May;20(5):350-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating leptin levels in elderly subjects with and without cerebrovasular disease.
  • Serum concentrations of leptin was investigated in 40 patients with ischemic stroke, in context of the size of the lesion and also in 40 non-diseased controls, matched according to age, gender and waist hip ratio.
  • Serum leptin concentrations were determined in ng/ml with ELISA and computer tomography (CT) scan was performed in patients to estimate lesion size in cms.
  • Serum leptin concentrations were found to be significantly higher (p < 0.001) in stroke patients (51.61+1.39), compared with controls (37.76+1.207).
  • Moreover, positive correlation (r=0.93) existed between serum leptin level and infarction size in patients with stroke.
  • [MeSH-major] Cerebrovascular Disorders / blood. Leptin / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20642935.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Leptin
  •  go-up   go-down


47. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon V, Marks P, Kelly WK: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol; 2006 Jan 1;24(1):166-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The spectrum of diseases included patients with diffuse large B-cell lymphoma (n = 12), Hodgkin's disease (HD; n = 12), multiple myeloma (n = 2), T-cell lymphoma (n = 3), mantle cell lymphoma (n = 2), small lymphocytic lymphoma (n = 2), and myeloid leukemia (n = 2).
  • One patient with transformed small lymphocytic lymphoma met criteria for complete response, whereas another met the criteria for partial response (PR).
  • CONCLUSION: These results suggest that SAHA has activity in hematologic malignancies including HD and select subtypes of non-Hodgkin's lymphoma.


48. Ioannou GN, Weiss NS, Kearney DJ: Is Helicobacter pylori seropositivity related to body mass index in the United States? Aliment Pharmacol Ther; 2005 Mar 15;21(6):765-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Helicobacter pylori infection may decrease serum ghrelin and increase gastric leptin levels, which may, in turn, decrease body mass index.
  • METHODS: Serum H. pylori and cytotoxin-associated gene product A (CagA) antibody levels were measured on 6724 adult participants of the third National Health and Nutrition Examination Survey (1988-91).
  • We also investigated whether H. pylori/cytotoxin-associated gene product A antibody status was associated with fasting serum leptin levels.
  • RESULTS: H. pylori/CagA antibody status was not associated with obesity (body mass index > or = 30 kg/m(2)) [adjusted odds ratio (OR) 1.2, 95% CI: 0.9-1.6 comparing (+/+) to (-/-) and adjusted OR 1.1, 95% CI: 0.8-1.5 comparing (+/-) to (-/-)], overweight (body mass index 25 to <30 kg/m(2)) [adjusted OR 1.0, 95% CI: 0.7-1.2 comparing (+/+) to (-/-) and adjusted OR 1.0, 95% CI: 0.8-1.3 comparing (+/-) to (-/-)], or fasting serum leptin level in the USA population.
  • CONCLUSIONS: H. pylori seropositivity and CagA antibody status are not associated with body mass index or fasting serum leptin level.
  • [MeSH-minor] Adult. Aged. Antigens, Bacterial / blood. Bacterial Proteins / blood. Enzyme-Linked Immunosorbent Assay. Epidemiologic Methods. Female. Humans. Leptin / blood. Male. Middle Aged. Obesity / blood. Obesity / epidemiology. Obesity / ethnology. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771763.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / Leptin; 0 / cagA protein, Helicobacter pylori
  •  go-up   go-down


49. Axelsson J, Qureshi AR, Heimbürger O, Lindholm B, Stenvinkel P, Bárány P: Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. Am J Kidney Dis; 2005 Oct;46(4):628-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD.
  • Furthermore, the adipokine leptin stimulates human erythroid development in vitro.
  • In the present study, we investigate the impact of fat mass and leptin level on epoetin sensitivity in patients with ESRD.
  • Body composition was analyzed by dual-energy X-ray absorptiometry and correlated with serum markers of inflammation and leptin (analyzed by enzyme-linked immunosorbent assays), as well as with epoetin dose, in international units administered per week (IU/wk).
  • To correct for differences in body mass and hemoglobin (Hb) levels, epoetin sensitivity was approximated as epoetin/Hb ratio, ie, epoetin dose per unit of Hb (IU/wk/g/dL) and epoetin/Hb/kg ratio, ie, epoetin dose per unit of Hb and kilogram of patient body weight (IU/wk/Hb/kg).
  • The 3 groups had significantly different serum levels of high-sensitivity C-reactive protein (hsCRP; median, 8.6 versus 3.1 and 8.0 mg/L, respectively; P < 0.05), neopterin (median, 112.4 versus 94.3 and 96.1 ng/L, respectively; P < 0.05), and IL-6 (median, 6.8 versus 4.1 and 6.5 ng/mL, respectively; P < 0.05).
  • Significant between-group differences also were found in fat mass and leptin levels (median, 14.8 versus 10.5 and 7.9 ng/mL, respectively; P = 0.02).
  • In univariate analyses, significant relationships between epoetin sensitivity indices, leptin levels, and levels of the inflammatory markers hsCRP and IL-6 were found.
  • In a multivariate stepwise regression model, log ferritin, parathyroid hormone, log leptin, log IL-6, and polycystic kidney disease were significantly associated with the epoetin/Hb ratio.
  • CONCLUSION: The present study shows that leptin level may be a predictor of epoetin sensitivity.
  • Although truncal fat is associated with secretion of proinflammatory cytokines, this secretion appears not to have inhibitory effects on epoetin sensitivity in the presence of high leptin levels.
  • [MeSH-major] Adipose Tissue / pathology. Anemia / drug therapy. Body Composition. Erythropoiesis / drug effects. Erythropoietin / analogs & derivatives. Kidney Failure, Chronic / complications. Leptin / blood

  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DARBEPOETIN ALFA .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Kidney Dis. 2006 Feb;47(2):371; author reply 372 [16431269.001]
  • (PMID = 16183417.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Interleukin-6; 0 / Leptin; 11096-26-7 / Erythropoietin; 15UQ94PT4P / Darbepoetin alfa; 9007-41-4 / C-Reactive Protein; 9007-73-2 / Ferritins
  •  go-up   go-down


50. Hirosawa M, Minata M, Harada KH, Hitomi T, Krust A, Koizumi A: Ablation of estrogen receptor alpha (ERalpha) prevents upregulation of POMC by leptin and insulin. Biochem Biophys Res Commun; 2008 Jun 27;371(2):320-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ablation of estrogen receptor alpha (ERalpha) prevents upregulation of POMC by leptin and insulin.
  • Ovariectomized diabetic (AFO) and nondiabetic (B6FO) mice had significantly lower food intake and elevated serum leptin levels.
  • ERaKOAkt and ERaKO mice also increased serum leptin concentrations, while hypoinsulinemia was observed in ERaKOAkt and hyperinsulinemia in ERaKO mice.
  • RT-PCR showed a significant attenuation of POMC expression in both ERaKOAkt and ERaKO mice, irrespective of the elevated leptin serum levels or hyperinsulinemia, while elevated serum leptin levels in AFO and B6FO mice upregulated POMC gene expression.
  • These results indicate that ERalpha plays an essential role in leptin- and insulin-stimulated upregulation of the POMC gene.
  • [MeSH-major] Estrogen Receptor alpha / physiology. Gene Expression Regulation. Hyperphagia / genetics. Insulin / metabolism. Leptin / metabolism. Pro-Opiomelanocortin / genetics

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18439911.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Insulin; 0 / Leptin; 66796-54-1 / Pro-Opiomelanocortin
  •  go-up   go-down


51. Wang HC, Yang YK, Chen PS, Lee IH, Yeh TL, Lu RB: Increased plasma leptin in antipsychotic-naïve females with schizophrenia, but not in males. Neuropsychobiology; 2007;56(4):213-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased plasma leptin in antipsychotic-naïve females with schizophrenia, but not in males.
  • BACKGROUND: Metabolic abnormalities, including insulin resistance and increased leptin levels, were noted in patients with schizophrenia who had received antipsychotics.
  • In this study, we examined the leptin levels of antipsychotic-naïve schizophrenic patients.
  • Serum leptin levels of the healthy controls and antipsychotic-naïve patients were compared.
  • The relationships between leptin level and gender, Positive and Negative Syndrome Scale score, and duration of illness were analyzed by Spearman's correlation.
  • RESULTS: Compared with sex-, age- and BMI-matched subjects, the female schizophrenic patients had elevated serum leptin levels.
  • In the male patients, the results of this preliminary study also revealed a positive correlation between leptin levels and the Aggression Risk Profile subscale of the PANSS.
  • CONCLUSION: This preliminary study suggests possible gender-specific leptin dysregulation in antipsychotic-naïve schizophrenic patients.
  • [MeSH-major] Leptin / blood. Schizophrenia / blood. Sex Characteristics

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18382119.001).
  • [ISSN] 1423-0224
  • [Journal-full-title] Neuropsychobiology
  • [ISO-abbreviation] Neuropsychobiology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


52. Zent CS, Kay NE: Autoimmune complications in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol; 2010 Mar;23(1):47-59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmune complications in chronic lymphocytic leukaemia (CLL).
  • Patients with B-chronic lymphocytic leukaemia /small lymphocytic lymphoma (CLL) have a 5-10% risk of developing autoimmune complications, which primarily cause cytopaenia.
  • The most common autoimmune complication is autoimmune haemolytic anaemia with a lower frequency of immune thrombocytopaenia and pure red blood cell aplasia and only rarely, autoimmune granulocytopaenia (AIG).
  • Autoimmune cytopaenia should always be considered in the differential diagnosis of cytopaenia in patients with CLL.
  • Optimal therapy will depend on a timely and accurate diagnosis of autoimmune cytopaenia and should be individualised according to the severity of the cytopaenia and the presence or absence of concomitant progressive CLL requiring therapy.

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Am J Hematol. 1999 Jun;61(2):98-102 [10367787.001]
  • [Cites] Br J Haematol. 1999 Jul;106(1):261-2 [10444204.001]
  • [Cites] Br J Haematol. 1999 Sep;106(3):836-7 [10469479.001]
  • [Cites] Am J Med. 1955 Jun;18(6):961-89 [14376415.001]
  • [Cites] Blood. 1956 Jul;11(7):648-64 [13328945.001]
  • [Cites] Am J Hematol. 2004 Dec;77(4):413-5 [15551407.001]
  • [Cites] Blood. 2000 May 1;95(9):2786-92 [10779422.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):791-4 [11309323.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1325-30 [11571749.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2016-22 [11596014.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1092-4 [11807020.001]
  • [Cites] Am J Hematol. 2002 Apr;69(4):258-71 [11921020.001]
  • [Cites] Blood. 2002 Jul 15;100(2):635-9 [12091358.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2092-5 [12357362.001]
  • [Cites] Hematol J. 2002;3(6):299-301 [12522452.001]
  • [Cites] Eur J Haematol. 2003 May;70(5):319-21 [12694169.001]
  • [Cites] Blood. 2007 Jan 15;109(2):405-11 [17008537.001]
  • [Cites] Leukemia. 2007 Mar;21(3):511-4 [17215854.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):793-8 [17283364.001]
  • [Cites] Br J Haematol. 2007 Mar;136(6):800-5 [17341265.001]
  • [Cites] Leuk Lymphoma. 2007 Dec;48(12):2412-7 [18067017.001]
  • [Cites] Haematologica. 2008 Jan;93(1):151-2 [18166805.001]
  • [Cites] Blood. 2008 Jan 15;111(2):680-7 [17761830.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1110-6 [17986663.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1820-6 [18055869.001]
  • [Cites] Blood Rev. 2008 Jan;22(1):17-31 [17904259.001]
  • [Cites] Br J Haematol. 2008 May;141(5):615-21 [18373706.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1325-8 [18420827.001]
  • [Cites] J Immunol. 2008 Sep 1;181(5):3674-83 [18714043.001]
  • [Cites] Br J Haematol. 2008 Oct;143(1):16-26 [18573111.001]
  • [Cites] Leuk Res. 2009 Mar;33(3):366-7 [18930543.001]
  • [Cites] Blood. 2009 Apr 2;113(14):3154-60 [19096013.001]
  • [Cites] Leuk Lymphoma. 2009 Jun;50(6):892-9 [19391041.001]
  • [Cites] Leuk Lymphoma. 2009 Jun;50(6):863-4 [19455465.001]
  • [Cites] Am J Hematol. 2003 Sep;74(1):1-8 [12949883.001]
  • [Cites] Br J Haematol. 2003 Oct;123(2):278-81 [14531909.001]
  • [Cites] Mayo Clin Proc. 2003 Nov;78(11):1340-6 [14601692.001]
  • [Cites] Leuk Lymphoma. 2003 Nov;44(11):1951-5 [14738149.001]
  • [Cites] Clin Exp Immunol. 1966 Jan;1(1):3-11 [5953036.001]
  • [Cites] Blood. 1967 Apr;29(4):Suppl:566-84 [6022294.001]
  • [Cites] Blood. 1975 Aug;46(2):219-34 [1139039.001]
  • [Cites] J Exp Med. 1980 Dec 1;152(6):1484-96 [6969771.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):198-206 [7237385.001]
  • [Cites] Cancer. 1983 Mar 1;51(5):844-50 [6821851.001]
  • [Cites] J Clin Pathol. 1986 Jul;39(7):713-6 [3488334.001]
  • [Cites] J Autoimmun. 1988 Oct;1(5):469-81 [2473761.001]
  • [Cites] Am J Hematol. 1992 Sep;41(1):5-12 [1503099.001]
  • [Cites] Am J Med. 1992 Oct;93(4):435-40 [1415307.001]
  • [Cites] J Clin Invest. 1993 Apr;91(4):1672-80 [8473510.001]
  • [Cites] Leuk Lymphoma. 1993 Jan;9(1-2):149-51 [8477195.001]
  • [Cites] Blood. 1993 May 15;81(10):2475-87 [8490163.001]
  • [Cites] Lancet. 1993 Aug 28;342(8870):555 [8102691.001]
  • [Cites] N Engl J Med. 1994 Jun 2;330(22):1560-4 [8177245.001]
  • [Cites] Clin Exp Immunol. 1994 May;96(2):297-302 [8187337.001]
  • [Cites] Am J Hematol. 1994 Aug;46(4):375-6 [8037200.001]
  • [Cites] Blood. 1994 Aug 15;84(4):1216-9 [8049436.001]
  • [Cites] Leuk Lymphoma. 1994 Sep;15(1-2):187-8 [7858499.001]
  • [Cites] Ann Oncol. 1995 Mar;6(3):300-1 [7612497.001]
  • [Cites] Br J Haematol. 1995 Oct;91(2):341-4 [8547072.001]
  • [Cites] Blood. 1996 May 1;87(9):3869-76 [8611714.001]
  • [Cites] Eur J Haematol. 1997 Feb;58(2):109-13 [9111592.001]
  • [Cites] Hematol J. 2004;5(6):546-7 [15570303.001]
  • [Cites] J Thromb Haemost. 2005 Jan;3(1):74-8 [15634268.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] Blood. 2005 Mar 1;105(5):2007-15 [15284121.001]
  • [Cites] Autoimmun Rev. 2005 Jun;4(5):264-9 [15990072.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2018-25 [15914560.001]
  • [Cites] Curr Opin Immunol. 2005 Dec;17(6):638-42 [16209918.001]
  • [Cites] Leuk Res. 2006 Jan;30(1):109-14 [16043218.001]
  • [Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]
  • [Cites] Blood. 2006 Feb 1;107(3):885-91 [16219797.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):230-9 [16616070.001]
  • [Cites] Blood. 2006 Jul 1;108(1):292-6 [16527887.001]
  • [Cites] Am J Hematol. 2006 Aug;81(8):598-602 [16823816.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1689-92 [17145607.001]
  • [Cites] Cancer Res. 2009 Jul 1;69(13):5424-32 [19549911.001]
  • [Cites] Leuk Res. 2009 Nov;33(11):1452-3 [19632721.001]
  • [Cites] Leuk Lymphoma. 2009 Aug;50(8):1261-8 [19811329.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2701-15 [9326237.001]
  • [Cites] Semin Oncol. 1998 Feb;25(1):80-97 [9482530.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1885-9 [9586905.001]
  • [Cites] Br J Haematol. 1999 Mar;104(3):442-7 [10086776.001]
  • (PMID = 20620970.001).
  • [ISSN] 1532-1924
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA097274-01; United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / CA97274; United States / NCI NIH HHS / CA / P50 CA097274-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 84
  • [Other-IDs] NLM/ NIHMS174960; NLM/ PMC2909690
  •  go-up   go-down


53. Horiguchi A, Sumitomo M, Asakuma J, Asano T, Zheng R, Asano T, Nanus DM, Hayakawa M: Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma. J Urol; 2006 Oct;176(4 Pt 1):1631-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma.
  • PURPOSE: Leptin, an adipocyte derived cytokine that is closely associated with obesity, was recently shown to be involved in carcinogenesis and cancer progression.
  • Because obesity is a significant risk factor for renal cell carcinoma, we investigated the link between leptin and the development of renal cell carcinoma.
  • MATERIALS AND METHODS: Associations between preoperative serum leptin levels and leptin receptor expression in tumor specimens and various clinicopathological parameters were analyzed in 57 patients with renal cell carcinoma.
  • RESULTS: Serum leptin levels were 1.2 to 16.2 ng/ml (mean 4.5).
  • Of 57 tumors 22 (38.6%) demonstrated high leptin receptor expression.
  • Serum leptin levels were significantly higher in patients with vs without tumor specimen venous invasion (p = 0.030) and higher in patients with high vs low leptin receptor expression (p = 0.019).
  • There were significant associations between high leptin receptor expression and the presence of venous invasion (p = 0.013), histological type (p = 0.0076) and regional lymph node metastasis (p = 0.047).
  • Of 42 patients with N0M0 disease those with serum leptin 5.0 ng/ml or more had significantly shorter progression-free survival than patients with lower levels (p = 0.0043).
  • Multivariate Cox proportional hazards model analysis demonstrated that higher serum leptin was an independent predictor of progression-free survival (p = 0.0406).
  • CONCLUSIONS: Leptin and leptin receptor could have a key role in the invasion of renal cell carcinoma and they could be valuable predictors of progression.
  • [MeSH-major] Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology. Leptin / blood. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Adult. Aged. Body Mass Index. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Receptors, Leptin. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16952705.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 0 / leptin receptor, human
  •  go-up   go-down


54. Gharote HP, Mody RN: Estimation of serum leptin in oral squamous cell carcinoma. J Oral Pathol Med; 2010 Jan;39(1):69-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of serum leptin in oral squamous cell carcinoma.
  • Leptin, a homologous protein of cytokine family, is found to be decreased in serum with cachexia.
  • The purpose of this study was to compare serum leptin levels of oral squamous cell carcinoma patients with that of control group and correlate it with body mass index.
  • METHOD: Serum samples of 31 oral squamous cell carcinoma patients and that of 28 healthy individuals were subjected to evaluation of serum leptin levels (ng/ml) using enzyme-linked immunosorbent assay.
  • RESULTS: A significant reduction in leptin level of oral squamous cell carcinoma patients was observed.
  • Definite correlation between body mass index and serum leptin and also between serum leptin levels of various histopathological variants of oral squamous cell carcinoma was observed.
  • CONCLUSION: The results of this study suggest that evaluation of serum leptin level can provide status of cachexia in oral squamous cell carcinoma patients.
  • [MeSH-major] Carcinoma, Squamous Cell / blood. Leptin / blood. Mouth Neoplasms / blood
  • [MeSH-minor] Adult. Age Factors. Aged. Area Under Curve. Biomarkers / blood. Body Mass Index. Cachexia / blood. Female. Humans. Male. Middle Aged. Neoplasm Staging. ROC Curve. Sensitivity and Specificity. Sex Factors. Young Adult

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817969.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Leptin
  •  go-up   go-down


55. Mendoza-Núñez VM, Correa-Muñoz E, Garfias-Cruz EA, Sánchez-Rodriguez MA, Galván-Duarte RE, Retana-Ugalde R: Hyperleptinemia as a risk factor for high blood pressure in the elderly. Arch Pathol Lab Med; 2006 Feb;130(2):170-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperleptinemia as a risk factor for high blood pressure in the elderly.
  • CONTEXT: Studies have demonstrated that high serum leptin levels are associated with aging.
  • We measured serum leptin levels through the radioimmunoassay method.
  • RESULTS: The elderly subjects with HBP had significantly higher leptin levels than the healthy elderly subjects (P = .02).
  • Furthermore, in female elderly subjects we observed a statistically significant correlation between systolic blood pressure and leptin (r = 0.37, P = .003), as well as systolic blood pressure and age (r = 0.29, P = .02), but not with diastolic blood pressure.
  • In male elderly subjects, there was no correlation between leptin and systolic blood pressure or leptin and diastolic blood pressure.
  • [MeSH-major] Hypertension / blood. Leptin / blood

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454556.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


56. Ly M, Belli E, Leobon B, Kortas C, Grollmüss OE, Piot D, Planché C, Serraf A: Results of the double switch operation for congenitally corrected transposition of the great arteries. Eur J Cardiothorac Surg; 2009 May;35(5):879-83; discussion 883-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Segmental anatomy was {SLL} in all patients, dextrocardia in two patients, mesocardia in two patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19346135.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


57. Brito N, Fonseca M, Dinis I, Mirante A: Metabolic factors in obesity. J Pediatr Endocrinol Metab; 2010 Jan-Feb;23(1-2):97-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leptin is an important hormone involved in the pathogenesis of obesity and has been under investigation as a risk marker for future complications. AIMS: 1.
  • To evaluate the relation between serum leptin levels and body mass index (BMI) and height.
  • 2. To compare leptin levels in obese and non-obese children.
  • 3. To evaluate the relation between leptin levels and insulin resistance index.
  • In the obese group we assessed sex, age, BMI SDS and height SDS for age and sex, and serum levels of glucose, insulin and leptin.
  • In the control group were obtained BMI SDS and height SDS for age and sex and leptin levels.
  • Leptin levels showed a positive correlation with BMI SDS (r = 0.69; p < 0.001) and height SDS (r = 0.31; p < 0.001).
  • When comparing leptin levels between obese and non-obese groups, we found a significant difference in boys (50.7 +/- 27.3 versus 7.0 +/- 6.8 ng/ml; p < 0.001) and in girls (57.6 +/- 25.5 versus 16.5 +/- 10.3 ng/ml; p < 0.001).
  • In the nonobese group, leptin levels were lower in boys.
  • Leptin showed a positive correlation with insulin resistance index in boys (r = 0.45, p = 0.05), but not in girls.
  • CONCLUSIONS: This study has confirmed a positive correlation between leptin levels and BMI SDS.
  • In obese children elevated leptin is associated with central resistance to its action.
  • The positive correlation of leptin with insulin resistance index may suggest a major role of leptin in insulin resistance.
  • [MeSH-major] Blood Glucose / metabolism. Insulin Resistance. Leptin / blood. Obesity / epidemiology. Obesity / metabolism

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Blood Sugar.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432812.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Insulin; 0 / Leptin
  •  go-up   go-down


58. Chang HH, Gean PW, Chou CH, Yang YK, Tsai HC, Lu RB, Chen PS: C825T polymorphism of the GNB3 gene on valproate-related metabolic abnormalities in bipolar disorder patients. J Clin Psychopharmacol; 2010 Oct;30(5):512-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C825T polymorphism of the GNB3 gene on valproate-related metabolic abnormalities in bipolar disorder patients.
  • BACKGROUND: Valproate (VPA) is a mood stabilizer for treating patients with bipolar disorder (BD).
  • RESULTS: The variation of GNB3 C825T showed an association with higher plasma total cholesterol (P = 0.037), triglyceride (P = 0.014), and leptin (P < 0.001) levels in BD patients treated with VPA.
  • After adjusting for age, sex, types of BDs, and serum concentration of VPA, the variation of GNB3 C825T remained significantly associated with the levels of serum leptin and body mass index (BMI; P < 0.001 and P = 0.030, respectively).
  • In addition, the GNB3 C825T showed significant drug-single-nucleotide polymorphism interactions with insulin levels (P = 0.033), triglyceride levels (P = 0.013), leptin levels (P = 0.013), and BMI (P = 0.018).
  • These results indicated that the T allele may be associated with lower serum leptin levels and BMI in BD patients treated with VPA.
  • [MeSH-major] Alleles. Bipolar Disorder / genetics. Bipolar Disorder / metabolism. Heterotrimeric GTP-Binding Proteins / genetics. Polymorphism, Single Nucleotide / genetics. Protein Subunits / genetics. Valproic Acid / adverse effects
  • [MeSH-minor] Adult. Body Mass Index. Female. Heterozygote Detection. Humans. Leptin / blood. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20814328.001).
  • [ISSN] 1533-712X
  • [Journal-full-title] Journal of clinical psychopharmacology
  • [ISO-abbreviation] J Clin Psychopharmacol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / G-protein beta3 subunit; 0 / Leptin; 0 / Protein Subunits; 614OI1Z5WI / Valproic Acid; EC 3.6.5.1 / Heterotrimeric GTP-Binding Proteins
  •  go-up   go-down


59. Peng Y, Wang HY, Molberg KH: Cutaneous colocalized invasive poorly differentiated carcinoma and chronic lymphocytic leukemia/small lymphocytic lymphoma of the head and neck region: a case report and review of the literature. Arch Otolaryngol Head Neck Surg; 2009 Jun;135(6):606-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous colocalized invasive poorly differentiated carcinoma and chronic lymphocytic leukemia/small lymphocytic lymphoma of the head and neck region: a case report and review of the literature.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Antibodies, Monoclonal. DNA-Binding Proteins / metabolism. Dermis / pathology. Flow Cytometry. Humans. Immunohistochemistry. Immunophenotyping. Keratin-7 / metabolism. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19528411.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / DNA-Binding Proteins; 0 / Keratin-7; 0 / TTF1 protein, human
  • [Number-of-references] 14
  •  go-up   go-down


60. Lin J, Yan GT, Gao XN, Liao J, Wang LH, Hao XH: [Distribution of leptin expression and its effect on the recovery of sepsis-induced internal disorders]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 May;39(3):360-3, 417
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distribution of leptin expression and its effect on the recovery of sepsis-induced internal disorders].
  • OBJECTIVE: To explore the distribution of leptin expression and the effect of sepsis on leptin protein and mRNA levels.
  • The mRNA expressions of leptin in those samples were determined by RT-PCR.
  • Radioimmunoassay was applied to measure serum leptin concentrations in each group at 12 h after injury, while RT-PCR was also used to detect Leptin mRNA expressions in hypothalamus, fat and lung after injury.
  • RESULTS: Leptin mRNA expressions were confirmed in all the above nine vital organs, with the highest in kidney but the lowest in testis.
  • The serum leptin level showed no significant difference between sham operation group and other four groups.
  • Compared with sham operation group, the Leptin mRNA level in CLP group decreased significantly in hypothalamus, fat and lung, while that in the other three groups showed different changes.
  • The effect of intralipid on Leptin mRNA expression was found to be a dual-direction pattern, with central stimulation but peripheral inhibition.
  • CONCLUSION: Leptin is widely expressed in multiple vital organs, and it may be a protective factor to promote recovery of sepsis-induced internal disorders.
  • [MeSH-major] Gene Expression Profiling. Leptin / physiology. Sepsis / physiopathology

  • MedlinePlus Health Information. consumer health - Sepsis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18575315.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Leptin; 0 / RNA, Messenger
  •  go-up   go-down


61. Tsimberidou AM, Wen S, McLaughlin P, O'Brien S, Wierda WG, Lerner S, Strom S, Freireich EJ, Medeiros LJ, Kantarjian HM, Keating MJ: Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol; 2009 Feb 20;27(6):904-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma.
  • PURPOSE: Other malignancies have been reported to occur with increased frequency in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
  • The aim of this study was to determine the frequency, outcomes, and factors associated with other cancers in patients with CLL/SLL.
  • PATIENTS AND METHODS: We reviewed the records of consecutive patients with previously untreated CLL/SLL seen at The University of Texas M. D.
  • Overall, 625 cancers were observed in 551 patients, including skin (30%), prostate (13%), breast (9%), melanoma (8%), lymphoma (8%), gastrointestinal (9%), lung (6%), and other cancers (17%).
  • In Cox analysis, independent factors predicting development of new cancers were older age, male sex, and elevated levels of beta2-microglobulin, lactate dehydrogenase, and creatinine.
  • In patients who were treated for CLL/SLL, the treatment regimen did not affect the risk of subsequent cancer (P = .49).
  • CONCLUSION: Patients with CLL/SLL have more than twice the risk of developing a second cancer and an increased frequency of certain cancer types.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology. Neoplasms, Second Primary / epidemiology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1978 Aug;61(2):337-40 [277720.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] Blood. 1993 Jun 1;81(11):2878-84 [8499626.001]
  • [Cites] Leuk Res. 2005 Oct;29(10):1103-4 [16111529.001]
  • [Cites] J Natl Cancer Inst. 1996 Mar 6;88(5):270-8 [8614005.001]
  • [Cites] Ann Hematol. 2004 Jun;83(6):356-63 [15024607.001]
  • [Cites] JAMA. 1975 Apr 21;232(3):267-9 [47401.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4648-56 [17925562.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2583-91 [15197800.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4079-88 [15767648.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):44-9 [1702145.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1414-20 [11230486.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3064-71 [15284112.001]
  • [Cites] Semin Oncol. 2000 Dec;27(6 Suppl 12):37-41 [11225999.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):15-25 [16391368.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1695-700 [8400226.001]
  • (PMID = 19114699.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC4979239
  •  go-up   go-down


62. Kartal O, Inal V, Baysan O, Sağlam K: [Relationship between serum leptin levels and left ventricular hypertrophy in obese hypertensive patients]. Anadolu Kardiyol Derg; 2008 Oct;8(5):342-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between serum leptin levels and left ventricular hypertrophy in obese hypertensive patients].
  • [Transliterated title] Sişman hipertansif hastalarda leptin düzeyleri ve sol ventrikül hipertrofisi ile ilişkisi.
  • OBJECTIVE: Previous studies showed relation between elevated serum leptin levels (SLL) and hypertension.
  • The aim of this study was to evaluate relationship between SLL and left ventricular hypertrophy (LVH) and body mass index (BMI) in obese hypertensive patients.
  • Hypertensive patients were classified as; level-I or level-II according to JNC-VII classification and as normal weighted (18-24.99 kg/m2), over weighted (25-26.99 kg/m2) and obese (27 kg/m2 and above) according to BMI's.
  • All the patients were evaluated by echocardiography and blood samples were withdrawn for determination SLL.
  • Logistic regression analysis was applied for the evaluation of relationship between SLL and clinical variables.
  • RESULTS: Mean levels of arterial blood pressure (ABP) of total 80 patients (36 males and 44 females) was 155+/-1.1/95.1+/-0.7 mmHg and the mean age was 48.9+/-1.3 years.
  • Patients with level I hypertension (n=32) had mean ABP of 149.7+/-0.5/90.9+/-0.6 mmHg and with level-II hypertension (n=48)--mean ABP 168.5+/-1.6/102.9+/-0.9 mmHg.
  • There were no differences in LVH incidence between hypertension level groups and BMI groups (p>0.05).
  • Serum leptin levels were similar in patients with level I and level II hypertension (33.5+/-2.9 ng/ml and 37.3+/-3.6 ng/ml, respectively, p>0.05).
  • However, leptin levels were higher in obese patients as compared with normal and over weighted patients (40.9+/-3.2 ng/ml versus 28.5+/-3.6 ng/ml and 32.8+/-4.9 ng/ml, p<0.01).
  • Patients with LVH had significantly higher levels of leptin as compared with patients without LVH (51.40+/-5.1 ng/ml versus 28.30+/-4.20 ng/ml, p<0.05).
  • Logistic regression analysis demonstrated that SLL independently of blood pressure and BMI is related with LVH (OR--1.7, %95 CI--1.2-1.9, p<0.05).
  • CONCLUSION: Our study showed that elevated serum leptin levels are significantly related with LVH independently of body mass index and level of blood pressure.
  • Thus, elevated SLLs, independently of hypertension level and BMI classification, coexist with LVH.
  • Sympathetic activation or direct cardiac receptor activation or proliferative effects of leptin may be responsible for this coexistence.
  • [MeSH-major] Hypertension / blood. Hypertrophy, Left Ventricular / blood. Hypertrophy, Left Ventricular / pathology. Leptin / blood. Obesity / blood

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Anadolu Kardiyol Derg. 2008 Oct;8(5):347-9 [18849225.001]
  • (PMID = 18849224.001).
  • [ISSN] 1308-0032
  • [Journal-full-title] Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology
  • [ISO-abbreviation] Anadolu Kardiyol Derg
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


63. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol; 2005 Feb 1;23(4):667-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
  • PURPOSE: Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
  • PATIENTS AND METHODS: Patients were stratified, based on preclinical data, into arm A (mantle-cell lymphoma) or arm B (other B-cell lymphomas) without limitation in number of prior therapies.
  • RESULTS: Sixty patients with a median number of prior therapies of 3.5 (range, one to 12 therapies) were enrolled; 33 patients were in arm A and 27 were in arm B, including 12 diffuse large B-cell lymphomas, five follicular lymphomas (FL), three transformed FLs, four small lymphocytic lymphomas (SLL), two Waldenstrom's macroglobulinemias (WM), and one marginal zone lymphoma.
  • In arm B, four of 21 assessable patients responded (one SLL patient had a CR, one FL patient had a CR unconfirmed, one diffuse large B-cell lymphoma patient had a PR, and one WM patient had a PR) for an ORR of 19% (95% CI, 5% to 42%).
  • CONCLUSION: Bortezomib showed promising activity in relapsed mantle-cell lymphoma and encouraging results in other B-cell lymphomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Lymphoma, B-Cell / drug therapy. Protease Inhibitors / therapeutic use. Pyrazines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Feb 1;23(4):657-8 [15613690.001]
  • (PMID = 15613697.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


64. Takeuchi H, Kitade M, Kikuchi I, Shimanuki H, Kumakiri J, Takeda S: Influencing factors of adhesion development and the efficacy of adhesion-preventing agents in patients undergoing laparoscopic myomectomy as evaluated by a second-look laparoscopy. Fertil Steril; 2008 May;89(5):1247-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTERVENTION(S): Video tape recording was performed during the second-look laparoscopy (SLL) to evaluate the postoperative uterine wound adhesions and adhesions around the uterine adnexa.
  • MAIN OUTCOME MEASURE(S): Evaluation of adhesions at the uterine wound and of de novo adhesions of the uterine adnexa by SLL.
  • RESULT(S): The SLL revealed uterine surgical wound adhesions in 141 patients (37.9%) and de novo adhesions of the uterine adnexa in 33 patients (8.9%).
  • The results of analysis to determine the factors influencing the development of postoperative adhesions revealed that the diameter of the largest myoma, number of myomas, and type of adhesion-preventing agent used (except for fibrin sheath, which had no effect) influenced the incidence of postoperative adhesions at the surgical wound, but only the diameter of the largest myoma influenced the incidence of de novo adhesions of the uterine adnexa.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18155700.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cellulose, Oxidized; 0 / Fibrin Tissue Adhesive; 0 / INTERCEED
  •  go-up   go-down


65. Xia D, Song Y, Li C, Zhang F, Wei M: The change of serum leptin and its relationship with platelet membrane glycoprotein Ib in patients with coronary heart disease. Front Med China; 2007 Oct;1(4):352-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The change of serum leptin and its relationship with platelet membrane glycoprotein Ib in patients with coronary heart disease.
  • The aim of this paper was to investigate the change of serum leptin and its relationship with platelet membrane glycoprotein Ib (GP Ib) in patients with coronary heart disease (CHD).
  • Serum leptin was detected by enzyme linked immunosorbent assay.
  • After correcting the differences of systolic blood pressure, body mass index (BMI), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), fasting glucose, PPBS, fasting insulin and quantitative insulin sensitive index, serum leptin level in the CHD group was significantly higher than that in the control group (P < 0.05).
  • Single factor correlative analysis revealed that serum leptin in CHD patients was negatively correlated with the average fluorescence intensity of platelet membrane GP Ib (P < 0.05).
  • Multifactorial stepwise regression analysis showed that serum leptin in CHD patients was independently negatively correlated with the average fluorescence intensity of platelet membrane GP Ib (P < 0.05).
  • Logistic analysis demonstrated that serum leptin was independently correlated with the risk of CHD (P < 0.05).
  • The increase of serum leptin could affect blood platelet activation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Pharmacol. 2005 Apr;5(2):160-4 [15780825.001]
  • [Cites] Trends Cardiovasc Med. 2004 Jan;14(1):18-22 [14720470.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Aug;89(8):3872-8 [15292320.001]
  • [Cites] J Cell Biol. 2001 Aug 6;154(3):485-90 [11489912.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):25096-100 [11342529.001]
  • [Cites] FASEB J. 1999 Jul;13(10):1231-8 [10385613.001]
  • [Cites] Med Hypotheses. 2006;67(1):82-6 [16500036.001]
  • [Cites] Kobe J Med Sci. 2001 Jun;47(3):141-50 [11729375.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Jan;27(1):13-8 [12532148.001]
  • [Cites] Eur Heart J. 2006 Oct;27(19):2294-9 [16543250.001]
  • [Cites] Diabetes. 1999 Sep;48(9):1787-93 [10480609.001]
  • [Cites] Circulation. 2001 Dec 18;104(25):3052-6 [11748099.001]
  • [Cites] Nature. 1998 Feb 5;391(6667):591-4 [9468137.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1998 Jun;18(6):928-33 [9633933.001]
  • [Cites] Atherosclerosis. 2007 Apr;191(2):418-26 [16712853.001]
  • [Cites] Blood. 1991 Feb 15;77(4):770-9 [1704263.001]
  • [Cites] Diabetes Care. 1998 May;21(5):782-6 [9589240.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Oct;289(4):E695-702 [15886225.001]
  • [Cites] Neurosci Lett. 2000 Oct 27;293(2):107-10 [11027845.001]
  • [Cites] Diabetes. 2003 Aug;52(8):2121-8 [12882931.001]
  • [Cites] Coron Artery Dis. 2003 Feb;14(1):65-79 [12629328.001]
  • [Cites] J Thromb Haemost. 2005 May;3(5):1042-9 [15869602.001]
  • [Cites] J Clin Invest. 1997 Jul 15;100(2):270-8 [9218503.001]
  • [Cites] Clin Exp Immunol. 2006 Mar;143(3):452-7 [16487244.001]
  • [Cites] Int J Obes Relat Metab Disord. 2001 Oct;25(10):1471-3 [11673768.001]
  • [Cites] Coron Artery Dis. 2003 Aug;14(5):357-63 [12878900.001]
  • [Cites] Diabet Med. 2005 Mar;22(3):278-85 [15717875.001]
  • [Cites] Angiology. 2006 May-Jun;57(3):267-72 [16703186.001]
  • (PMID = 24573923.001).
  • [ISSN] 1673-7342
  • [Journal-full-title] Frontiers of medicine in China
  • [ISO-abbreviation] Front Med China
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


66. Shen XH, Tang QY, Huang J, Cai W: Vitamin E regulates adipocytokine expression in a rat model of dietary-induced obesity. Exp Biol Med (Maywood); 2010 Jan;235(1):47-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to determine the effect of the antioxidant vitamin E (VE) on adiponectin and leptin expression in obese rats.
  • Blood and adipose tissues were then immediately collected; mRNA and protein levels of leptin and adiponectin were measured by realtime reverse transcription-polymerase chain reaction and Western blotting.
  • Biomarkers of oxidative stress, including serum levels of 8-epi-prostaglandin-F(2)alpha (8-epi-PGF(2)alpha) and glutathione peroxidase activity, were also examined.
  • Adiponectin and leptin levels were lower in the DIO group than in the control group.
  • VE intervention increased the expression of both leptin and adiponectin (P values < 0.05).
  • Association analysis showed that serum leptin levels correlated positively with body fat mass (r = 0.601, P < 0.05).
  • Both serum leptin and adiponectin levels were associated with the presence of serum 8-epi-PGF2 alpha (leptin, r = 0.513, P < 0.05; adiponectin, r = -0.422, P < 0.05).
  • Administration of VE decreases leptin and adiponectin expression in obese rats.
  • [MeSH-major] Adiponectin / blood. Adiponectin / genetics. Antioxidants / pharmacology. Leptin / blood. Leptin / genetics. Obesity / blood. Obesity / genetics. Vitamin E / pharmacology

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Vitamin E.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. PROSTAGLANDIN F2ALPHA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20404018.001).
  • [ISSN] 1535-3699
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Antioxidants; 0 / Biomarkers; 0 / DNA Primers; 0 / Dietary Fats; 0 / Leptin; 0 / RNA, Messenger; 1406-18-4 / Vitamin E; 27415-26-5 / 8-epi-prostaglandin F2alpha; B7IN85G1HY / Dinoprost; EC 1.11.1.9 / Glutathione Peroxidase
  •  go-up   go-down


67. Lassiter TL, Ryde IT, Levin ED, Seidler FJ, Slotkin TA: Neonatal exposure to parathion alters lipid metabolism in adulthood: Interactions with dietary fat intake and implications for neurodevelopmental deficits. Brain Res Bull; 2010 Jan 15;81(1):85-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We assessed serum leptin and adiponectin, tumor necrosis factor-alpha (TNFalpha) in adipose tissues, and thiobarbituric acid reactive species (TBARS) in peripheral tissues and brain regions.
  • Neonatal parathion exposure uncoupled serum leptin levels from their dependence on body weight, suppressed adiponectin and elevated TNFalpha in white adipose tissue.
  • Our results are consistent with impaired fat utilization and prediabetes, as well as exposing a potential relationship between effects on fat metabolism and on synaptic function in the brain.

  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PARATHION .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Health Perspect. 2008 Nov;116(11):1456-62 [19057696.001]
  • [Cites] Neurotoxicol Teratol. 2009 Nov-Dec;31(6):390-9 [19616088.001]
  • [Cites] J Physiol Pharmacol. 2000 Dec;51(4 Pt 2):883-96 [11220496.001]
  • [Cites] Diabetes. 2001 May;50(5):1126-33 [11334417.001]
  • [Cites] Environ Health Perspect. 2002 Dec;110(12):A787-92 [12460819.001]
  • [Cites] Neurochem Int. 2003 Aug;43(3):243-9 [12689604.001]
  • [Cites] Environ Health Perspect. 2004 Feb;112(2):170-8 [14754571.001]
  • [Cites] Metabolism. 2004 May;53(5):589-93 [15131762.001]
  • [Cites] Comp Biochem Physiol C Toxicol Pharmacol. 2004 Apr;137(4):343-7 [15228952.001]
  • [Cites] Chem Res Toxicol. 2004 Aug;17(8):983-98 [15310231.001]
  • [Cites] Arch Environ Contam Toxicol. 1980;9(3):349-82 [7396557.001]
  • [Cites] Comp Biochem Physiol B. 1983;76(2):335-9 [6641163.001]
  • [Cites] Biochim Biophys Acta. 1990 Sep 18;1046(2):159-66 [2223854.001]
  • [Cites] Free Radic Res Commun. 1991;12-13 Pt 1:147-52 [2071030.001]
  • [Cites] J Neurochem. 1995 Jun;64(6):2755-64 [7760056.001]
  • [Cites] Toxicol Appl Pharmacol. 1995 Sep;134(1):53-62 [7545834.001]
  • [Cites] Environ Health Perspect. 2009 Jun;117(6):916-22 [19590683.001]
  • [Cites] Environ Health Perspect. 2009 Feb;117(2):159-66 [19270782.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2005 Jul;15(4):297-309 [15367928.001]
  • [Cites] Neurotoxicology. 2005 Aug;26(4):573-87 [16112323.001]
  • [Cites] Environ Health Perspect. 2005 Oct;113(10):1291-4 [16203236.001]
  • [Cites] Environ Health Perspect. 2006 May;114(5):691-6 [16675422.001]
  • [Cites] Environ Health Perspect. 2006 May;114(5):746-51 [16675431.001]
  • [Cites] Int J Occup Environ Health. 2006 Apr-Jun;12(2):134-41 [16722193.001]
  • [Cites] Diabetes. 2006 Jun;55(6):1537-45 [16731815.001]
  • [Cites] Obesity (Silver Spring). 2006 Aug;14 Suppl 5:242S-249S [17021375.001]
  • [Cites] Environ Health Perspect. 2006 Oct;114(10):1542-6 [17035140.001]
  • [Cites] Ann N Y Acad Sci. 2006 Nov;1084:89-117 [17151295.001]
  • [Cites] Diabetes Care. 2007 Mar;30(3):529-34 [17327316.001]
  • [Cites] Environ Health Perspect. 2007 May;115(5):792-8 [17520070.001]
  • [Cites] J Med Toxicol. 2007 Sep;3(3):89-93 [18072142.001]
  • [Cites] Brain Res Bull. 2008 Jan 31;75(1):166-72 [18158111.001]
  • [Cites] Neurotoxicol Teratol. 2008 Mar-Apr;30(2):125-30 [18166376.001]
  • [Cites] Int J Androl. 2008 Apr;31(2):201-8 [18315718.001]
  • [Cites] Environ Health Perspect. 2008 Oct;116(10):1308-14 [18941570.001]
  • [Cites] Brain Res Bull. 2008 Dec 16;77(6):404-11 [18817854.001]
  • [Cites] Mol Cell Biochem. 1996 Oct-Nov;163-164:137-43 [8974049.001]
  • [Cites] Shock. 1998 Nov;10(5):329-34 [9840647.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 1999;107(2):119-25 [10320052.001]
  • [Cites] Lipids. 1999 May;34(5):457-66 [10380117.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 1999 Jul-Sep;2(3):211-55 [10429680.001]
  • [Cites] Diabetes. 2005 Apr;54(4):917-27 [15793228.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 Aug 1;206(1):17-26 [15963341.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 Aug 7;206(2):246-54 [15967215.001]
  • [Cites] Neurotoxicol Teratol. 2009 Jan-Feb;31(1):11-7 [18773955.001]
  • [Cites] Environ Health Perspect. 2000 Jun;108(6):515-20 [10856024.001]
  • (PMID = 19615431.001).
  • [ISSN] 1873-2747
  • [Journal-full-title] Brain research bulletin
  • [ISO-abbreviation] Brain Res. Bull.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES010356-090001; United States / NIEHS NIH HHS / ES / P42 ES010356; United States / NIEHS NIH HHS / ES / ES10356; United States / NIEHS NIH HHS / ES / P42 ES010356-090001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Cholinesterase Inhibitors; 0 / Dietary Fats; 0 / Leptin; 0 / Thiobarbituric Acid Reactive Substances; 0 / Tumor Necrosis Factor-alpha; 61G466064D / Parathion
  • [Other-IDs] NLM/ NIHMS132377; NLM/ PMC2795103
  •  go-up   go-down


68. Konishi N, Otaka M, Odashima M, Jin M, Wada I, Komatsu K, Sato T, Kato S, Matsuhashi T, Watanabe S: Systemic stress increases serum leptin level. J Gastroenterol Hepatol; 2006 Jul;21(7):1099-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic stress increases serum leptin level.
  • BACKGROUND AND AIM: Leptin, the product of the obese (ob) gene, is a circulating peptide mainly synthesized by adipocytes.
  • Leptin inhibits food intake and decreases body weight.
  • A recent report has suggested that the gastric mucosa is also the source of leptin, and that the stomach leptin also contributes to the regulation of the serum leptin level.
  • The aim of the present study was to investigate the effect of water-immersion stress on serum, stomach and adipose tissue leptin levels to understand the relationship between stress and eating behavior.
  • The leptin level in the serum, gastric mucosa and adipose tissue was measured using ELISA system before and after the initiation of water-immersion stress.
  • RESULTS: The serum leptin level was significantly increased by water-immersion stress.
  • However, the gastric leptin level significantly decreased 6 and 9 h after the stress.
  • The adipose tissue leptin level significantly increased 3 h after the stress.
  • CONCLUSIONS: The results suggest that changes in serum leptin levels could be associated with stimulation of leptin secretion from the gastric mucosa and leptin production in the adipose tissue by systemic stress and that leptin might be regulated by stress-related events.
  • [MeSH-major] Leptin / blood. Stress, Physiological / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16824059.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Leptin
  •  go-up   go-down


69. Yin CC, Lin KI, Ketterling RP, Knudson RA, Medeiros LJ, Barron LL, Huh YO, Luthra R, Keating MJ, Abruzzo LV: Chronic lymphocytic leukemia With t(2;14)(p16;q32) involves the BCL11A and IgH genes and is associated with atypical morphologic features and unmutated IgVH genes. Am J Clin Pathol; 2009 May;131(5):663-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukemia With t(2;14)(p16;q32) involves the BCL11A and IgH genes and is associated with atypical morphologic features and unmutated IgVH genes.
  • The t(2;14)(p16;q32) has been reported previously in only 12 cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
  • We describe 6 new cases of CLL/SLL with t(2;14)(p16;q32).
  • All showed atypical lymphocyte morphologic features with plasmacytoid differentiation and irregular nuclei; 3 had increased prolymphocytes.
  • Karyotyping identified t(2;14)(p16;q32) as the sole abnormality in 1, primary abnormality in 2, and part of a complex karyotype in 3.
  • We conclude that CLL/SLL with t(2;14) (p16;q32) and BCL11A/IgH rearrangement is characterized by atypical morphologic features and unmutated IgV(H) genes.
  • [MeSH-major] Carrier Proteins / genetics. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 2. Genes, Immunoglobulin Heavy Chain. Immunoglobulin Heavy Chains / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Nuclear Proteins / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Bone Marrow / pathology. DNA Mutational Analysis. DNA, Neoplasm / analysis. Female. Flow Cytometry. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. ZAP-70 Protein-Tyrosine Kinase / metabolism

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19369625.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL11A protein, human; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / DNA, Neoplasm; 0 / Immunoglobulin Heavy Chains; 0 / Nuclear Proteins; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


70. Aguilar-Chavez EA, Gamez-Nava JI, Lopez-Olivo MA, Galvan-Melendres S, Corona-Sanchez EG, Loaiza-Cardenas CA, Celis A, Cardona-Muñoz EG, Gonzalez-Lopez L: Circulating leptin and bone mineral density in rheumatoid arthritis. J Rheumatol; 2009 Mar;36(3):512-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating leptin and bone mineral density in rheumatoid arthritis.
  • OBJECTIVE: To evaluate the association between circulating leptin and bone mineral density (BMD) in patients with rheumatoid arthritis (RA).
  • Serum leptin concentrations were measured by ELISA.
  • Spearman's correlation coefficients (rho) were determined between BMD and leptin and other variables.
  • RESULTS: Patients' serum leptin levels varied widely (range 2-128 ng/ml).
  • Higher levels of leptin correlated significantly with BMD in the lumbar spine (rho = 0.17, p = 0.04) and total hip (rho = 0.21, p = 0.01).
  • After adjustment for confounders, leptin was no longer associated with BMD.
  • CONCLUSION: No relevant association was found between circulating leptin levels and BMD in patients with RA in this cross-sectional study.
  • Followup studies are needed to evaluate whether abnormal leptin levels confer a risk for fractures due to osteoporosis.
  • [MeSH-major] Arthritis, Rheumatoid / blood. Bone Density. Leptin / blood


71. Kumakiri J, Kikuchi I, Kitade M, Kumakiri Y, Kuroda K, Matsuoka S, Tokita S, Takeda S: Evaluation of factors contributing to uterine scar formation after laparoscopic myomectomy. Acta Obstet Gynecol Scand; 2010 Aug;89(8):1078-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • POPULATION: A total of 692 patients who underwent second-look laparoscopy (SLL) after LM.
  • METHOD: Video-tape recording during SLL to evaluate the conditions of uterine suture wound healing, with univariate and logistic regression analysis.
  • RESULTS: SLL revealed that 628 patients (90.8%) had a normal uterus and 64 patients (9.2%) had a scarred uterus.

  • MedlinePlus Health Information. consumer health - Scars.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20636246.001).
  • [ISSN] 1600-0412
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


72. Khaled S, Gotlieb V, Schuster IP, Saif MW: Multiple lymphomatous polyposis associated with small lymphocytic lymphoma: a unique presentation. J Gastrointestin Liver Dis; 2008 Dec;17(4):461-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple lymphomatous polyposis associated with small lymphocytic lymphoma: a unique presentation.
  • Multiple lymphomatous polyposis (MLP) is a rare extra-nodal manifestation of lymphoma.
  • In most cases, MLP is associated with mantle cell lymphoma (MCL).
  • We report a 66-year-old male diagnosed with small lymphocytic lymphoma (SLL)/chronic lymphocytic lymphoma (CLL), who showed evidence of rectal bleeding.
  • A CT-scan of the abdomen and pelvis showed an enlarged spleen, multiple paraaortic and mesenteric lymph nodes, and some diverticular pouching along the antimesenteric border of the pelvic colon.
  • A colonoscopy revealed the presence of multiple polypoid lesions, biopsies of which showed diffuse lymphoid infiltrate without any identifiable follicles.
  • Immunohistochemical analysis combined with a Fluorescence In-Situ Hybridization (FISH) study excluded the diagnosis of MCL.
  • A bone marrow aspiration biopsy demonstrated diffuse infiltration of the bone marrow with low grade lymphocytes that expressed CD 20, CD5 and CD23, with negative BCL-1, t (11;.
  • A diagnosis of B-cell CLL with kappa light chain restriction was made.
  • Multiple lymphomatous polyposis is considered to be a digestive counterpart to MCL and can therefore be considered as a presentation of MCL.
  • The patient's bone marrow revealed a B-cell lymphoma of CLL/SLL phenotype, which to our knowledge has not been linked to MLP in previously reported cases.
  • [MeSH-major] Colonic Polyps / diagnosis. Colorectal Neoplasms / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymphoma, Mantle-Cell / diagnosis
  • [MeSH-minor] Aged. B-Lymphocytes / metabolism. Biomarkers, Tumor / metabolism. Bone Marrow / pathology. Diagnosis, Differential. Humans. Male


73. Lin J, Yan GT, Hao XH, Wang LH, Zhang K, Xue H: Effect of intestinal ischemia-reperfusion injury on protein levels of leptin and orexin-A in peripheral blood and central secretory tissues. World J Gastroenterol; 2005 Feb 21;11(7):1000-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of intestinal ischemia-reperfusion injury on protein levels of leptin and orexin-A in peripheral blood and central secretory tissues.
  • AIM: To explore the effect of intestinal ischemia-reperfusion injury on protein levels of leptin and orexin-A in peripheral blood and their central secretory tissues and to find out the role leptin and orexin-A play in acute inflammatory responses.
  • Two highly-sensitive radioimmunoassays for leptin and orexin-A were established and used to check the change of their concentrations in peripheral blood and central secretory tissues before and after intestinal I/R injury.
  • RESULTS: Compared with the serum leptin level before injury, it decreased significantly in I60'R30' group and increased significantly in I60'R360' group; compared to sham-operation group after injury, serum leptin level increased significantly in I60'R360' group; compared to sham-operation group after injury, adipose leptin levels decreased significantly in I60'R30' and I60'R90' groups, while increased significantly in I60'R360' group.
  • There was no significant difference between the expression levels of orexin-A before and after I/R injury.
  • CONCLUSION: Leptin has a time-dependent response and orexin-A has a delayed response to acute inflammatory stimuli such as intestinal I/R injury and they may participate in metabolic disorders in injury as inflammatory cytokines.
  • [MeSH-major] Adipose Tissue / metabolism. Hypothalamus / metabolism. Intestines / pathology. Intracellular Signaling Peptides and Proteins / blood. Leptin / blood. Neuropeptides / blood. Reperfusion Injury / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15742403.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies; 0 / Intracellular Signaling Peptides and Proteins; 0 / Leptin; 0 / Neuropeptides; 0 / Orexins
  • [Other-IDs] NLM/ PMC4250760
  •  go-up   go-down


74. Rico L, Del Rio M, Bravo A, Ramirez A, Jorcano JL, Page MA, Larcher F: Targeted overexpression of leptin to keratinocytes in transgenic mice results in lack of skin phenotype but induction of early leptin resistance. Endocrinology; 2005 Oct;146(10):4167-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted overexpression of leptin to keratinocytes in transgenic mice results in lack of skin phenotype but induction of early leptin resistance.
  • The epidermis has a great potential as a bioreactor to produce proteins with systemic action.
  • Thus, the long-term effects of leptin on skin physiology have not been studied, and the metabolic consequences of sustained keratinocyte-derived leptin overexpression are unknown.
  • Herein we describe that very high serum leptin levels can be achieved from a cutaneous source in transgenic mice in which leptin cDNA overexpression was driven by the keratin K5 gene regulatory sequences.
  • Histopathological analysis including the study of skin differentiation and proliferation markers in these transgenic mice revealed that keratinocyte-derived leptin overexpression appears not to have any impact on cutaneous homeostasis.
  • Although young K5-leptin transgenic mice showed remarkable thinness and high glucose metabolism as shown in other leptin transgenic mouse models, a marked leptin insensitivity become apparent as early as 3-4 months of age as demonstrated by increased weight gain and insulin resistance development.
  • Other signs of leptin/insulin resistance included increased bone mass, organomegaly, and wound healing impairment.
  • In addition, to provide evidence for the lack of untoward effects of leptin on epidermis, this transgenic mouse helps us to establish the safe ranges of keratinocyte-derived leptin overexpression and may be useful as a model to study leptin resistance.
  • [MeSH-major] Keratinocytes / physiology. Leptin / genetics. Skin / cytology
  • [MeSH-minor] Adipose Tissue / cytology. Animals. Animals, Newborn. Body Weight. Cell Differentiation. Drug Resistance / genetics. Energy Intake. Epidermis / cytology. Epidermis / physiology. Keratin-15. Keratin-5. Keratins / genetics. Mice. Mice, Inbred C57BL. Mice, Inbred DBA. Mice, Transgenic. Wound Healing


75. Panichi V, Manca-Rizza G, Paoletti S, Taccola D, Consani C, Filippi C, Mantuano E, Sidoti A, Grazi G, Antonelli A, Angelini D, Petrone I, Mura C, Tolaini P, Saloi F, Ghezzi PM, Barsotti G, Palla R: Effects on inflammatory and nutritional markers of haemodiafiltration with online regeneration of ultrafiltrate (HFR) vs online haemodiafiltration: a cross-over randomized multicentre trial. Nephrol Dial Transplant; 2006 Mar;21(3):756-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CRP levels were measured by a highly sensitive nephelometric assay (Dade, Behring) with a sensitivity of 0.1 microg/ml.
  • Serum leptin was determined with a ELISA method (Biosource, USA).
  • No significant variation in serum leptin levels were observed during the study.
  • CRP and IL-6 were highly correlated (r = 0.54; P < 0.001) as was serum albumin and prealbumin (r = 0.39; P < 0.001).
  • Serum albumin was negatively correlated with CRP (r = -0.26; P < 0.01) and IL-6 (r = -0.19; P < 0.05); serum prealbumin was correlated with IL-6 (r = 0.37; P < 0.001) and with CRP (r = 0.24; P < 0.01).


76. Oumeish OY, Oumeish I, Tarawneh M, Salman T, Sharaiha A: Necrobiotic xanthogranuloma associated with paraproteinemia and non-Hodgkin's lymphoma developing into chronic lymphocytic leukemia: the first case reported in the literature and review of the literature. Int J Dermatol; 2006 Mar;45(3):306-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Necrobiotic xanthogranuloma associated with paraproteinemia and non-Hodgkin's lymphoma developing into chronic lymphocytic leukemia: the first case reported in the literature and review of the literature.
  • A 56-year-old married female presented in May 1998 with a 5-month history of xanthelasma of the eyelids, followed 4 months later by two enlarged lymph nodes of the left side of the neck and three of the left axilla.
  • In July 1998, computed tomography (CT) scans of the chest and abdomen with contrast medium showed pretracheal, bilateral axillary, right retrochural, paracaval, aortocaval, and para-aortic lymph node enlargement.
  • These findings were suggestive of lymphoma.
  • One cervical and two left axillary lymph nodes were excised.
  • They revealed total replacement of the nodular architecture by a diffuse proliferation of mature lymphoid cells having small nuclei and a crumbled chromatin pattern, and very rare mitosis.
  • It was concluded from the lymph node biopsies that these changes were typical of non-Hodgkin's lymphoma, diffuse and small cell type, of low-grade malignancy.
  • The bone marrow picture was consistent with diffuse, well-differentiated non-Hodgkin's lymphoma, developing into chronic lymphocytic leukemia (CLL).
  • Endoscopy showed antral-type gastric mucosa exhibiting mild chronic gastritis.
  • Skin biopsy from a fresh lesion on the back showed a diffuse inflammatory cell infiltrate with collections of histiocytic cells.
  • The blood picture also showed monoclonal IgG paraprotein (3170 mg/dL) of the kappa light chain type.
  • The patient was treated by the oncologist for her lymphoma, and was given Cytoxan, prednisolone, endoxan, Leukeran, and melphalan.
  • She also responded to Leukeran at a dose of 5 mg daily for 5 days every month for 6 months, and showed regression in the size of the lymph nodes.
  • [MeSH-major] Granuloma / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / etiology. Lymphoma, Non-Hodgkin / complications. Necrobiotic Disorders / pathology. Paraproteinemias / etiology. Xanthomatosis / pathology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Xanthogranuloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533236.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Glucocorticoids; 18D0SL7309 / Chlorambucil; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan
  •  go-up   go-down


77. Vestergaard ET, Hansen TK, Nielsen S, Moller N, Christiansen JS, Jorgensen JO: Effects of GH replacement therapy in adults on serum levels of leptin and ghrelin: the role of lipolysis. Eur J Endocrinol; 2005 Oct;153(4):545-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of GH replacement therapy in adults on serum levels of leptin and ghrelin: the role of lipolysis.
  • OBJECTIVE: The regulation and function of systemic ghrelin levels appear to be associated with food intake and energy balance rather than GH.
  • Since GH, in turn, acutely induces lipolysis and insulin resistance in skeletal muscle, we aimed to study the isolated and combined effects of GH, free fatty acids (FFAs) and insulin sensitivity on circulating ghrelin levels in human subjects.
  • )) were studied on four occasions in a 2 x 2 factorial design with and without GH substitution and with and without administration of acipimox, which lowers FFA levels by inhibition of the hormone-sensitive lipase, in the basal state and during a hyperinsulinemic euglycemic clamp.
  • RESULTS: Serum FFA levels decreased with acipimox administration irrespective of GH status.
  • Fasting ghrelin levels decreased insignificantly during GH administration alone, but were reduced by 33% during co-administration of GH and acipimox (Aci) (in ng/l): 860 +/- 120 (-GH - Aci), 711 +/- 130 (-GH + Aci), 806 +/- 130 (+GH - Aci), 574 +/- 129 (+GH + Aci), P < 0.01.
  • GH and acipimox induced a reciprocal 25% increase in serum leptin levels (microg/l): 11.2 +/- 4.4 (-GH - Aci), 11.7 +/- 4.4 (-GH + Aci), 11.5 +/- 4.4 (+GH - Aci), 13.9 +/- 4.2 (+GH + Aci), P = 0.005.
  • CONCLUSION: Our data suggest that antilipolysis via suppression of the hormone-sensitive lipase in combination with GH administration is associated with significant and reciprocal changes in ghrelin and leptin.

  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Endocrinol. 2005 Nov;153(5):721
  • (PMID = 16189176.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Fatty Acids, Nonesterified; 0 / Ghrelin; 0 / Hypolipidemic Agents; 0 / Leptin; 0 / Peptide Hormones; 0 / Pyrazines; 12629-01-5 / Human Growth Hormone; 9002-72-6 / Growth Hormone; EC 3.1.1.13 / Sterol Esterase; K9AY9IR2SD / acipimox
  •  go-up   go-down


78. Leonard WR, Sorensen MV, Mosher MJ, Spitsyn V, Comuzzie AG: Reduced fat oxidation and obesity risks among the Buryat of Southern Siberia. Am J Hum Biol; 2009 Sep-Oct;21(5):664-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Shorter Buryat women (height-for-age Z-scores < or = -1) have significantly lower fasting fat oxidation levels compared to their taller counterparts.
  • Shorter women are also significantly heavier and fatter, and have higher serum lipid levels.
  • Among all Buryat women, reduced fat oxidation is significantly correlated with percent body fatness, serum triglyceride levels, and serum leptin levels, after controlling for relevant covariates.
  • Additionally, Buryat women with high dietary fat intakes and low fat oxidation are significantly fatter and have higher lipid and leptin levels than those with low fat intakes and high fat oxidation.
  • [MeSH-minor] Adolescent. Adult. Basal Metabolism. Body Weights and Measures. Cultural Evolution. Dietary Fats / metabolism. Female. Humans. Leptin / blood. Lipids / blood. Male. Middle Aged. Nutrition Disorders / ethnology. Oxidation-Reduction. Sex Factors. Siberia / epidemiology. Young Adult

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19322885.001).
  • [ISSN] 1520-6300
  • [Journal-full-title] American journal of human biology : the official journal of the Human Biology Council
  • [ISO-abbreviation] Am. J. Hum. Biol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1 C06 RR017515
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Leptin; 0 / Lipids
  •  go-up   go-down


79. O'Malley DP, Vance GH, Orazi A: Chronic lymphocytic leukemia/small lymphocytic lymphoma with trisomy 12 and focal cyclin d1 expression: a potential diagnostic pitfall. Arch Pathol Lab Med; 2005 Jan;129(1):92-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukemia/small lymphocytic lymphoma with trisomy 12 and focal cyclin d1 expression: a potential diagnostic pitfall.
  • Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma usually are distinctly different in regard to clinical presentation, morphology, immunophenotype, and molecular/genetic findings.
  • Cyclin D1 immunohistochemical staining is usually envisioned as a definitive method for resolving this differential diagnosis, with positivity supporting a diagnosis of mantle cell lymphoma.
  • We report a case involving a 58-year-old man with a diagnosis of CLL/SLL for several years.
  • A lymph node excision was performed after increased adenopathy was noted in the cervical region.
  • The excised lymph node showed typical morphologic findings of CLL/SLL, including the presence of characteristic proliferation centers.
  • Fluorescence in situ hybridization and conventional cytogenetics demonstrated trisomy 12 and an absence of t(11;14) in lymph node tissue.
  • Focal cyclin D1 expression by immunohistochemistry in nodal CLL/SLL is quite unusual and is discussed as a potential diagnostic pitfall.
  • [MeSH-major] Chromosomes, Human, Pair 12 / genetics. Cyclin D1 / biosynthesis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymphoma, Mantle-Cell / diagnosis. Trisomy / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunophenotyping / methods. Male. Middle Aged


80. Wang LJ, Zhou L, Yuan B, Wang L: [Regulative effect of leptin on gastric motility: experiment with conscious rats]. Zhonghua Yi Xue Za Zhi; 2006 Aug 29;86(32):2266-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Regulative effect of leptin on gastric motility: experiment with conscious rats].
  • OBJECTIVE: To observe the role of leptin on the regulation of inter-digestive migrating motor complex (MMC) and gastric motility of postprandial period, as well as the serum leptin level and its relationship with motilin during different fast and postprandial periods.
  • Blood samples were collected during the phases I, II, III, and IV, 3 minutes after feeding and then every 5 minutes to test the serum leptin and motilin. (2) Leptin group.
  • After the recording of the first MMC, leptin was perfused during the second MMC to observe its effect on the stomach motility. (3) Anti-leptin serum group.
  • During the second MMC, 5 minutes before feeding and 60 minutes after feeding, anti-leptin serum was perfused to observe its effect on the postprandial stomach motility. (4) Leptin + atropine group.
  • During the first MMC perfusion of atropine was followed by perfusion of leptin. and (5) leptin + cholecystokinin (CCK)-A receptor blocker group.
  • Perfusion of CCK-A receptor blocker was followed by perfusion of leptin.
  • Serum leptin and motilin levels were measured by radioimmunoassay.
  • When the stomach was empty, the mean concentration of serum leptin was (5.6 +/- 1.0) microg/L, (11.4 +/- 2.1) microg/L, and (2.1 +/- 0.7) microg/L during the phase I, II and III respectively, being the highest in the phase II, significantly higher than those in the phase I and III (both P < 0.01).
  • During digestive period, the serum concentration of leptin began to increase 3 minutes after the meal and reached its peak of (28.1 +/- 4.4) microg/L 10 minutes after the meal.
  • The serum concentration of leptin remained on a high level till 30 minutes later (compared with that in the inter-digestive period, P < 0.01).
  • On the contrary, the serum concentration of motilin was the highest in the phase III of MMC and the lowest in the digestive period.
  • Intravenous infusion of leptin (2.5 microg x kg(-1) x 10 min) turned the inter-digestive pattern of gastric motility to digestive period pattern with corpus distension and contraction of antrum and pylorus.
  • The effects of leptin on gastric motility were blocked by anti-leptin serum, atropine, and CCK-A receptor blocker loxiglumide.
  • CONCLUSION: Leptin is a hormone to promote the inter-digestive MMC phase II and postprandial digestive motility activities of stomach, the concentration fluctuation of which will cause satiety related delay of gastric emptying.
  • The effect of leptin on gastric motility is mediated by cholinergic nerve and CCK-A receptors.
  • [MeSH-major] Gastrointestinal Motility / physiology. Leptin / blood. Motilin / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064572.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Leptin; 52906-92-0 / Motilin
  •  go-up   go-down


81. Lin TS, Naumovski L, Lecane PS, Lucas MS, Moran ME, Cheney C, Lucas DM, Phan SC, Miller RA, Byrd JC: Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia. Leuk Lymphoma; 2009 Dec;50(12):1977-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia.
  • Chronic lymphocytic leukemia (CLL) cells are susceptible to oxidative stress.
  • A phase II trial administered MGd 5 mg/kg/day IV for 5 days every 3 weeks until disease progression to patients with previously treated CLL and small lymphocytic lymphoma.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Metalloporphyrins / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Chromosome Deletion. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 17 / genetics. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Flow Cytometry. Humans. Immunoblotting. In Situ Hybridization, Fluorescence. Male. Middle Aged. Phosphorylation / drug effects. Proto-Oncogene Proteins c-akt / metabolism. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19860624.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Metalloporphyrins; 6433A42F4F / motexafin gadolinium; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


82. Zent CS, Call TG, Hogan WJ, Shanafelt TD, Kay NE: Update on risk-stratified management for chronic lymphocytic leukemia. Leuk Lymphoma; 2006 Sep;47(9):1738-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on risk-stratified management for chronic lymphocytic leukemia.
  • Major recent advances in understanding the biology of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) have improved clinical evaluation and influenced treatment decisions.
  • CLL can be diagnosed early and accurately, and biological measurements can be used to predict a prognosis at diagnosis.
  • However, recent developments suggest that allogeneic stem cell transplant could have a larger role in a selected group of these patients.
  • Potential new treatment modalities include targeted molecules that interrupt key components of CLL cell survival pathways, and active and passive immunotherapy.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Risk Management
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Hematopoietic Stem Cell Transplantation. Humans

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064983.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Number-of-references] 73
  •  go-up   go-down


83. Shoemaker RC, House DE: A time-series study of sick building syndrome: chronic, biotoxin-associated illness from exposure to water-damaged buildings. Neurotoxicol Teratol; 2005 Jan-Feb;27(1):29-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serum leptin levels were abnormally high and alpha melanocyte stimulating hormone (MSH) levels were abnormally low.
  • Leptin and MSH levels showed statistically significant improvement.

  • MedlinePlus Health Information. consumer health - Indoor Air Pollution.
  • Hazardous Substances Data Bank. CHOLESTYRAMINE RESIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15681119.001).
  • [ISSN] 0892-0362
  • [Journal-full-title] Neurotoxicology and teratology
  • [ISO-abbreviation] Neurotoxicol Teratol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anion Exchange Resins; 0 / Anti-Infective Agents; 0 / Bacterial Toxins; 0 / Mycotoxins; 11041-12-6 / Cholestyramine Resin
  •  go-up   go-down


84. Ustundag B, Gungor S, Aygün AD, Turgut M, Yilmaz E: Oxidative status and serum leptin levels in obese prepubertal children. Cell Biochem Funct; 2007 Sep-Oct;25(5):479-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxidative status and serum leptin levels in obese prepubertal children.
  • The aim of this study was to evaluate the oxidative and antioxidant status and any correlation with leptin in obese prepubertal children.
  • Mean plasma leptin concentration was significantly higher in the obese children.
  • Homocysteine and malondialdehyde (MDA) levels were also significantly higher in the obese group.
  • In conclusion, in prepubertal obese children oxidative stress was increased and MDA and homocysteine levels were well correlated with serum leptin level and BMI.
  • [MeSH-major] Leptin / blood. Obesity / blood. Puberty / blood

  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity in Children.
  • MedlinePlus Health Information. consumer health - Puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16874844.001).
  • [ISSN] 0263-6484
  • [Journal-full-title] Cell biochemistry and function
  • [ISO-abbreviation] Cell Biochem. Funct.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


85. Yakut A, Dinleyici EC, Idem S, Yarar C, Dogruel N, Colak O: Serum leptin levels in children with cerebral palsy: relationship with growth and nutritional status. Neuro Endocrinol Lett; 2006 Aug;27(4):507-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum leptin levels in children with cerebral palsy: relationship with growth and nutritional status.
  • Several studies indicated that leptin which is produced by adipocytes, might regulate energy intake and expenditure.
  • The aim of this study is to determine serum leptin levels in children with CP and to investigate the relationship between nutritional status and anthropometric measurements.
  • Serum leptin, growth hormone, C-peptide and cortisol levels were studied.
  • Group DSF had lower leptin concentrations compared to Group non-DSF and controls (p<0.001, p<0.001).
  • On the other hand non DSF group had higher leptin levels than controls (p<0.05).
  • There was a positive and significant correlation between leptin and anthropometric measurements, especially TST in children with CP.
  • Serum leptin levels were also lower in non-ambulatory children than ambulatory children with CP (p<0.05).
  • Serum leptin levels were lower in CP, especially in DSF group.
  • We concluded that leptin which regulates energy intake might have a role of nutritional disorders in cerebral palsy.
  • [MeSH-major] Cerebral Palsy / metabolism. Child Nutrition Disorders / metabolism. Growth Disorders / metabolism. Leptin / blood. Nutritional Status


86. Karaosmanoglu D, Karcaaltincaba M, Oguz B, Akata D, Ozmen M, Akhan O: CT findings of lymphoma with peritoneal, omental and mesenteric involvement: peritoneal lymphomatosis. Eur J Radiol; 2009 Aug;71(2):313-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT findings of lymphoma with peritoneal, omental and mesenteric involvement: peritoneal lymphomatosis.
  • PURPOSE: We aimed to describe computed tomography (CT) findings in patients with peritoneal, omental and mesenteric lymphoma involvement.
  • MATERIALS AND METHODS: We searched our archive retrospectively to find out patients with peritoneal, omental and mesenteric lymphoma involvement.
  • We found 16 patients with non-Hodgkin lymphoma meeting these criteria.
  • RESULTS: There were 14 males and 2 females with peritoneal and/or mesenteric and omental lymphoma involvement.
  • Subgroups of non-Hodgkin lymphoma were diffuse large B-cell lymphoma (n=11), small cell lymphocytic lymphoma (n=2), small cleaved cell lymphoma (n=1), T-cell lymphoma (n=1) and Burkitt's lymphoma (n=1).
  • CONCLUSION: Peritoneal involvement can be seen in many subtypes of lymphoma and most frequently in diffuse large B-cell lymphoma.
  • Peritoneal lymphomatosis can mimic peritoneal carcinomatosis and should be included in the differential diagnosis list in patients with ascites, hepatosplenic lesions and unidentified cause of peritoneal thickening on CT in a male patient.
  • [MeSH-major] Lymphoma / radiography. Mesentery / radiography. Omentum / radiography. Peritoneal Neoplasms / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18513906.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


87. Li CW, Jiang DL, Qiao J, Sun JM, Huang JP, Chen HP, Zhu H: [Changes of leptin resistance, blood lipids and inflammatory response before and after the exercise therapy in children with obesity]. Zhongguo Dang Dai Er Ke Za Zhi; 2010 Jan;12(1):40-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes of leptin resistance, blood lipids and inflammatory response before and after the exercise therapy in children with obesity].
  • OBJECTIVE: Some research has shown that C-reactive protein (CRP), leptin, soluble leptin receptor (sLR) and blood lipids are involved in the development of obesity.
  • This study aimed to investigate the changes of leptin resistance, blood lipids and inflammatory response before and after the exercise therapy in children with obesity.
  • The levels of serum leptin, sLR, triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP) were measured before and after the exercise therapy.
  • RESULTS: Compared with the control group, serum levels of leptin, TG, TC, LDL-C and hs-CRP and the body mass index (BMI) in the obese group increased (p<0.01), while the serum level of sLR decreased significantly (p<0.05).
  • The levels of hs-CRP, leptin, TC, TG, LDL-C and BMI in the obese group were significantly reduced after the exercise therapy (p<0.05).
  • In the obese group, the serum leptin level was positively correlated with the levels of blood lipids and hs-CRP (p<0.05); serum levels of leptin and hs-CRP were negatively correlated with the sLR level (p<0.05); the hs-CRP level was positively correlated with the levels of blood lipids (p<0.01).
  • CONCLUSIONS: Leptin resistance and the changes of blood lipids and inflammatory response are found in children with obesity.
  • [MeSH-major] C-Reactive Protein / analysis. Exercise Therapy. Leptin / blood. Lipids / blood. Obesity / therapy
  • [MeSH-minor] Body Mass Index. Child. Female. Humans. Male. Receptors, Leptin / blood

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity in Children.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20113633.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Leptin; 0 / Lipids; 0 / Receptors, Leptin; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


88. Lei X, Peng X, Wu N, Hu M, Sun Z: [Serum adiponectin, leptin level, and bone mineral density in postmenopausal women]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jun;34(6):559-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Serum adiponectin, leptin level, and bone mineral density in postmenopausal women].
  • OBJECTIVE: To determine whether serum adipocytokines and leptin level are associated with bone mineral density (BMD) in postmenopausal women.
  • METHODS: Serum adiponectin and leptin level were measured by ELISA in 336 postmenopausal women.
  • RESULTS: Serum adiponectin levels were negatively related to BMD at the whole body, the lumbar spine, the hip, and the forearm (r = -0.181, r = -0.208, r = -0.228, r = -0.203, and P < 0.05, respectively).
  • Serum leptin levels were positively related to BMD was at the hip and the forearm (r = 0.162, r = 0.210, and P < 0.05, respectively).
  • [MeSH-major] Adiponectin / blood. Bone Density / physiology. Leptin / blood. Postmenopause / blood

  • MedlinePlus Health Information. consumer health - Bone Density.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19587442.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Leptin
  •  go-up   go-down


89. Gunaydin R, Kaya T, Atay A, Olmez N, Hur A, Koseoglu M: Serum leptin levels in rheumatoid arthritis and relationship with disease activity. South Med J; 2006 Oct;99(10):1078-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum leptin levels in rheumatoid arthritis and relationship with disease activity.
  • OBJECTIVES: This study was performed to evaluate serum leptin levels in rheumatoid arthritis (RA) patients and investigate the correlation with serum tumor necrosis factor alpha (TNF-alpha) levels and clinical and laboratory parameters of disease activity.
  • Immunoradiometric assay was used for measuring serum leptin levels (ng/mL).
  • Serum TNF-alpha levels (pg/mL) were measured by sandwich enzyme-linked immunosorbent assay method in 41 of 50 RA patients and in 24 control subjects.
  • Serum leptin levels were higher in RA (P = 0.000).
  • In RA patients, there were no correlations between serum leptin levels and disease duration, swollen and tender joint counts, DAS28, CRP, ESR, serum TNF-alpha levels, oral glucocorticoid and methotrexate usage (P > 0.05).
  • There was no statistically significant serum leptin level difference between patients with high disease activity and mild and low disease activity (P = 0.892).
  • Serum leptin levels positively correlated with BMI in both patient and control groups (P < 0.05).
  • In both groups, mean serum leptin levels were higher in women than men.
  • CONCLUSIONS: Even though serum leptin levels were found to be significantly higher in RA patients than in control subjects in this study, there was no correlation between serum leptin levels and TNF-alpha levels, clinical and laboratory parameters of disease activity.
  • However serum leptin levels positively correlated with BMI in both patient and control groups.
  • In RA, circulating leptin levels do not seem to reflect disease activity.
  • [MeSH-major] Arthritis, Rheumatoid / blood. Leptin / blood


90. Antoniades L, Eftychiou C, Petrou PM, Bagatzounis A, Minas M: Primary cardiac lymphoma: case report and brief review of the literature. Echocardiography; 2009 Feb;26(2):214-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cardiac lymphoma: case report and brief review of the literature.
  • Primary cardiac lymphoma is defined as a non-Hodgkin's lymphoma mainly located in the heart and/or the pericardium.
  • Diagnosis is usually late and prognosis is poor.
  • We report a case of a patient with a large primary cardiac lymphoma who presented with chest pain and negative T-waves in electrocardiogram.
  • Tissue biopsy showed a high-grade B-cell diffuse lymphocytic lymphoma.
  • [MeSH-major] Heart Neoplasms / diagnosis. Heart Neoplasms / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy
  • [MeSH-minor] Aged. Chest Pain / etiology. Diagnosis, Differential. Echocardiography. Electrocardiography. Follow-Up Studies. Heart Atria / ultrasonography. Heart Ventricles / ultrasonography. Humans. Male. Rare Diseases. Remission Induction / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138175.001).
  • [ISSN] 1540-8175
  • [Journal-full-title] Echocardiography (Mount Kisco, N.Y.)
  • [ISO-abbreviation] Echocardiography
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


91. Carver JD, Calverley D, Shen P: Chronic lymphocytic leukemia/small lymphocytic lymphoma presenting in urinary bladder without peripheral blood lymphocytosis: case report and literature review. Leuk Lymphoma; 2006 Jun;47(6):1163-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukemia/small lymphocytic lymphoma presenting in urinary bladder without peripheral blood lymphocytosis: case report and literature review.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Cell Proliferation. Epithelial Cells / metabolism. Humans. Immunohistochemistry. Lymphocytes / metabolism. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840214.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


92. Turner CA, Rubin CM, Royle GT, Flynn M, Theaker JM: Screen detected sclerosing lymphocytic lobulitis and amyloid of the breast in the same patient--a possible causal link. Breast; 2006 Apr;15(2):281-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screen detected sclerosing lymphocytic lobulitis and amyloid of the breast in the same patient--a possible causal link.
  • Sclerosing lymphocytic lobulitis (SLL) and amyloidosis of the breast are both rare.
  • Wire-guided excision biopsy showed features typical of SLL but also localised amyloid deposits within the specimen.
  • Amyloidosis and SLL may have similar immunological causes.
  • [MeSH-major] Amyloidosis / diagnosis. Breast / pathology. Breast Diseases / diagnosis
  • [MeSH-minor] Biopsy, Needle. Diagnosis, Differential. Female. Humans. Mammography. Middle Aged. Sclerosis / complications. Sclerosis / diagnosis. Sclerosis / pathology. Sclerosis / radiography

  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982886.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


93. Deemer SE, King GA, Dorgo S, Vella CA, Tomaka JW, Thompson DL: Relationship of leptin, resting metabolic rate, and body composition in premenopausal hispanic and non-Hispanic White women. Endocr Res; 2010;35(3):95-105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of leptin, resting metabolic rate, and body composition in premenopausal hispanic and non-Hispanic White women.
  • OBJECTIVE: The purpose was to evaluate the relationships between fasting serum leptin, resting metabolic rate (RMR), and body composition in premenopausal Hispanic and non-Hispanic White (White) women.
  • Serum leptin levels were determined by EIA.
  • Leptin was not a significant predictor of RMR.
  • CONCLUSION: Further research needs to be done to examine the role of leptin on metabolism, especially in ethnic groups predisposed to development of obesity and related disorders.

  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20712423.001).
  • [ISSN] 1532-4206
  • [Journal-full-title] Endocrine research
  • [ISO-abbreviation] Endocr. Res.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / G12 RR008124; United States / NIMHD NIH HHS / MD / P20 MD000548; United States / NCRR NIH HHS / RR / 5G12RR008124; United States / NIMHD NIH HHS / MD / P 20 MD000548
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Leptin
  • [Other-IDs] NLM/ NIHMS732174; NLM/ PMC4635679
  •  go-up   go-down


94. Kim HJ, Kim SK, Shim WS, Lee JH, Hur KY, Kang ES, Ahn CW, Lim SK, Lee HC, Cha BS: Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract; 2008 Jul;81(1):42-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus.
  • Leptin is highly correlated with adiposity, while the activation of PPARgamma is known to inhibit Lep gene expression and leptin release.
  • This study was performed to evaluate the relationship between changes in circulating leptin levels, insulin sensitivity and regional adiposity after RSG treatment.
  • Two hundred fifty-one type 2 diabetic patients (176 men and 75 women) who had been treated with sulfonylurea and/or metformin received 4 mg of RSG daily, in addition to the previous medications.
  • Before and after RSG treatment (average duration 5.6+/-0.9 months), indices of insulin resistance, metabolic parameters, and serum leptin and adiponectin levels were measured.
  • After RSG treatment, HOMA-IR index decreased significantly (2.82+/-1.94 vs. 2.01+/-1.58), while BMI and SFT(max) increased, and leptin (4.72+/-3.77 vs. 5.69+/-4.30 ng/ml) and adiponectin levels (7.54+/-10.20 vs. 12.89+/-10.13 microg/ml) increased.
  • The increase in serum leptin correlated with an increase in SFT(max) (r=0.511, p<0.001) and with a reduction in HOMA-IR (r=-0.368, p<0.001).
  • The correlation of Delta leptin with Delta HOMA-IR and with Delta SFT(max) was higher in females and among insulin-resistant subjects.
  • In conclusion, RSG improves the insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus, which is related to an increase in subcutaneous adiposity.
  • [MeSH-major] Diabetes Mellitus, Type 2 / blood. Diabetes Mellitus, Type 2 / drug therapy. Hypoglycemic Agents / therapeutic use. Leptin / blood. Thiazolidinediones / therapeutic use


95. Venkatraman L, Catherwood M, Benson G, Drake M: Hodgkin transformation of small lymphocytic lymphoma: gene usage, mutational status and clonal relationship. Histopathology; 2007 Dec;51(6):866-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin transformation of small lymphocytic lymphoma: gene usage, mutational status and clonal relationship.
  • [MeSH-major] Mixed Tumor, Malignant / pathology. Salivary Gland Neoplasms / pathology. Tracheal Neoplasms / pathology
  • [MeSH-minor] Adenoma, Pleomorphic / pathology. Adenoma, Pleomorphic / surgery. Aged. Carcinoma, Adenoid Cystic / pathology. Diagnosis, Differential. Humans. Male. Pulmonary Disease, Chronic Obstructive / pathology. Smoking

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18042076.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


96. Lam MF, Leung JC, Lo WK, Tam S, Chong MC, Lui SL, Tse KC, Chan TM, Lai KN: Hyperleptinaemia and chronic inflammation after peritonitis predicts poor nutritional status and mortality in patients on peritoneal dialysis. Nephrol Dial Transplant; 2007 May;22(5):1445-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The serum leptin level is elevated in patients undergoing peritoneal dialysis (PD) and associated with a loss of lean body mass.
  • Blood samples were obtained as baseline (D0) before the onset of peritonitis, and once peritonitis developed, leptin, adiponectin (ADPN) and other inflammatory markers were collected, on day 1 (D1), day 7 (D7) and day 42 (D42) of peritonitis.
  • The serum leptin levels increased significantly from baseline to day 1 and 7, but fell back to the premorbid state at day 42.
  • In contrast, the ADPN level decreased from a baseline value of 15.60+/-10.4 microg/ml to 13.01+/-8.1 microg/ml on day 1 (P=0.01) but rose to 14.39+/-8.9 microg/ml on day 7 (P=0.28) and 13.87+/-7.9 microg/ml on day 42 (P=0.21).
  • CONCLUSIONS: Our study confirmed an increase in serum leptin during acute peritonitis and a prolonged course of systemic inflammation after apparent clinical remission of peritonitis.
  • [MeSH-major] Inflammation / etiology. Kidney Failure, Chronic / mortality. Leptin / blood. Peritoneal Dialysis. Peritonitis / blood. Peritonitis / complications. Protein-Energy Malnutrition / etiology

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277343.001).
  • [ISSN] 0931-0509
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Interleukin-6; 0 / Leptin; 0 / Tumor Necrosis Factor-alpha; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


97. Zukauskaite S, Seibokaite A, Lasas L, Lasiene D, Urbonaite B, Kiesylyte J: Serum hormone levels and anthropometric characteristics in girls with hyperandrogenism. Medicina (Kaunas); 2005;41(4):305-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum hormone levels and anthropometric characteristics in girls with hyperandrogenism.
  • RESULTS: Serum testosterone and dehydroepiandrosterone sulphate levels were significantly higher in all patients than in controls.
  • Free androgen index and leptin levels were significantly higher, and sex-hormone-binding globulin lower in hirsute adolescents vs. controls.
  • Serum dehydroepiandrosterone sulphate negatively correlated with birth weight standard deviation scores in the group of girls with premature adrenarche (r=-0.57, p<0.001).
  • By linear regression, 76% in variation of serum leptin levels could be explained by subscapular skinfold thickness standard deviation scores, and by serum sex-hormone-binding globulin, insulin, and dehydroepiandrosterone sulphate levels in all participants.
  • CONCLUSIONS: Inverse correlation of dehydroepiandrosterone sulphate levels and weight at birth indicates relationship between premature adrenarche in girls and fetal growth.
  • Higher leptin levels in adolescents with hyperandrogenism than in healthy girls show possible involvement of leptin in pathogenesis of hyperandrogenism.
  • [MeSH-minor] Adolescent. Age Factors. Birth Weight. Body Height. Body Mass Index. Body Weight. Child. Child, Preschool. Female. Hirsutism / diagnosis. Humans. Insulin / blood. Leptin / blood. Linear Models. Menarche. Polycystic Ovary Syndrome / diagnosis. Puberty, Precocious. Risk Factors

  • Genetic Alliance. consumer health - Hyperandrogenism.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15864003.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Lithuania
  • [Chemical-registry-number] 0 / Insulin; 0 / Leptin; 3XMK78S47O / Testosterone; 57B09Q7FJR / Dehydroepiandrosterone Sulfate
  •  go-up   go-down


98. Remmers F, Fodor M, Delemarre-van de Waal HA: Neonatal food restriction permanently alters rat body dimensions and energy intake. Physiol Behav; 2008 Sep 3;95(1-2):208-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neonatal food restriction (FR) in rats, by means of increased litter size, has been used as a model for developmental programming by several investigators.
  • Serum leptin levels were determined in four subsets of different ages.
  • FR acutely reduced growth in all body dimensions and serum leptin levels.
  • These results suggest that neonatal food restriction programmed both male and female Wistar rats to remain small and lean in adult life, with a lower food intake.
  • Low neonatal leptin levels may play a mechanistic role in this process.
  • [MeSH-minor] Age Factors. Analysis of Variance. Animals. Body Mass Index. Body Weight / physiology. Eating / physiology. Female. Leptin / blood. Male. Nutritional Status. Pregnancy. Radioimmunoassay / methods. Random Allocation. Rats. Rats, Wistar. Sex Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18588905.001).
  • [ISSN] 0031-9384
  • [Journal-full-title] Physiology & behavior
  • [ISO-abbreviation] Physiol. Behav.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin
  •  go-up